The systematic review (appendix 4) by Probst, Heidi et al.
The systematic review (appendix 4)
PROBST, Heidi <http://orcid.org/0000-0003-0035-1946>, BURKE, Gemma 
and FAITHFULL, Sara
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/26246/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
PROBST, Heidi, BURKE, Gemma and FAITHFULL, Sara (2020). The systematic 
review (appendix 4). In: The Society and College of Radiographers Practice 
Guideline Document Radiation Dermatitis Guidelines for Radiotherapy Healthcare 
Professionals. The Society of Radiographers. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
Endorsed by
The Society and College 
of Radiographers
Practice Guideline Document 
Radiation Dermatitis Guidelines for 
Radiotherapy Healthcare Professionals
Second revised edition
April 2020
Review date: 2025
ISBN: 978-1-909802-49-0
SCoR
THE SOCIETY & COLLEGE 
OF RADIOGRAPHERS
Contents Page 
Executive summary 1
1.  Introduction 4
2.  Scope and purpose 8
3.  Guideline question 8
4.  Guideline development process 8
5.  Guideline methodology 9
6.  Radiotherapy skin care 26
7.  Guideline recommendations 28
8.  Implementation strategies 32
9.  Recommendations for future research 33
10.  Date of publication, review and updating 34
11.  References  35
12.  List of appendices (separate documents)
Appendix 1 Group members
Appendix 2  Stakeholder consultation combined and outcomes
Appendix 3  External stakeholder comment form
Appendix 4  2014 Systematic review 2014
Appendix 5  2014 On-going trails table (1)
Appendix 6  2014 On-going trials table (2)
Appendix 7  2019 Summary of evidence table
Appendix 8  2019 Review summary of evidence table
Appendix 9  Other interventions
Appendix 10  Staff infosheet skin care
Appendix 11  Staff infosheet skin care A5 leaflet
Appendix 11  Staff infosheet skin care A5 leaflet – PRINT READY
Appendix 12  Patient information sheet
Appendix 13  Patient infosheet skin care A5 leaflet
Appendix 13  Patient infosheet skin care A5 leaflet – PRINT READY
Appendix 14  Skin care presentation
Oncology Nursing Society (UKONS) colleagues have been involved in the writing of this document
and UKONS recognises it as expert guidelines.
 
 
 1 
Executive summary  
 
The Society and College of Radiographers (SCoR) has a responsibility to provide national guidance 
promoting equitable and consistent practice across the UK, informing policy and standards. All 
patients have the right to receive a high standard of evidence-based care irrespective of where they 
receive their treatment. This guidance is based on an expert consensus and review of the available 
evidence base; it supports the need for further research into new products before they are 
recommended for radiotherapy skin care. 
 
Skin reactions from external beam radiotherapy are a common side effect of treatment and may cause 
distress to some patients; a skin reaction may also be a factor that can limit radiation dose and 
treatment schedules. 
 
It has been widely acknowledged that despite the publication of a number of best practice guidelines 
for skin care, radiotherapy departmental practice with respect to the prevention and management of 
acute radiotherapy and skin toxicity has been slow to change. A wide variety of methods and topical 
applications are still utilised at a local level, often with very little or no evidence base. 
  
Hence, the purpose of this current review was to determine if new research evidence had emerged 
that could improve skin care practices in radiotherapy. This systematic review aimed to assess the 
effectiveness of interventions and practices that may prevent, reduce (or alter) radiation induced skin 
reactions (RISRs) in patients undergoing external beam radiotherapy for cancer, with an emphasis on 
research published since November 2014. The review proposal was registered on PROSPERO: 
International prospective register of systematic reviews (CRD42019148161).  
 
Despite reviewing a significant amount of published evidence, still very few definitive 
recommendations can be made with respect to the optimal intervention for the management or 
prevention of radiation induced skin reactions.  
 
The use of steroid-based creams is the one area where evidence shows consistent positive benefit 
across studies assessed as having a low risk of bias. However, it is important to note that even in cases 
where positive results were presented, those benefits may not be translated to cases where 
hypofractionated dose schedules are employed or where the comparator does not include a cream 
considered to potentially cause irritation. Therefore, the use of steroid-based cream is only 
recommended for RISR prevention in patients assessed as being at high risk of developing a high-grade 
radiation dermatitis. 
 
Barrier films and dressings still seem to be widely used. However, the results of studies included in 
this review are not significant enough to recommend a change in practice. This is partly due to 
limitations in the design of some of the studies, as well as the variety of products investigated, the 
high drop-out rate in some cases (due to tolerability of the product), and the limited positive outcomes 
presented in some studies.  
 
Photobiomodulation therapy (PBMT) is an emerging intervention to reduce RISR. The use of PBMT has 
been recognised in other areas of radiotherapy toxicity, such as the treatment of oral mucositis and 
lymphoedema. Further research is needed on the long-term effects of the use of PBMT as a 
prophylactic intervention for RISRs before it could be recommended for widespread use and future 
research should consider assessment of patients having modern dose fractionation schedules. 
 
A significant amount of research is still being undertaken to investigate topical emollients, as shown 
by the number of such studies included in this review and trials currently recruiting participants. 
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However, these are often single institution studies of one particular product, and as more enter the 
market the research base is spread across a number of small sample studies of different products. 
Hence, the review team are unable to draw confident conclusions as it is not possible to pool data in 
the form of a meta-analysis. Therefore, there is still not enough strong evidence to recommend or 
endorse any one specific product.  
 
In addition, some of the issues highlighted by the review team with respect to study design and 
analysis only add to the uncertainty, with a lack of reporting or stratifying for many of the possible 
patient-related variables as well as variations in radiotherapy technique, planning and dose 
fractionation regimens.  
 
There may be benefits to risk stratifying patients to allow those at high risk of developing severe (or 
high-grade) radiation dermatitis to be treated with appropriate interventions. For example, there may 
be cases where it is appropriate for patients to use steroid cream, but currently there is limited data 
to confirm exactly which groups of patients with specific levels of risk would benefit. Choice of a 
control or placebo also requires careful consideration and justification within the research method. 
As identified in this review, some researchers adopted a cream for the comparator that may 
exacerbate skin irritation experienced by the control arm and thus may invalidate or limit the usability 
of the study results.   
 
A wide variation in the timing of the assessment of skin reactions was observed, making it difficult to 
make comparisons across studies, and very few of the studies reviewed included assessment of inter- 
and intra-rater reliability of the clinician assessed reactions; where this was undertaken, poor 
reliability of the assessment process was evident. Furthermore, in the topical emollient studies 
reviewed, patient adherence to the intervention was rarely assessed; patient compliance is an 
important consideration when considering changes to practice, along with cost and resource use. 
 
In light of these concerns, the review team have therefore produced a set of recommendations for 
skin care research design, based on the assessment of the existing literature. In order to move the 
evidence base forward for interventions to prevent or treat RISRs we need high-quality research 
studies and we would recommend that researchers in this field try to implement some of the 
recommendations when designing future studies. 
 
Overall, the evidence base is not strong enough to either support or refute the use of any particular 
product for topical application.   
 
These clinical practice guidelines are a set of evidence-based recommendations to support 
radiotherapy healthcare professionals in advising patients about skin care and radiation dermatitis. 
They have been developed systematically using evidence from research and expert opinions, and have 
been subjected to peer, professional and lay assessment. They include guidance on assessing and 
managing radiation induced skin toxicity. These guidelines would be of value to individual 
practitioners, service managers and academic institutions. 
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The following eight key principles of effective skin care management are recommended: 
 
1. Knowledge of intrinsic and extrinsic factors that may affect the development and severity of radiation 
dermatitis. Prior to the start of radiotherapy, patients should be identified as being at low, medium or 
high risk based on intrinsic and extrinsic factors. 
 
2. Documentation of current skin care regimen and existing skin conditions, including sensitivities and 
allergies to certain products. 
 
3. Use of a standardised tool for radiation dermatitis assessment of all patients undergoing a course of 
radiotherapy. Using the agreed validated tool and scoring criteria, radiotherapy departments should 
standardise the initial assessment and continued regular monitoring of skin reactions, and ensure that 
these are recorded.   
 
4. Adherence to a standardised assessment process that includes a baseline assessment and weekly 
assessments during treatment using the standardised assessment tool. 
 
5. Mandatory local training for all staff assessing skin toxicity, to ensure accurate reporting and 
maintenance of consistent management protocols. 
 
6. Regular audit of skin reactions to collate accurate data on frequency and severity. 
 
7. An emphasis on empowering patients to use products they are familiar with and to self-monitor their 
skin, being proactive to improve comfort and minimise the risk of developing severe skin reactions. 
Recording of patient acceptability/satisfaction and compliance with skin care advice is recommended 
as such information can be used to evaluate the appropriateness of skin care products for future 
patients.  
 
8. Testing within a well-designed randomised controlled trial any new product or device designed to 
reduce radiation dermatitis, before its implementation. 
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1. Introduction 
 
1.1 How was the topic identified? 
 
Since publication in 2015, a variety of new skin care products have emerged on the market, while 
some previously used products have been removed by pharmacy suppliers. Technological 
developments, such as proton therapy and innovative treatment techniques, have become more 
widely used in the UK. Therefore, a review of the 2015 skin care guidelines (SCoR, 2015) was necessary, 
alongside the recommendation in the guidelines themselves to perform regular reviews in order to 
remain consistent with current evidence. 
 
1.2 Why is it important? 
 
Skin reactions from external beam radiotherapy are a common side effect of treatment and may cause 
pain and distress to some patients; a skin reaction may also be a factor that can limit radiation dose 
and treatment schedules (Royal College of Radiologists, 2008). 
 
Radiotherapy delivered in the megavoltage range using modern equipment has skin sparing properties 
that significantly reduce the severity of reactions from this type of treatment (Harris, 2002b). The use 
of immobilisation devices (as frequently used in head and neck radiotherapy) will cause this skin 
sparing effect to be lost. 
 
The use of accelerated radiation dose schedules and the concurrent use of chemotherapy or biological 
agents, such as epidermal growth factor receptor (EGFR) inhibitors, will also lead to an increase in skin 
reactions (Bernier et al., 2008). The most severe reactions tend to be seen in those patients receiving 
high doses to large fields and where there are folds of skin (for example inframammary fold, groin, 
axilla) (Porock et al., 1998; Richardson et al., 2005). Bolus material is still frequently used, especially 
for some breast cancer treatments, and this will also increase skin toxicity rates. 
 
The use of intensity modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) 
offers the potential to reduce skin toxicity in some cases by increasing the number of beams and 
simultaneously reducing the dose contribution from each beam. The reduction in rates of dry and 
moist desquamation when using IMRT is particularly well demonstrated when treating cancers in the 
head and neck region (Freedman et al., 2004; Harsolia et al., 2006; Price et al., 2006; Freedman et al., 
2006; Harsolia et al., 2007; Pignol et al., 2008; Freedman et al., 2009; Ciammella, et al., 2014). Despite 
these reductions, significant acute toxicity is still often observed when treating head and neck cancers.  
 
Proton beam therapy has the potential to cause more severe skin reactions due to loss of the skin 
sparing effect when using protons, and protons can be used for dose escalation. The difference in skin 
reactions compared to photons is due to the variations in beam characteristics, beam dosimetry and 
beam arrangement. With the opening of proton beam centres in the UK, it is expected that reported 
toxicities associated with proton therapy will be researched and published.  
 
Results from large scale multicentre trials have led to adoption of hypofractionation (using fewer 
doses of radiotherapy at higher dose per fraction), particularly in the common cancers of breast and 
prostate, will also change the pattern of observed skin toxicity. 
 
Despite changes in radiotherapy practice and numerous published skin care guidelines (NHS Quality 
Improvement Scotland, 2004; SCoR, 2001; NHS Quality Improvement Scotland, 2010; SCoR, 2011a, 
2015), patient skin care appears to have changed little over time, with no consensus among centres 
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on product use, approaches, and skin care regimens (Barkham, 1993; Harris, 2002a; Harris et al., 
2012). 
 
Complete prevention of skin reactions seems unlikely, but there should be a constant drive to delay 
onset and minimise the severity of a reaction, to reduce discomfort and prevent further complications. 
Radiobiologically, skin reactions tend to peak towards the end of the treatment course and are often 
at their worst in the first two weeks after treatment has completed. Skin reactions may be acute or 
chronic, but currently there is insufficient data to indicate if acute reactions are more common than 
chronic. The extent of a skin reaction is often dependent upon  clinical factors (see section 1.5.2), 
making patients more vulnerable to intensified skin reactions and possible interruptions in 
radiotherapy, which can have a detrimental effect on treatment outcome (RCR, 2008). 
 
Radiation may cause chronic late effects as well as acute reactions. Late skin reactions may be 
characterised by fibrosis of subcutaneous tissues, and telangiectasia. Advice on the management of 
late effects is beyond the scope of this document. However, there is a lack of evidence that links acute 
reaction severity to the risk of chronic late effects and this would merit further investigation. 
 
1.3 How does it fit with existing radiotherapy practice? 
 
The SCoR and the United Kingdom Oncology Nursing Society (UKONS) offer advice and guidance for 
professional development to promote patient-centred care and the highest quality services. The SCoR 
document library contains policies, advice and guidance on a range of topics. 
 
1.4 The policy context 
 
The SCoR has a responsibility to provide national guidance promoting equitable and consistent 
practice across the UK, informing policy and standards. All patients have the right to receive a high 
standard of evidence-based care irrespective of where they receive their treatment. This guidance is 
based on an expert consensus and review of the available evidence base; it supports the need for 
further research into new products before they are recommended for radiotherapy skin care. 
 
As part of NHS England specialised commissioning, the SCoR supports the reduction of variation in 
quality by adopting standardised best practice protocols and so improving user outcomes, including 
quality of life, mortality and morbidity from adverse side effects. Access to high-quality, protocol-
driven services focused around patients’ needs must be equitable, and the review of radiotherapy skin 
care advice works towards this. 
 
The results of surveys (SCoR, 2011b; Harris et al., 2012; SCoR, 2014) conducted by the Society and 
College of Radiographers and Nisbet et al. (2018, 2019) identified variance in practices in UK 
radiotherapy departments with respect to both the prevention and management of radiation induced 
skin reactions. These surveys highlighted that, despite the published guidance, not all departments 
were following recommendations for baseline skin assessments and the prevention/management of 
skin reactions, or recording potential risk factors; much of the existing evidence base was 
contradictory and many references were old, with a disappointing scarcity of contemporary evidence. 
Audit and data collection are too limited to provide an accurate record of radiotherapy reactions 
across clinical departments. This makes quantifying the extent of the problem difficult. 
 
 
The evidence base was not found to be strong enough to make definitive recommendations around 
any specific interventions; however, recommendations have been made around practice to alleviate 
symptoms and promote comfort. 
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The UK is not alone in facing difficulties in standardising guidance and advice – a survey in Canada also 
demonstrated variance in managing radiotherapy skin reactions across departments (Bolderston et 
al., 2018). 
 
1.5 Background information 
 
1.5.1 Radiobiology 
The timing of acute skin reactions has been extensively studied, with well-documented experiments 
dating back to the 1920s. Early radiotherapy treatment times were determined by the time it took for 
the skin to become erythematous. The timing of acute skin reactions relates to cell turnover and the 
relatively rapid turnover of skin cells, leading to early (within weeks) manifestations of radiotherapy 
effect (Hopewell, 1990). 
 
Skin toxicity is radiation-dose dependent although threshold levels will vary between patients. Ryan 
et al. (2012) described erythema at doses of 10–12Gy and moist desquamation occasionally occurring 
at doses of 30–40Gy (when giving 2Gy per fraction). 
 
Various attempts have been made to produce dosimetric guidance as to the likelihood of radiotherapy 
effects, but usually only late effects. The original National Cancer Institute (NCI) study by Emami et al. 
(1991) calculated a five-year risk of a 5% increase of necrosis and ulceration when a 30cm2 area of skin 
receives a dose of 60Gy (V60) or a 10cm2 area of skin receives a dose of 70Gy (when giving 2Gy per 
fraction). The updated quantitative analyses of normal tissue effects in the clinic (QUANTEC) 
dosimetric guidance (Bentzen et al., 2010) does not consider effects on skin at all. 
 
There have been subsequent efforts in the current era to produce normal tissue complication 
probabilities (NTCPs), almost exclusively in the breast. The possibility to model and calculate NTCPs 
arises from the potential of modern treatment planning systems (TPSs) to outline the skin as an organ 
at risk. Many commercially available TPSs have calculation grid sizes of 3mm, which approximates to 
the thickness of skin, and if grid sizes are reduced then calculations will become more accurate. In a 
study of 55 patients of average body mass index (BMI) who had breast treatment with intensity 
modulated radiotherapy (IMRT), an NTCP calculation determined that skin volume receiving a dose 
>35Gy (V35) should be limited to <85.7mL to keep the incidence of radiation dermatitis (RD) grade 2+ 
toxicity below 50% (Lee, 2018). 
 
Turesson et al. (1996) demonstrated that the number of basal cells in the epidermis declines during 
fractionated radiotherapy due to increased cell cycle arrest and reduced mitosis. The reduction in 
basal cells causes a thinning of the epidermis and an inflammatory reaction, and variation in the 
reaction appears to be a genetic predisposition related to individual DNA repair capacity (Tucker et 
al., 1992; Lopez et al., 2002; Twardella et al., 2003; Popanda et al., 2003; Chang-Claude et al., 2005; 
Pinar et al., 2007; Andreassen and Alsner, 2009), to genetic radiosensitivity (Barber et al., 2000; Burrill 
et al., 2000; Suga et al., 2007), and/or to intravascular thrombin generation (Lincz et al., 2009). 
  
1.5.2 Clinical factors 
Certain clinical factors (Table 1) can aid in the prediction of which patients are more likely to 
experience a significant radiation reaction (Russell et al., 1994; Russell, 2010). Extrinsic factors, which 
are treatment related, include: dose, volume, fractionation, adjuvant treatment, treatment in a skin 
fold area (e.g. inframammary fold or anal cleft), use of bolus material, type of immobilisation, and 
treatment technique (Porock and Kristjanson, 1999). In the last decade, there have been rapid changes 
and progressive developments in the technology used for planning and delivery of radiotherapy. 
Intensity modulated radiotherapy (IMRT) and rotational intensity modulated radiotherapy (RIMRT), 
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including volumetric modulated arc therapy (VMAT) and tomotherapy are now commonly 
implemented for clinical use (Miles and Venables, 2012).  
 
Intrinsic factors, which are individually patient related, include: larger breast size (only relevant when 
treating the breast) (Porock and Kristjanson, 1999; Harris, 2002b; Goldsmith et al., 2011); higher body 
mass index (BMI) (Kouvaris et al., 2001; Twardella et al., 2003; Wells et al., 2004); and/or pre-existing 
conditions and comorbidities, such as diabetes (Turesson et al., 1996; Porock et al., 1999). Such 
intrinsic factors may enhance an individual’s propensity to experience a skin reaction and therefore 
should be recorded when taking baseline observations and closely monitored throughout, and after, 
a course of radiotherapy (Porock et al., 1998; Fisher et al., 2000; Richardson et al., 2005; NHS Quality 
Improvement Scotland, 2010). Smoking has also been shown to be an independent risk factor; patients 
should be advised about this and supported to change behaviours wherever possible (Wells et al., 
2004; Kraus-Tiefenbacher et al., 2012; Sharp et al., 2013 (a) and (b)). 
 
Table 1: Intrinsic and extrinsic factors that may influence the severity of skin reactions 
Intrinsic factors Extrinsic factors 
Demographic or disease-related characteristics Treatment-related characteristics 
Age, ethnic origin, smoking, obesity, breast size, 
hormonal status, presence of infection, co-
existing diseases (such as diabetes, 
cardiovascular disease, hypermobile Ehlers–
Danlos syndrome, autoimmune conditions e.g. 
systemic lupus erythematosus and 
scleroderma), skin type. 
Technique, dose, volume, fractionation, beam 
energy, use of bolus, immobilisation devices, 
addition of systemic anti-cancer therapies 
(SACTs). Clinical site of treatment, e.g. areas 
containing skin folds, such as the head and neck, 
breast and axilla. 
Based on Porock and Kristjanson, 1999 
 
The 2015 skin care guidelines (SCoR, 2015) showed a significant amount of research being undertaken, 
but that  very few definitive recommendations could be made with respect to the optimal intervention 
for the management of, and potential to reduce, radiation induced skin reactions. Gosselin (2010) 
noted that some skin care products showed promising results but comparing data across studies is 
difficult because of the wide variety of assessment tools used. 
 
The use of a validated skin assessment tool on at least a weekly basis is recommended. This practice 
allows monitoring and recording of an individual patient’s skin reaction. An example of a validated 
assessment scale recommended by these guidelines is that developed by the Radiation Therapy 
Oncology Group (RTOG) (Cox et al., 1995). The use of an effective monitoring system (Campbell and 
Lane, 1996; O'Shea et al., 2003) would assist in a robust approach to radiation skin care management, 
aiding product evaluation and justification of practice. 
 
Another important aspect of skin care during radiotherapy is quality of life. Patients often have fears 
and misconceptions about radiotherapy; therefore, consistent, current and relevant reinforced 
information can help to alleviate some of these concerns (Harris, 1997). It may not be possible to stop 
or reduce the rates of skin reactions, but skin care products may provide comfort and enhance self-
care (Gosselin, 2010). 
 
Studies have showcased the benefits of utilising a patient reported outcome measure (PROM) in skin 
care evaluation studies. Recording of patient symptoms, acceptability/satisfaction and compliance, as 
incorporated into some existing scales (Noble-Adams, 1999), would also be helpful indicators of how 
appropriate a product will be for future use. 
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Of significant note is the identification of certain products contraindicated for use on radiotherapy 
skin reactions: 
• topical antibiotics, unless there is a proven infection (Sitton, 1992; Campbell and Lane, 
1996; Korinko and Yurick, 1997) 
• gentian violet, due to potential carcinogenic side effects (Campbell and Lane, 1996; 
Rice, 1997; Boot-Vickers and Eaton, 1999) 
• aqueous cream – now classified in the British National Formulary (BNF) (Joint Advisory 
Committee, 2019) as a soap substitute. 
 
Petroleum (Sitton, 1992; Blackmar, 1997; Korinko and Yurick, 1997) and silver sulfadiazine (Fackrell, 
2013; Fackrell et al., 2015) based products have been considered to create a build-up effect due to 
their radiation attenuation properties. However, more recent evaluation (Morley et al., 2013) of 
dosimetric considerations has shown that the amount of product layering required to cause a problem 
would be far in excess of normal skin care use. Zinc oxide creams (e.g. SudocremR) still do not appear 
to be suitable for use (Fackrell et al., 2015). 
 
2. Scope and purpose  
 
The practice guideline is for the whole professional radiotherapy workforce, including students and 
learners. This encompasses clinical and non-clinical, registered and other practitioners, service 
managers, educationists, and researchers. The population covered in the guideline is patients 
receiving external beam radiotherapy. The setting for the guideline is radiotherapy departments in 
the United Kingdom. 
 
3. Guideline question 
 
What current evidence is there to assist radiotherapy healthcare professionals giving the optimal skin 
care advice to patients undergoing radical external beam radiotherapy? 
 
4. Guideline development process 
 
4.1 Core group 
 
The core group of nine was established in March 2019 by the lead professional officer, who is also the 
core group leader. The remaining eight members were: three experienced academics (two therapeutic 
radiographers and one nurse) who led the systematic review; an academic and clinical radiographer 
who led the updates to the background information; two patients and a lay person who ensured there 
was a patient voice throughout and who led on the review of the patient information. 
 
4.2 Stakeholder group 
 
The stakeholder group comprised thirty-two members: eighteen therapeutic radiographers, two 
oncology nurses, two clinical oncologists, one dosimetrist, three therapeutic radiographer 
representatives from Canada to compare across country reviews, and six patients/users. Several of 
the ‘professional members’ were also radiotherapy service users and brought that perspective to their 
feedback. The names of both core and stakeholder group members are listed in Appendix 1. 
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4.3 Peer review and consultation process 
 
The 2015 practice guidelines were circulated to the stakeholder group for comment in May 2019. Most 
stakeholders responded and their comments were assimilated in an action log. The form to record 
comments can be found in Appendix 2. Sub-teams then worked on: updating the background 
information; undertaking an updated systematic review; updating staff information; and updating 
patient information. A second round of consultation, including the systematic review report, was 
conducted at the end of November 2019. Drafts of the patient and staff infographics were shared at 
the College of Radiographers Annual Radiotherapy Conference in January 2020; feedback received 
from delegates was positive.  A third round of consultation, comprising a draft of the practice 
guideline, was conducted in February 2020. A final and fourth round of consultation to the core group 
to agree final consensus occurred in March 2020. Final consensus was achieved via email discussion 
and evaluation of the evidence.  
 
Further guideline versions were updates on wording and minor amendments that did not affect the 
recommendations agreed by the core and stakeholder groups. 
 
The SCoR Patient Advisory Group (PAG), SCoR Radiotherapy Advisory Group (RAG), SCoR Information, 
Support and Review Radiographer Forum, Macmillan Cancer Support, Breast Cancer Now and Cancer 
Research UK (CRUK) were sent the draft guidelines and appendices and asked to review and comment 
on them during February to March 2020. The form to record comments can be found in Appendix 3.  
 
SCoR UK Council signed off the work in April 2020. 
 
4.4 Funding arrangements 
 
An academic researcher on the core group was paid £500 to conduct and assimilate the literature 
review. Patient and lay representatives were each offered a gift voucher of thanks to the value of £70. 
All other core and stakeholder group members gave their time and expertise voluntarily.  
 
4.5 Conflict of interest  
 
The SCoR policy and procedures for managing conflicts of interest was adhered to (Process Manual 
for Practice Guideline Development (Appendix G)). All members of the core and stakeholder groups 
have signed the conflicts of interest declaration form. No conflicts of interest were declared. 
 
4.6 SCoR approval process 
 
The finalised practice guideline was submitted to the UK Council of the SCoR in April 2020. 
 
5. Guideline methodology 
 
5.1 Literature search 
 
The current review included a search of multiple databases, as well as a hand search of a number of 
relevant journals, and was supplemented by searches of the ‘grey literature’ to include ongoing trials.  
 
The results and discussion covered 33 studies. All included research was assessed for quality, with 
recommendations based on the studies assessed as having low opportunity for bias. Ongoing clinical 
trials were also listed, demonstrating a number of investigations that should be considered for 
inclusion in any future updates to this review.   
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The review identified a number of key areas that have been or are currently being researched, 
including the use of topical prophylactic steroids, a wide variety of topical emollients and 
photobiomodulation therapy. However, significant challenges still arise with respect to the breadth of 
research methods adopted, the skin care practices used in the control arms, methods of data analysis 
and stratification of results for the plethora of confounding patient and radiotherapy treatment 
related variables, all of which can have significant impact on the risk of bias and hence the reliability 
of the results being presented.  
 
5.2 Introduction and background to systematic review 
 
It has been widely acknowledged that despite the publication of a number of best practice guidelines 
for skin care, radiotherapy departmental practice with respect to the prevention and management of 
acute radiotherapy and skin toxicity has been slow to change. A wide variety of methods and topical 
applications are still utilised at a local level, often with very little or no evidence base (Harris et al., 
2012).  
 
The last skin care guidelines were published by the Society and College of Radiographers in 2015 
(SCoR, 2015). The 2015 guidelines were informed by a systematic review of the literature from 2011 
to 2014 (Appendices 4, 5 and 6). The guidelines recognised that there is often a disparity between the 
evidence base and clinical practice and the literature reviewed as part of the 2015 guidelines 
demonstrated that although additional research had been published in the field, the scope of this 
research and the results were quite wide-ranging, both in their methods and in the aspect of radiation 
induced skin reaction being researched. Many of the studies published between 2011 and 2014 
focused on a topical application, with some studies focused on the benefits of dressings to minimise 
discomfort and speed healing once a high-grade skin reaction had occurred. While the research 
published between 2011 and 2014 was potentially valuable to the radiotherapy community, only 30% 
of the research reviewed for the 2015 guidelines was assessed as high quality (i.e. assessed as having 
limited opportunity for bias that may affect the research results). The SCoR 2015 guidelines listed nine 
key recommendations as well as several best practice suggestions. Recommendations for further 
research were also published, which included the need to consider specifically the impact of proton 
therapy. It was also acknowledged within the 2015 guidelines that national guidelines need to be 
regularly reviewed and revised to ensure they are consistent with emerging evidence (Faithfull et al., 
2002). 
 
Hence, the purpose of the current review (2019) was to determine if new research evidence had 
emerged that could improve skin care practices in radiotherapy. This systematic review aimed to 
assess the effectiveness of interventions and practices that may prevent, reduce (or alter) radiation 
induced skin reactions (RISRs) in patients undergoing external beam radiotherapy for cancer, with an 
emphasis on research published since November 2014. The review proposal was registered on 
PROSPERO: International prospective register of systematic reviews (CRD42019148161).  
 
5.3 Method 
 
Initially a search question was formulated using the Population, Intervention, Control, Outcome (PICO) 
method (Table 2). 
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 Table 2: PICO method 
Population 
  
Patients undergoing external beam photon radiotherapy 
Patients undergoing proton beam radiotherapy 
Patients undergoing electron beam radiotherapy 
Intervention 
  
Preventative measures including the use of topical applications, use of 
barrier films and deodorant guidance   
Management measures – dressings, topical and medical applications 
Control 
  
Standard skin care practice including normal washing and use of non-
specific moisturisers 
Outcome 
  
Radiation induced skin reactions (RISRs), skin reactions, radiation 
dermatitis, erythema, dry and moist desquamation, Radiation Therapy 
Oncology Group (RTOG)/Common Terminology Criteria for Adverse 
Events (CTCAE) and radiation induced skin reaction assessment scale 
(RISRAS) scores 
 
 
5.3.1 The overarching guiding question for this systematic review 
How effective are preventative practices and management interventions compared with the 2015 skin 
care guidelines (SCoR, 2015) for reducing radiation induced skin reactions (RISRs) in cancer patients 
undergoing external beam photon, proton beam or electron beam therapy? 
 
5.3.2 The review aimed to answer the following questions: 
● Is there new research evidence to support a change in advice given to patients undergoing 
radiotherapy about how to care for their skin before, during and after a course of 
radiotherapy in terms of washing, drying, deodorant or cream use? 
● Is there new evidence to support the use of topical agents to reduce RISRs? 
● Is there new evidence to support the use of dressings, medical devices, oral medications or 
barrier films to reduce RISRs? 
 
The review was based on a systematic search of a variety of resources. As evidence from 2011 to 2014 
was reviewed in the previous systematic review (Appendices 4, 5 and 6), and this is a continuation of 
that work, it was deemed appropriate to map out and replicate the initial search strategy and then, 
where appropriate, include any additional resources. 
 
A modified ‘pearl growing’ method was employed to support the development of the search terms 
for the review. This method uses multiple key documents to inform the bank of search terms and is 
deemed an appropriate method to be used for yielding results in a systematic review (Schlosser et al., 
2006). Table 3 identifies the two key documents used. 
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Table 3: Pearl documents 
Skin care advice for patients undergoing radical external beam megavoltage radiotherapy (2015) 
https://www.sor.org/learning/document-library/skin-care-advice-patients-undergoing-radical-
external-beam-megavoltage-radiotherapy-0 
Key terms: radiotherapy, radiation therapy, skin care, radiation dermatitis, skin reactions, 
evidence-based practice 
Chan, R., Webster, J., Chung, B., Marquart, L., Ahmed, M. and Garantziotis, S. 2014. Prevention 
and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis 
of randomized controlled trials. BMC Cancer. 14: 53. 
Keywords: radiation induced skin reactions, radiation dermatitis, systematic review, meta-
analysis, randomised controlled trials 
  
5.3.3 Search strategy 
A systematic search of the literature was undertaken using the following databases:   
● MEDLINE   
● CINAHL 
● PreMEDLINE 
● ScienceDirect 
● Index to Theses. 
 
A search of clinical trials included the following databases: 
1. The ISRCTN clinical trials database (http://www.controlled-trials.com) 
2. The U.S. National Institutes of Health trials register (http://www.clinicaltrials.gov) 
3. The Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au) 
4. The World Health Organization International Clinical Trials Registry Platform 
(http://www.who.int/trialsearch). 
 
Individual journal searches were performed on the following key journals: 
● Journal of Radiotherapy in Practice (JRP) 
● European Journal of Cancer (EJC) 
● Radiography 
● Journal of Medical Imaging and Radiation Sciences (JMIRS) 
● Journal of Medical Radiation Sciences (JMRS) 
● International Journal of Radiation Oncology • Biology • Physics (IJROBP) 
● Radiotherapy & Oncology 
● Practical Radiation Oncology. 
 
A secondary evaluation of the 2014 systematic review clinical trials table was undertaken to identify 
if any of the trials still open at the time of the last review had now been published. 
 
A search of the grey literature, including Index to Theses and conference papers, was undertaken to 
ensure publication bias was minimised, and a search of Google Scholar using a selection of the key 
search terms was also carried out to ensure no additional relevant research had been missed.  
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5.3.4 Key terms 
Key terms were searched using standard Boolean operators, wildcards and truncations (Table 4).   
 
Table 4: Key terms 
Aspect Key terms 
 Radiotherapy Radiotherapy, radiation therapy, irradiation   
Proton radiotherapy, proton therapy, proton beam therapy 
Photon therapy 
Electron therapy 
Stereotactic ablative radiotherapy (SABR) 
Immunotherapy in combination with radiotherapy 
Interventions Preventative measures 
washing with soap, deodorant, antiperspirant, topical agents, creams, 
oils, gels, emollients, E45®, aqueous cream, Calendula officinalis, 
steroidal cream, non-steroidal cream, StrataXRT®, Mepitel®, Mepilex®, 
barrier film, hyaluronic acid and trolamine, mometasone furoate cream, 
betamethasone cream, methylprednisolone, dexpanthenol, RadiaCare® 
gel, Aquaphor® ointment, qingdiyou medication, wheatgrass extract 
cream, sucralfate cream, shaving (dry) and electric shaving 
 
Management measures 
dressings, topical and medical applications, foam dressing, colloid 
dressings, hydrogel dressings, silver nylon dressings, Wobe-Mugos E®, 
oral zinc supplements, oral pentoxifylline, oral antioxidant, oral 
sucralfate suspensions, DermaSilk® 
Outcomes Skin reactions 
radiation effect, adverse effect, radiation dermatitis, erythema, moist (or 
dry) desquamation, skin reactions, RISR, radiation induced skin reaction, 
RTOG acute toxicity, Radiation Therapy Oncology Group toxicity, CTC, 
common toxicity criteria score, pain, itch(ing), redness, soreness, 
ulceration, burning, rash, swelling 
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Table 5: Inclusion/exclusion criteria 
Criteria Inclusion Exclusion 
Date range All literature from November 
2014 to October 2019 
Skin reactions caused by a pre-existing 
genetic or medical disposition 
Language All papers that have an English 
abstract 
Papers where either the full text is not 
available in English or the required detail of 
the study cannot be obtained directly from 
the authors in a translated format 
Focus of the research Papers that assess the use of a 
topical agent, dressing or 
intervention, and where the 
primary focus is skin reaction 
to photon or electron beam 
radiotherapy or proton beam 
therapy 
Rare skin reactions caused by topical agents 
or chemotherapy drugs 
Papers where the primary focus is the 
impact of an immobilisation device or 
radiotherapy planning technique on the skin 
reaction 
Types of studies Systematic reviews (SRs), 
randomised controlled trials 
(RCTs), non-randomised trials 
and case series 
Discussion papers and single case studies 
 
5.3.5 Quality assessment, data synthesis 
For the purpose of review, the following quality assessment approaches were used: 
● The RoB (Risk of Bias) tool was used to assess the quality of randomised trials and the 
ROBINS-I tool to assess the quality of non-randomised studies (Higgins and Thomas, 2019). 
● Case studies were not assessed for quality and not included in the summary tables. This 
data has only been used to inform further research recommendations. 
● Systematic reviews were assessed using the Scottish Intercollegiate Guidelines Network 
(SIGN, 2019) checklist for systematic reviews. 
 
Quality assessment was completed by three academic researchers, who were part of the core group, 
assessing study quality independently; two independent reviews were completed on each article 
included in the review. The review has been reported using the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) group guidelines (PRISMA, 2009) to ensure 
transparency and improve the quality of the reporting process (Figure 1). 
 
Initially articles were selected based upon their title relevance. Further selection was undertaken using 
the title and abstract and whether they matched the inclusion/exclusion criteria (Table 5).  
 
Data extraction was undertaken using a verified extraction tool. Quality assessment used the 
appropriate method depending on whether the study involved randomisation or not (see above).  
Data from each article was recorded and saved electronically in a summary evidence table 
(Appendices 7 and 8). Narrative synthesis has been primarily used to report study findings using the 
Centre for Reviews and Dissemination (CRD) guidelines and strategy (CRD, 2008). 
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5.4 Results  
 
Figure 1: PRISMA diagram 
 
 
Quality assessment using the appropriate RoB, ROBINS-I or SIGN quality assessment tool (Scottish 
Intercollegiate Guidelines Network, 2019) was undertaken. A total of 33 articles were available for 
review: 21 RCTs, two feasibility studies, nine non-randomised trials and one pilot study. 
 
Of the 33 studies included (n=33):  13/33 (39.4%) were assessed as having a high risk of bias; 6/33 
(18.2%) were assessed as having a moderate risk of bias; and 13/33 (39.4%) were assessed as having 
a low risk of bias. There was one pilot study not assessed for bias (Appendices 7 and 8). 
 
5.4.1 Ongoing trials 
In order to ascertain current research being undertaken in this field, a search of clinical trials databases 
was undertaken. The following studies were identified (Table 6). 
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Table 6: Ongoing trials  
Study title  Author(s)  Trial 
registration 
number 
Method  Anatomical areas 
  
Country/ 
hospital(s) 
Stage of study  
Effects of Herbal Products on Reduction of 
Radiation-induced Dermatitis in Breast 
Cancer Patients 
----- NCT02922244 
 
Randomised triple 
blinded  
Breast cancer Thailand  Completed July 
2018 
Laser Therapy for the Prevention of 
Radiodermatitis in Head and Neck Patients 
(DERMISHEAD) 
Prof Dr 
Jeroen 
Mebis 
NCT02738268 
 
Double blinded RCT Head and neck 
cancer  
Belgium  Recruiting  
Evaluating the Efficacy of Mepitel in Post-
mastectomy Breast Cancer Patients, and 
Examining the Role of the Skin Microbiome in 
Radiation Dermatitis 
Kimberly S 
Corbin  
NCT03519438 
 
Cohort study  Breast cancer Mayo Clinic USA Active, not 
recruiting  
Photobiomodulation for Breast Cancer 
Radiodermatitis Prevention. A Randomized 
Controlled Trial 
Francine 
Sgrott 
NCT04059809 
 
Randomised single 
blind controlled 
trial 
Breast cancer  Brazil  Recruiting  
StrataXRT vs Standard Clinical Practice for the 
Prevention of Acute Dermatitis in Patients 
Receiving Concurrent Chemoradiation for 
Head and Neck Cancers 
David Chia NCT03394417 
 
Blinded RCT Head and neck 
cancer  
Singapore Not yet 
recruiting  
Prophylactic Interventions in the 
Management of Radiodermatitis in Patients 
With Breast or Head and Neck Cancer: a 
Randomized Clinical Trial 
Elaine 
Barros 
Ferreira, RN 
NCT02247830 
 
Double blinded RCT  Breast cancer 
Head and neck 
cancer  
Brazil Active, not 
recruiting  
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Radiotherapy Related Skin Toxicity: Mepitel® 
Film vs. Standard Care in Patients With 
Locally Advanced Head-and-Neck Cancer 
Prof Dr Dirk 
Rades  
NCT03047174 
 
Non-blinded RCT  Head and neck 
cancer  
Germany  Completed, not 
published  
Topical Doxepin for Prevention and 
Management of Radiation-induced 
Dermatitis 
Golnaz 
Vaseghi 
NCT02447211 
 
Quadruple blinded 
RCT  
Breast cancer Iran  Recruiting  
Urtica Comp. Gel for Prevention and Therapy 
of Radiation Dermatitis (An Interdisciplinary, 
Interprofessional Phase II Randomized 
Controlled Trial in Patients With Breast 
Cancer) 
Gisa A 
Gerstenber
g, MD PhD 
NCT03494205 
 
Non-blinded RCT Breast cancer  Switzerland  Recruiting  
Utilization of Low Level Laser Therapy for 
Radiation Induced Dermatitis in Patients With 
Head and Neck Squamous Cell Carcinoma 
Karen 
Holeva 
NCT02384434 
 
Cohort study  Head and neck 
cancer  
USA   Recruiting 
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5.5 Discussion  
 
The results of the review are presented in four subsections. These subsections represent suitable 
groupings of research on the same or similar interventions for the prevention or treatment of RISRs 
as follows:  
 
1. Steroid creams  
2. Low-level laser (or photobiomodulation) therapy 
3. Barrier films  
4. Topical emollients 
 
In each subsection, a summary table shows the studies reviewed on that topic, highlighting whether 
the research found statistically significant improvements in RISRs or patient reported measures of 
discomfort.  
 
5.5.1 Steroid creams  
 
Table 7: Steroid cream studies 
 
(NS) not significant  
 
                 
Green= Low risk of bias, Orange= moderate risk of bias, Red=high risk of bias, White= not assessed as pilot study 
 
In the 2014 systematic review undertaken as part of the SCoR’s 2015 guidelines a number of studies 
investigated the use of topical steroids for the management of radiation dermatitis. Wong et al. (2013) 
made strong recommendations in their guidelines for the use of prophylactic topical steroids. In spite 
of this, some of the published research recommended exercising a degree of caution and a need for 
more work to be undertaken, particularly to determine any long-term implications of using steroids.  
 
The rationale for using steroid creams is based on the known anti-inflammatory properties of steroids. 
Six studies included in this review reported equal or positive outcomes in relation to the use of topical 
steroid creams (Table 7). However, both the studies by Erridge et al. (2016) and Fenton-Kerimian et 
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al. (2015) were at high risk of bias due to a lack of reporting or controlling for many patient or 
treatment related confounding variables e.g. patient BMI, smoking status, breast size, or use of bolus. 
No information was provided in either of the papers as to any stratification and/or blinding of the 
assessors, and no information on assessment of inter- or intra-rater reliability of skin assessment. The 
control used in the study by Erridge et al. (2016) for cohort one was aqueous cream, which may affect 
the overall outcome, as the previous SCoR 2015 guidelines recommended it only be used as a soap 
substitute not a leave-on moisturiser due to its reclassification in the British National Formulary. In 
addition, Tsang and Guy (2010) and Patel et al. (2013) recommended using a moisturiser that is sodium 
lauryl sulphate free. 
 
The studies by Ho et al. (2018), Sio et al. (2016) and Ulff et al. (2017a, 2017b) all reported statistically 
significant outcomes when using steroid creams and scored low for potential bias; all three were 
conducted on patients undergoing radiotherapy for breast cancer. The studies by Ho et al. (2018) and 
Sio et al. (2016) had a significantly lower rate of grade 2 or grade 3 (moist desquamation) using 0.1% 
mometasone furoate than the control arms. Ho et al. (2018) reported 43.8% vs 66.7% intervention vs 
control respectively (P=0.012) and a lower incidence of maximum grade radiation dermatitis, 
reporting 18.8% vs 33.3% (P=0.036) in their intervention arm. Yet lower rates of grade 2 dermatitis 
have been reported by others from just employing hypofractionated regimens. For example, Ahlawat 
et al. (2016) reported an incidence of 34% grade 2 radiation dermatitis and one patient with a grade 
3 RISR (n=83) when a dose fractionation of 36.63Gy in eleven fractions (followed by a four-fraction 
boost) was given. Similarly, Deantonio et al. (2010) reported acute RISR toxicity of grade 2 and above 
in 24% of their sample of patients undergoing whole breast irradiation using a hypofractionated 
regimen. 
 
There were no reported differences in patient reported outcome measures (PROMs) between the 
intervention and control arm for the study by Ho et al. (2018). However, longitudinal analysis by Sio 
et al. (2016) did show significant differences. There was good control of confounding variables in both 
studies, with assessors and patients blind to the intervention. However, the control arm in the study 
by Ho et al. (2018) used a cream containing ingredients that may have exacerbated skin reaction, 
including petroleum jelly and phenoxyethanol (which if used in large quantities can irritate the skin). 
Sio et al. (2016) did not use a control cream at all. The research reviewed from Ulff et al. (2017a, 
2017b) considered two publications. One study reported acute toxicity following administration of 
betamethasone 17-valerate cream. The second reported long-term follow-up data (average follow-up 
was six years) to evaluate late toxicity. The cohorts in both the studies were patients diagnosed with 
breast cancer. 
 
In the study of acute toxicity, Ulff et al. (2017a) aimed to test the hypothesis that preventative topical 
steroid treatment starting at the beginning of radiotherapy can ameliorate acute radiation dermatitis 
compared to a control moisturiser. Results from this study showed that the patients in the 
intervention (steroid cream) arm developed fewer skin reactions than those treated with a normal 
moisturiser (P<0.001) and this was regardless of the radiotherapy fractionation regimen used. 
However, the data clearly showed that patients treated with a hypofractionated (2.67Gy/fraction) 
course of radiotherapy had significantly lower acute toxicity than those treated with a conventional 
fractionation (2Gy/fraction). For those treated with hypofractionated regimens the incidence of grade 
3 toxicity was 7% for those using the moisturiser vs 0% in the steroid cream arm. The sample size in 
the hypofractionated group is small (n=61) and it is possible that the differences seen are related to 
other factors, including radiation planning differences such as volume of tissue receiving 107% of the 
dose, or patient BMI status (slightly more patients had a BMI of 25 or more in the moisturiser arm 
compared with the steroid cream arm, 31% vs 26% respectively). All these variables are known to have 
an impact on RISRs. The differences observed between intervention and control for those treated with 
a hypofractionated regimen could be because the moisturiser used in the control arm, 
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Essex® cream (essentially aqueous cream), is an emollient no longer recommended for use as a leave-
on topical cream because of the potential to cause irritation. 
 
The long-term follow-up (average follow-up was six years) analysis by Ulff et al. (2017a) found no 
evidence of skin atrophy in any of the 60 patients included in the original analysis. There were also no 
significant differences between normal tissue and the tissue treated with steroids. Only ten patients 
(17%) had noticeable skin changes and three (5%) were reported as having altered skin pigmentation. 
 
It is worth noting that not all studies assessing steroid creams included a PROM within their study 
design, and this is something the review team would strongly recommend. Although all clinical 
reporting tools were recognised and validated, a number of different combinations and review 
schedules were utilised, again making it difficult to draw comparisons across studies. Dose 
fractionation regimens across the studies that included breast cancer patients also varied. It is worth 
noting that Ho et al. (2018)1 and Sio et al. (2016), and the studies by Ulff et al. (2017a, 2017b), all 
utilised up to and in excess of 50Gy for their radiotherapy schedules; we know that conventional 
fractionation schedules result in a higher incidence of acute RISRs compared with hypofractionated 
regimens (typically 40Gy in 15 fractions). 
 
In summary, of the studies assessed as having a low or moderate risk of bias, all samples involved the 
assessment of steroid cream on patients undergoing radiotherapy for breast cancer. The positive 
outcomes identified are confounded by the use of conventional dose fractionations (e.g. 50Gy in 25 
fractions) compared with the UK consensus guidelines recommendation of hypofractionated regimens 
(i.e. 40Gy in 15 fractions) where it is known that acute toxicity is lower in the hypofractionated 
schedules (Hickey et al., 2017),  as well as other possible confounding variables such as BMI, volume 
of tissue receiving 107% (or 110%) of the prescribed dose or the use of a cream in the control arm that 
may exacerbate skin irritation (such as aqueous cream). For this reason, based on the studies reviewed 
these guidelines do not recommend the early use of steroid creams as a preventative intervention for 
women undergoing breast irradiation, given that most women undergoing breast or chest wall 
irradiation in the UK would be prescribed a hypofractionated regimen.  
 
Instead it is recommended that steroids are reserved only for those patients identified as being at a 
high risk of developing a high-grade RISR i.e. moist desquamation (grade 3). There is likely to be a 
higher risk of an RISR when a bolus is used, the patient is a smoker (and is unable to give up smoking 
during radiotherapy), the total dose of radiation is >40Gy and the patient has a high BMI. There needs 
to be more high-quality research to identify the hazard ratios for these identified high-risk variables. 
The review team would particularly recommend more research to correlate planning parameters such 
as V107/V110, and acute skin toxicity, in order that an evidence-based risk stratification algorithm can 
be developed to support the appropriate preventative use of steroid creams. 
 
It is important to note that primary care practitioners may be recommending the use of topical 
hydrocortisone in a related context for patients having radiotherapy with various comorbidities. This 
is however beyond the scope of this document. 
 
5.5.2 Low-level laser or photobiomodulation therapy studies  
Photobiomodulation therapy (PBMT) is the application of low-power infrared light to the skin to 
stimulate the natural healing process that may be interrupted by the impact of radiation interactions. 
The purpose of PBMT is to reduce inflammation and pain that is associated with the RISR, but 
researchers are also investigating whether PBMT can be used as a preventative tool to reduce or delay 
the development of acute radiation dermatitis.  
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Table 8: Low-level laser therapy studies 
 
 
Two studies investigated the use of photobiomodulation therapy (PBMT) to reduce or prevent the 
incidence of moist desquamation or radiation dermatitis; both studies involved samples of patients 
treated for breast cancer. Both Robijns et al. (2018) and Strouthos et al. (2017) demonstrated a 
statistically significant reduction in moist desquamation or radiation dermatitis when compared to 
either a placebo intervention (Robijns et al., 2018) or no intervention at all (Strouthos et al., 2017). 
The study by Robijns et al. (2018) demonstrated a significantly higher incidence of RISR in the control 
arm at the 66Gy time point compared to the intervention arm (P= 0.004). 
 
Strouthos et al. (2017) also reported a lower incidence of radiation dermatitis in the PBMT group 
compared to control (P=0.0211). In addition, Strouthos et al. (2017) analysed pain level and intensity 
using a weekly patient reported visual analogue scale (VAS) and reported pain intensity in the PBMT 
group was significantly lower (P=0.003). Both studies were assessed as having a low risk of bias. 
However, PROMs were not studied by Robijns et al. (2018). The review team would strongly 
recommend the inclusion of PROMs in any future trials.  
 
In summary, the use of PBMT is an emerging area, as noted by the two studies included in this review, 
with a number of ongoing trials that are currently recruiting (Table 6). There are some potential 
concerns about the long-term impact of PBMT and further research on this is needed. Both the studies 
included in this review involved samples of patients treated for breast cancer with total radiation 
doses of 50Gy and above, based on conventional dose fractionation schedules. As already indicated, 
there is sufficient evidence that hypofractionated regimens for breast cancer (compared with 
conventional fractionation) result in a lower incidence of grade 2 or 3 radiation dermatitis. It is not 
clear whether the benefits from PBMT presented from these two studies would be replicated in 
patients receiving whole breast radiotherapy with hypofractionated schedules. Therefore, these 
guidelines do not recommend the use of PBMT at this time. The work in this field is promising but 
future research needs to replicate these benefits reported with conventional dose fractionation in 
samples where modern dose fractionation schedules are employed, or demonstrate benefits in 
patients where there is likely to be a high risk of RISR, such as those treated with bolus or concomitant 
chemotherapy, or where there are skin folds. 
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5.5.3. Barrier films  
A barrier film is a thin, often transparent, self-adhesive sheet. Barrier films may offer a protective layer 
to the surface layers of the skin that may be damaged by radiation treatment. By preventing further 
trauma or risk of infection, barrier films are proposed as a treatment or preventative measure for 
RISRs.  
 
Table 9: Barrier film studies  
 
Seven studies were identified that investigated the use of a barrier film or dressing to reduce skin 
reactions; five were conducted with patients diagnosed with a primary breast cancer, one with 
patients treated for a head and neck cancer, and one with patients treated for prostate cancer.  
 
Rades et al. (2019) and Møller et al. (2018) investigated the use of Mepitel film in patients with a 
head and neck cancer and breast cancer respectively. Rades et al. (2019) used their standard skin care 
protocol as the control while the control group in Møller et al. (2018) received 2–5% urea and fatty 
acid cream. These differences in the comparators may influence any differences observed between 
study groups. Neither study reported statistically significant improvements in reaction when using the 
Mepitel® film.  
 
In the study by Rades et al. (2019), the study was halted at the point of the interim analysis (when 
some patients had received a total dose of 50Gy). The premature closure of the study was due to a 
high proportion of the sample being unable to tolerate the product (46.4% n=13).  
 
Common toxicity criteria (CTC) scores in the Møller et al. (2018) study showed no significant difference 
between intervention and control in the incidence of grades 1 to 3 skin toxicity at the end of treatment 
or at 14 days post treatment. However, the PROMs showed significant differences in favour of the 
barrier film, with patients stating that the film was comfortable and that it made a difference. At 14 
days, pain was reduced (P=0.001), and sensitivity of the skin, as well as itching, was also reduced 
(P<0.01).  
The remaining five studies investigated a variety of different products. Schmeel et al. (2018) and 
Censabella et al. (2016) conducted studies into hydrofilm and hydroactive colloid gel respectively in 
patients undergoing radiotherapy for breast cancer. Schmeel et al. (2018) compared prophylactically 
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applied hydrofilm dressings with standard skin care (using moisturising 5% urea) and reported a 
statistically significant decrease in the severity of mean RTOG scores, with a mean of 0.35 compared 
with the control mean of 1.33 (P<0.001). Unfortunately, there was a high withdrawal rate in this study 
and intention-to-treat analysis does not appear to have been employed.  
 
Censabella et al. (2016) conducted a non-randomised single centre study that used two historical 
control groups as comparators. Significant reductions in the onset of radiation induced moist 
desquamation using the hydroactive colloid gel were reported, an incidence of 6.9% in the 
intervention arm vs 35.1% and 12.6% in the historical control arms.  However, this study was assessed 
as having a high risk of bias due to a lack of control of potentially confounding variables. The data was 
also censored at 50Gy because of differences in the use of electrons for the boost across the 
intervention and control arms, there was no blinding of assessors and no reporting of inter- or intra-
rater reliability of skin assessments. 
 
Chan et al. (2019) and Lam et al. (2019) both investigated the use of barrier film wound dressings (e.g. 
StrataXRT® or alternative product) in patients undergoing radiotherapy for head and neck cancer, lung 
cancer and breast cancer. In these two studies the control groups either had the standard local care, 
which included using Glaxal Base® cream, similar to aqueous cream (Chan et al., 2019), or sorbolene, 
a paraffin-based cream (Lam et al., 2019). Neither study included PROMs and both were assessed as 
having a moderate risk of bias. In the study by Chan et al. (2019), at the end of treatment grade 2 skin 
reactions were identified in 80% of patients in the StrataXRT® arm and grade 3 in 28%, compared with 
91% and 45% respectively in the control arm. After controlling for the cancer drug cetuximab, the 
StrataXRT® arm had a 12% lower risk of experiencing grade 2 skin toxicity (RRR=0.876, 95% CI 0.778-
0.987) and a 36% lower risk of developing a grade 3 reaction (RRR=0.648, 95% CI 0.442-0.947) P=0.025. 
 
In the study by Lam et al. (2019), patients with breast cancer in the sample were treated with either a 
conventional fractionation (50Gy in 25 fractions) or a hypofractionated biologically equivalent dose. 
There was no statistically significant difference in PROMs for burning, pulling and tenderness for those 
where the barrier film was applied to the medial half of the chest, except for itching, where a 
significant improvement was seen (1.14 vs 2.06 barrier film vs control cream P=0.035). For cases where 
the barrier film was applied to the lateral half, only for burning was there a statistically significant 
difference in patient reported scores, 0.92 vs 1.83 (P=0.047, no confidence intervals presented). There 
was no significant difference seen between barrier film and standard local care for time taken to 
develop grade 2 radiation dermatitis. In those patients where the barrier film was applied to the lateral 
half of the chest, a grade 2 or more radiation dermatitis was reported in 17.3% of cases compared 
with 27.6% in the no film half (P=0.041). For those where the barrier film was applied to the medial 
half, a grade 2 dermatitis was reported in 17.2% of cases and 9.6% for no film (P=0.76). Post treatment, 
no difference was seen in grade 2, or above, scores for barrier film vs no film. Inter-rater reliability of 
skin assessments was poor. Intra-class correlation coefficient was r=0.45, indicating possible variability 
in the assessment of skin scores. 
 
In summary, the review team acknowledge the difficulty of trying to implement a strong research 
design when using a barrier film as an intervention. For example, blinding assessors (or patients) to 
the intervention is difficult and there needs to be considerable care to ensure comparability in areas 
covered (or not covered) by the barrier film. Unfortunately, many of the studies reviewed in this 
section were considered to have some moderate or high risk of bias due to potentially confounding 
variables, lack of blinding of assessors, or use of a cream in the control arm that may have exacerbated 
skin irritation in those arms of the study. In addition, the high rate of intolerance of the barrier film in 
the study by Rades et al. (2019) leads to questions about the value of barrier films in patients having 
radiotherapy for head and neck cancer. Hence, the review team do not recommend use of barrier 
films for patients undergoing breast irradiation, particularly where hypofractionated dose schedules 
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are employed, or for patients receiving radiotherapy to the head and neck. Recommendations for 
improvements to study design for future research with barrier films are presented along with general 
recommendations for future research. 
 
More evidence is also required on the potential practical implications of using barrier film in 
radiotherapy, to include potential dose inhomogeneity and inconsistency in applying and maintaining 
the film during treatment in the immobilised position. 
 
5.5.4 Topical emollients  
Topical emollients are used commonly to prevent RISRs or to provide comfort for patients once a 
reaction has occurred. As radiation damages the basal cell layer of the skin, the normal desquamation 
of cells and growth of replacement cells are both interrupted and dehydration of the skin occurs. 
Topical emollients are used to try to hydrate the skin and to ameliorate feelings of itching and 
soreness.  
 
Table 10: Topical emollient studies  
 
 
Green= Low risk of bias, Orange= moderate risk of bias, Red=high risk of bias, White= not assessed as pilot study 
 
A total of 15 studies investigated the use of a topical emollient. Across the studies 14 different 
products were investigated, including boron gel (Aysan at al., 2017), heparinoid (Sekiguchi et al. 2015 
and 2018), emu oil (Rollman et al., 2015),  high-quality aloe (Hoopfer et al., 2015), an emulsion 
containing melatonin (Ben-David et al., 2016), and  an olive oil-based product (Cui et al., 2015). 
Ten out of the 15 studies were assessed as having either a moderate or high risk of bias, with only four 
rated as low risk; one study was not assessed as it was a pilot study. Both Table 10 and the summary 
of evidence table (Appendices 7 and 8) demonstrate the breadth of choice and timing of outcome 
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measurements, the controls used and the person(s) assessing the skin reactions. Only seven of the 
studies used a PROM, and of those only two demonstrated statistically significant outcomes in either 
clinician reported or patient reported measures. Two studies were assessed as having a low risk of 
bias and statistically significant outcomes (Karbasforooshan et al., 2018; Ben-David et al., 2016). 
Karbasforooshan et al. (2018) studied the use of silymarin, a herbal medicine (dried extract of Silybum 
marianum, also known as milk thistle) given as a gel. At week 5 grade 1 radiation dermatitis was 
reported as 100% in the silymarin group, while in the control group grade 1 was reported as 55%, 
grade 2 as 40% and grade 3 as 5% (P=0.003). While these results look promising, a larger study is 
needed to replicate this data before the results and this product could be recommended for use in 
practice.  
 
Ben-David et al. (2016) investigated a melatonin-containing emulsion in patients treated for breast 
cancer. The highest grade of radiation dermatitis was grade 2 (15% of cases). During treatment, no 
significant differences were observed between the two groups for clinician assessed skin toxicity in 
terms of dryness, erythema, tanning, swelling, rash, desquamation, bleeding, cellulitis and 
hyperpigmentation. For weeks 5-7 there was an interaction between time and group in favour of the 
melatonin emulsion group (P=0.049). At two weeks follow-up (week 7) the melatonin group were 
reported as having 59% grade 0, 41% grade 1 or 2, vs 11% grade 0 and 90% grade 1 or 2 in the placebo 
group (P=0.03). No differences in patient reported subjective measures were identified between the 
intervention or control groups. Patients in this study received a conventional fractionation (50Gy in 
25 fractions) and further research is needed to identify whether the benefits reported in this study 
could be replicated in cases where a hypofractionated regimen is adopted. 
 
In summary, there is no strong evidence to support or recommend any of the emollients reviewed. 
There are some promising interventions identified in the studies reviewed, but further research is 
required to replicate the results in wider populations or in samples using modern dose fractionation 
schedules before recommendations for use in practice can be made. 
 
5.5.5 Other studies 
Two further studies (Appendix 9) include one large multi-centre randomised placebo-controlled trial 
of oral curcumin C3 complex (n=283 intervention, n=295 placebo). This study was unable to identify 
any beneficial effects of using oral curcumin on levels of radiation dermatitis in the sample of patients 
with breast cancer studied (Ryan Wolf et al., 2018).  
  
The second study (Appendix 9) is a dosimetry study on a phantom to test the dosimetric impact of 
aluminium based deodorant versus non-aluminium based deodorant. Surface dose was measured in 
tissue equivalent material using optically stimulated luminescent dosimeters (OSLDs). Two 
antiperspirants containing aluminium, both commercially available, were tested; one had 15% 
aluminium zirconium tetrachlorohydrex glycine and the other contained 25%. Eight roll on 
applications were applied to a 5x5 paper square to ensure a thick coating with a control of no coating. 
OSLDs were placed below the paper and 6MV photons were delivered using 200mu at 100cm SSD at 
angles 0, 30, 60 and 90 degrees using a Truebeam© linear accelerator. The OSLDs were replaced after 
each exposure fraction and the same process repeated with the extra strength antiperspirant. No 
difference in measured surface dose was seen between no antiperspirant and the two strengths of 
aluminium based antiperspirants tested (Baumann et al., 2017). These results provide further support 
to reassure patients that antiperspirant can be used safely during radiotherapy without concerns that 
it may increase the risk of radiation induced dermatitis. 
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6. Conclusions  
 
Despite reviewing a significant amount of published evidence, still very few definitive 
recommendations can be made with respect to the optimal intervention for the management or 
prevention of radiation induced skin reactions.  
 
The use of steroid-based creams is the one area where evidence shows consistent positive benefit 
across studies assessed as having a low risk of bias. Studies such as Ulff et al. (2017 (a) and (b)), which 
have reported no significant long-term impact, offer reassurance for their use in specific cases. 
However, it is important to note that even in cases where positive results were presented, those 
benefits may not be translated to cases where hypofractionated dose schedules are employed or 
where the comparator does not include a cream considered to potentially cause irritation. Therefore, 
the use of steroid-based cream is only recommended for RISR prevention in patients assessed as being 
at high risk of developing a high-grade radiation dermatitis. 
 
Barrier films and dressings still seem to be widely used. However, the results of studies included in 
this review are not significant enough to recommend a change in practice. This is partly due to 
limitations in the design of some of the studies, as well as the variety of products investigated, the 
high drop-out rate in some cases (due to tolerability of the product), and the limited positive outcomes 
presented in some studies.   
 
Photobiomodulation therapy (PBMT) is an emerging intervention to reduce RISRs. The use of PBMT 
has been recognised in other areas of radiotherapy toxicity, such as the treatment of oral mucositis 
and lymphoedema. Further research is needed on the long-term effects of the use of PBMT as a 
prophylactic intervention for RISRs before it could be recommended for widespread use, and future 
research should consider assessment on patients having modern dose fractionation schedules who 
are at higher risk of developing radiation induced skin reactions. 
 
A significant amount of research is still being undertaken to investigate topical emollients, as shown 
by the number of such studies included in this review and trials currently recruiting participants. 
However, these are often single institution studies on one particular product, and as more enter the 
market the research base is spread across a number of small sample studies of different products. 
Hence, the review team are unable to draw confident conclusions as it is not possible to pool data in 
the form of a meta-analysis. Therefore, there is still not enough strong evidence to recommend or 
endorse any one specific product.  
 
In addition, some of the issues highlighted by the review team with respect to study design and 
analysis only add to the uncertainty, with a lack of reporting or stratifying for many of the possible 
patient-related variables as well as variations in radiotherapy technique, planning and dose 
fractionation regimens.  
 
There may be benefits to risk stratifying patients to allow those at high risk of developing severe (or 
high grade) radiation dermatitis to be treated with appropriate interventions. For example, there may 
be cases where it is appropriate for patients to use steroid cream, but currently there is limited data 
to confirm exactly which groups of patients with specific levels of risk would benefit. Choice of a 
control or placebo also requires careful consideration and justification within the research method. 
As identified in this review, some researchers adopted a cream for the comparator that may 
exacerbate skin irritation experienced by the control arm and thus may invalidate or limit the usability 
of the study results.   
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A wide variation in the timing of the assessment of skin reactions was observed, making it difficult to 
make comparisons across studies, and very few of the studies reviewed included assessment of inter- 
and intra-rater reliability of the clinician assessed reactions; where this was undertaken, poor 
reliability of the assessment process was evident. Furthermore, in the topical emollient studies 
reviewed, patient adherence to the intervention was rarely assessed; patient compliance is an 
important consideration when considering changes to practice, along with cost and resource use. 
 
Many of the studies reviewed included patients treated for breast cancer prescribed 50Gy in 25 
fractions in the adjuvant/post-operative setting. Evidence from good quality clinical trials has shown 
that hypofractionated regimens (e.g. 40Gy in 15 fractions), as recommended by the NHS England 2016 
Clinical Commissioning Policy: Radiotherapy after primary cancer for breast cancer and the UK 
consensus guidelines for breast cancer radiotherapy, would reduce the incidence of acute skin 
toxicities compared with conventional (50Gy in 25 fractions) dose regimens.  
 
In light of these concerns, the review team have therefore produced a set of recommendations for 
skin care research design, based on the assessment of the existing literature. In order to move the 
evidence base forward for interventions to prevent or treat RISRs we need high-quality research 
studies and we would recommend researchers in this field try to implement some of the 
recommendations when designing future studies (see section 9). 
 
The review team recommend future research focuses on identifying the relationship between specific 
radiotherapy planning parameters (e.g. V107/V110) and acute skin toxicity as well as specific high-risk 
factors that can be attributed to a high-grade RISR in order that a risk stratification algorithm can be 
developed to support appropriate decision-making in practice. 
 
The current methods used to evaluate skin toxicity (clinical examination, visual inspection and patient 
reported symptoms) are all objective. Therefore, collecting data about radiation dermatitis and 
comparability of studies is difficult. In their study, Saednia et al. (2020) focused on the physiological 
changes associated with radiation induced dermatitis in breast cancer patients, such as inflammation, 
which may increase body-surface temperature and can be detected by thermal imaging. They 
identified quantitative thermal imaging markers that were used in supervised machine learning to 
develop a predictive model for radiation dermatitis. Saednia et al. (2020) concluded that quantitative 
thermal imaging has the potential to reduce the biases in current grading systems. Such technologies 
require further research but may be used to predict those patients who require support and symptom 
management. 
 
Faithfull et al. (2002) noted “a growing awareness of the need for evidence based practice in 
radiotherapy” but that there are “well documented disparities between clinical practice and research 
findings”, reflecting that supportive care is often based on no, little, or poor evidence. Comparing data 
across radiotherapy skin care studies is difficult as often the methods used are unclear, patient 
randomisations differ, different skin assessment scales are used, and follow-up data is inconsistent 
(Kedge, 2009). The findings from SCoR surveys and the survey by Nisbet et al. (2018, 2019) would 
support such a view. 
 
The surveys highlighted that few departments are following updated national guidelines and 
undertaking baseline assessment of a patient’s current skin condition. Despite papers emphasising the 
potential risk factors (Russell et al., 1994; Porock and Kristjanson, 1999; McQuestion, 2011) that may 
exacerbate a skin reaction, 52% of departments (SCoR, 2014) stated they did not record this 
information. Without the collection of such data it is difficult to attain a complete picture of the extent 
of radiotherapy induced reactions, which will be essential for improved research and skin care studies. 
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Furthermore, 49% of departments (SCoR, 2014) failed to assess and record skin care products 
currently being used by patients. 
 
Linking with other sectors of care, tissue viability nurses (TVNs) or their equivalent, and district nursing 
staff with an understanding of radiation induced skin reactions would strengthen improved 
communication. Understanding and consistency of radiotherapy skincare across the care pathway is 
needed to reduce patient and staff confusion (Harris, 1997; Cumming and Routsis, 2009).   
 
A main area of variation across departments relates to washing instructions and the use of soap and 
deodorant (also confirmed by other studies by Barkham, 1993; Lavery, 1995; D'Haese et al., 2009). 
The traditional patient advice of ‘not to wash’ the affected area with soap and water, or even to use 
water alone and no soap, is still given, despite updated evidence that this is unnecessary and there 
should be no restriction to using a specific type of soap (Campbell and Illingworth, 1992; Burch et al., 
1997; Westbury et al., 2000; Roy et al., 2001; Rudd and Dempsey, 2002; Aistars, 2006; Bolderston et 
al., 2006; Aistars and Vehlow, 2007; Butcher and Williamson, 2012). 74% of departments (SCoR, 2014) 
reported washing restrictions (i.e. either no soap or limited to specific brands such as Simple® and 
Dove®); this has the potential to control unnecessarily the choices and preferences that an individual 
may have. 
 
Expecting patients to follow traditional practice advice of ‘not to wash’ and ‘not to use deodorant’, 
may affect their social wellbeing. For example, breast cancer patients who are advised not to use a 
deodorant often cite this as one less area of control they have in their life and they note concern 
regarding body odour (Komarnicki, 2010). In the past it was felt that the metallic compounds, 
particularly aluminium, within deodorants might cause a secondary radiation effect (Korinko and 
Yurick, 1997). However, more recent studies contradict this advice as unfounded and outdated 
(Bennett, 2009; Watson et al., 2012; Wong et al., 2013; Lewis et al., 2014). Currently, 55% of 
departments advise patients not to use a deodorant under the axilla of the affected side being treated 
for breast cancer (SCoR, 2014). Patient compliance with these requests has not been assessed 
(Gosselin, 2010).  
 
There appears to be a propensity to continue with familiar traditional practice rather than an openness 
to test the effectiveness of products. With the introduction of more expensive skin care treatments to 
a potentially vulnerable patient group, health care professionals need to consider if such products are 
more effective than their cheaper comparators and why they choose one product over another (Fisher 
et al., 1999; Fisher et al., 2000; Pommier et al., 2004; Swamy et al., 2009).  
 
An evaluation of treatment aftercare also requires review to ensure local continuity of care across the 
pathway; this is a general need highlighted by a Department of Health cancer patient experience 
survey (DH, 2013).  
 
Radiation induced skin reactions can be uncomfortable and distressing, thereby affecting a patient’s 
quality of life (Lawton and Twoomey, 1991). Skin care advice to patients undergoing external beam 
megavoltage radiotherapy in the UK is varied. Currently, some of the skin care provided may not 
alleviate the problem and indeed may even cause skin irritation. This area of patient care is time 
consuming and expensive, therefore it is important to understand what is being done and why (Harris, 
2002b).  
 
7. Guideline recommendations  
 
Overall, the evidence base is not strong enough to either support or refute the use of any particular 
product for topical application. However, as Gosselin et al. (2010) noted, “patients prefer to take 
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action rather than do nothing”, so the focus for skin care should be on alleviating symptoms and 
providing comfort.  
 
Therefore, the following eight key principles of effective skin care management are recommended 
(Appendices 10 and 11): 
 
1. Knowledge of intrinsic and extrinsic factors that may affect the development and severity of 
radiation dermatitis. Prior to the start of radiotherapy, patients should be identified as being at 
low, medium or high risk based on intrinsic and extrinsic factors. 
2. Documentation of current skin care regimen and existing skin conditions, including sensitivities 
and allergies to certain products. 
3. Use of a standardised tool for radiation dermatitis assessment for all patients undergoing a 
course of radiotherapy (RTOG is recommended; see Table 11). Using the agreed validated tool 
and scoring criteria, radiotherapy departments should standardise the initial assessment and 
continued regular monitoring of skin reactions, and ensure that these are recorded.  (Cox et al., 
1995; Campbell and Lane, 1996; Harris, 2002 (a) and (b); O'Shea et al., 2003). 
4. Adherence to a standardised assessment process that includes a baseline assessment and 
weekly assessments during treatment using the standardised assessment tool. 
5. Mandatory local training for all staff assessing skin toxicity, to ensure accurate reporting and 
maintenance of consistent management protocols. 
6. Regular audit of skin reactions to collate accurate data on frequency and severity. 
7. An emphasis on empowering patients to use products they are familiar with and to self-monitor 
their skin, being proactive to improve comfort and minimise the risk of developing severe skin 
reactions. Recording of patient acceptability/satisfaction and compliance with skin care advice 
is recommended as such information can be used to evaluate the appropriateness of skin care 
products for future patients (Harris, 1997; Noble-Adams, 1999; Gosselin, 2010). 
8. Testing within a well-designed randomised controlled trial any new product or device designed 
to reduce radiation dermatitis, before its implementation. 
 
Before radiotherapy begins (baseline assessment) 
• Formally assess and document RTOG score (Table 11). 
• Discuss and document the condition of the skin on and around the site of treatment. 
• Ensure any pre-existing skin conditions, such as infection, sunburn, eczema and psoriasis, are 
recorded, even if they currently appear latent. 
• Discuss and document patients’ skin care routines, including any products that are already being 
used for a medicinal nature (e.g. creams for eczema, such as hydrocortisone). 
• Assess, discuss and document intrinsic and extrinsic factors, providing appropriate support and 
information (e.g. smoking cessation, extra care if skin folds in the treatment area). Those 
patients with intrinsic or extrinsic influencing factors are at a higher risk of developing a 
significant skin reaction and should therefore be monitored frequently. Comorbidities, such as 
diabetes, cardiovascular disease and hypermobile Ehlers–Danlos syndrome (hEDS), may also 
increase the likelihood of a skin reaction during radiotherapy and should be recorded. 
• Provide self-care advice. Education and health promotion strategies and interventions given to 
patients before treatment, such as nutritional advice and smoking cessation, would be 
beneficial and are advised (Wells et al., 2004; Kraus-Tiefenbacher, et al., 2012; Sharp, et al., 
2013 (a) and (b)). 
• Discuss the likelihood of radiation dermatitis developing and the possibility of permanent 
radiotherapy-related side effects to the skin, e.g. increased skin sensitivity, hyperpigmentation 
or hypopigmentation, and what precautions to take. For example, advise patients to reduce sun 
exposure to the treatment area and to use sunscreen with SPF50 (sun protection factor 50). 
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During radiotherapy 
Throughout radiotherapy, the skin should be checked every day and patients should be asked if they 
have noticed any changes to their skin. The following assessments are recommended on (at least) a 
weekly basis (Fisher et al., 2000; Richardson et al., 2005; NHS Quality Improvement Scotland, 2010). 
• Assess, discuss and document any changes to the patient’s skin or skin care routines. 
• Encourage self-monitoring of skin changes and support documentation and discussion of these 
with the radiotherapy team. 
• Ask about any symptoms experienced, including pain, itching or sleep disturbance. 
• Formally assess and document the RTOG score (see Table 11). 
• Provide advice and support to promote comfort (see the summary information leaflet 
Radiotherapy Skin Reactions: Information for Patients in Appendices 12 and 13). 
• Consider over-the-counter or prescription medicines such as analgesics as appropriate.  
 
At the end of radiotherapy 
• Inform patients of the potential for skin reactions to worsen and ‘peak’ around 10–14 days after 
the last treatment session. 
• If patients require ongoing wound management, ensure this is communicated to primary care 
teams. 
• Encourage patients to contact the radiotherapy department or clinical nurse specialist if they 
have ongoing skin reactions that they are concerned about or that are not as expected.  
• Establish effective, ongoing liaison with community care/GP services on post treatment skin 
(and other) care (Harris, 1997; Cumming and Routsis, 2009; SCoR, 2011a). 
• Explain the possibility of permanent radiotherapy-related side effects to the skin, e.g. increased 
skin sensitivity, hyperpigmentation or hypopigmentation, and what precautions to take. For 
example, advise patients to reduce sun exposure to the treatment area and to use sunscreen 
with SPF50 (sun protection factor 50). 
 
Late effects of radiotherapy 
There is a small risk that patients may have a delayed skin reaction months or years after their 
treatment. There is an increased risk for patients who received systemic anti-cancer therapy (SACT) in 
addition to radiotherapy. Patients with long-term complications may be encountered at follow-up 
clinics, in the community, or when being seen for re-treatment. Examples of late effects include: 
• fibrosis 
• lymphoedema 
• cellulitis  
• telangiectasia. 
 
These late effects can impact on the quality of patients’ lives and may not resolve over time; therefore, 
they should be included in any local site-specific patient information where particularly relevant. 
Referral to a late effects clinic, dermatologist or appropriate lymphoedema management service may 
be required.   
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Table 11: Adapted Radiation Therapy Oncology Group (RTOG) acute radiation dermatitis grading 
criteria 
 
Grade 0 Grade 1 Grade 2a Grade 2b Grade 3 
No visible change to 
the skin 
 
Faint or dull 
erythema 
 
Mild tightness of the 
skin and mild itching 
may occur. 
Tender or bright 
erythema 
 
Skin may feel tighter, 
itchy and/or sore.  
Patchy moist 
desquamation 
 
Areas where skin has 
broken down can be 
seen. Yellow/pale 
green exudate may 
be visible on the 
surface. Soreness and 
oedema are evident.  
Confluent moist 
desquamation 
 
More pronounced 
areas of broken skin 
can be seen. 
Yellow/pale green 
exudate are visible. 
Soreness and oedema 
are evident.  
ASSESSMENTS 
Weekly assessments and RTOG score Daily assessments and RTOG score 
AIMS OF CARE 
 To promote hydrated skin and maintain skin integrity 
 To promote comfort 
 To reduce risk of complications of further 
trauma and infection 
 To promote comfort 
GUIDANCE 
MOISTURISE: 
Advise the patient to continue moisturising with preferred products. 
If the patient is not already using a moisturiser, advise them to start. 
 
ENCOURAGE SELF-CARE: 
Discuss self-care guidelines and ensure that the patient has sources of 
information to refer to, including ‘Radiotherapy skin reactions - 
Information for patients’. 
 
STEROID OR CORTISONE CREAMS: 
Steroid or cortisone creams should only be used following advice from 
an independent prescriber or from staff qualified to dispense 
medication under patient group directions (PGDs). Contraindications 
for using these creams are broken skin or signs of infection. 
 
ANALGESIA: 
Ensure adequate analgesia is prescribed for the patient if needed. 
 
IF THE SKIN BREAKS: 
Patients should be advised to discontinue using any cream and should 
be advised on, or provided with, appropriate dressings. If there are 
signs of infection, undertake screening. Increase skin assessments to 
daily frequency. Seek further advice, if required, from a practitioner 
trained in radiotherapy induced skin reactions and wound care or tissue 
viability. 
MOISTURISE: 
Continue to apply moisturiser to skin within 
the treatment field that is still intact. 
 
ENCOURAGE SELF-CARE: 
Discuss self-care guidelines and ensure that 
the patient has sources of information to refer 
to. 
Follow skin care guidelines and ensure patient 
has information sources to refer to.  including 
‘Radiotherapy skin reactions - Information for 
patients’. 
 
 
DRESSINGS: 
Use appropriate dressings/products on broken 
skin, e.g. non-adhesive, silicone low adhesion. 
Do not use paraffin/petroleum jelly-based 
products or gentian violet. 
 
ANALGESIA: 
Ensure adequate analgesia is prescribed for 
the patient if needed. 
 
INFECTION SCREENING: 
Take a swab if there are signs of infection and 
arrange antibiotic treatment if infection is 
indicated. 
If you are unsure, seek advice from the wound care team, tissue viability specialists or dermatology. 
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Summary of skin care advice for patients and staff 
To reduce friction to the treatment area, patients should be advised to: 
• wash the skin gently with soap and water and gently pat dry (Aistars, 2006; Bolderston et al., 
2006; Aistars and Vehlow, 2007; Butcher and Williamson, 2012; Wong et al., 2013) 
• wash hair gently with usual shampoo (if the scalp is in the treatment field) but not to dry it 
with a hairdryer (Westbury et al., 2000; Bolderston et al., 2006). 
• avoid rubbing, shaving (if possible), and using heat and cooling pads/ice, wax for hair removal 
and all hair removing creams/products, and adhesive tape (Harris, 2002 (a) and (b); Gosselin, 
2010). 
 
To reduce irritation in the treatment area, patients should be advised to: 
• use a moisturiser that is preferably sodium lauryl sulphate free (Tsang and Guy, 2013; Patel et 
al., 2013) and avoid zinc oxide-based creams (Fackrell et al., 2013) 
• avoid topical antibiotics unless there is a proven infection (Campbell and Lane, 1996; Korinko 
and Yurick, 1997) 
• continue to use normal deodorant (unless this irritates the skin), but discontinue use if the 
skin is broken (Bennett, 2009; Butcher and Williamson, 2012; Watson et al., 2012; Wong et 
al., 2013; Lewis et al., 2014) 
• avoid sun exposure, shield the area from direct sunlight and use a high SPF sunscreen or 
sunblock (Harris, 2002 (a) and (b)). 
 
On broken skin, staff should: 
• use an appropriate dressing/product to reduce further trauma and infection. Suitable 
products would be non-adhesive or silicone low adhesion.  
 
Additional recommendations on training and use of skin assessment tools  
The core and stakeholder groups also suggest the following are necessary to ensure consistent patient 
care: 
• Standardised skin care education of all staff caring for patients receiving radiotherapy. All 
radiotherapy departments should implement pre-treatment skin assessment with baseline 
observations and pre-radiotherapy review and health promotion strategies. This should be 
followed with regular reviews (at least weekly, and more often depending on individual 
needs). 
• The reviews can be undertaken by members of the radiotherapy team who have been 
trained to use the tools, and inter-observer variability between clinicians, radiographers, 
and radiotherapy nurses should be assessed periodically. 
• Agreement on standardisation of assessment tools across departments in the United 
Kingdom would aid in gathering information nationally. 
• Further investigations into the skin care reactions caused by superficial, orthovoltage, and 
proton beam radiotherapy are required. 
 
8. Implementation strategies 
 
8.1 Implementation and dissemination of learning resources 
 
The core group has developed the following resources: 
• A practice guideline for health professionals in Word and infographic format (Appendices 10 
and 11). 
• A patient information summary leaflet in Word and infographic format (Appendices 12 and 13). 
• A presentation for use at conference and events in PowerPoint format (Appendix 14). 
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8.2 Impact measures and audit tools 
 
• Departments will be encouraged and expected to use the RTOG scale to monitor rates of 
skin reaction and to share these in a national data collection.  
• Departments will also be expected to undertake patient satisfaction audits. 
 
8.3 Organisational or financial barriers to implementation 
 
The majority of the recommendations have no financial implications. There is a requirement for 
additional training and some additional resources. The main blocks to implementation are likely to be 
organisational and cultural since the recommendations require changes to established working 
practices. However, many departments are working through the changes needed to embed person-
centred care more fully into daily practice and this guideline’s recommendations should be integral to 
this process.  
 
9. Recommendations for future research 
 
The following recommendations are made following assessment of the existing literature on products 
or interventions designed to reduce the development of radiation induced dermatitis. 
There is a need for more research investigating the impact of dosimetry in modern radiotherapy 
planning on subsequent skin reactions. For example, more studies like Borm et al. (2018) need to be 
conducted to inform radiotherapy planning, particularly for patients who are already identified as 
being at a higher risk of developing significant radiation dermatitis. 
 
Where centres want to consider implementing a new topical intervention or a new device to reduce 
radiation dermatitis, it is recommended that teams first test the new product/device within a well-
designed randomised controlled trial (RCT) that includes the following features, to ensure the 
evidence is robust enough to inform practice: 
 
a) There should be a clear scientific rationale for introduction of the new product or device. 
b) Where possible, RCTs testing a topical agent or device should be placebo controlled. 
c) Where barrier films are the focus of the investigation, researchers should use a within-subjects 
design, with the barrier film placed on half of the area of skin to be irradiated; standard skin 
care using simple moisturisers and standard washing instructions should be used on the other 
half of the treated area. The area that is covered by the barrier film should be randomly assigned 
at an individual level to ensure the impact of positioning does not affect the study outcomes. 
This is particularly relevant for breast irradiation where the lateral half of the breast is likely to 
contain more skin folds than the medial half. 
d) Assessors should be blinded to the intervention, as should patients, if possible. 
e) Skin should be measured/scored at baseline prior to radiotherapy. 
f) A standard skin toxicity scoring system should be used, for example RTOG. Assessors should be 
trained to use the tool and an assessment of inter- and intra-rater reliability should be 
undertaken and presented along with the results. 
g) RTOG scores are categorical (ordinal level) data and, as such, presentation of the data should 
be by percentage of each grade at each measurement interval during radiotherapy (i.e. week 1, 
week 2, week 3, etc.), at the end of radiotherapy, and at any measurement points post 
radiotherapy. Using a mean score to make judgements about the performance of an 
intervention can be misleading. For example, where a mean score of 2.1 vs 2.3 is presented for 
different interventions, can it be said that one intervention is better than the other when both 
are in the grade 2 category? Similarly, what difference in mean score would be considered a 
sufficient difference for one intervention to be considered better than the other? i.e. is a mean 
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score of 2.3 better than a mean score of 2.1? What about a mean score of 2.42 vs 2.40? It is 
understandable why researchers choose to calculate a mean score, but for this score to be 
relevant, percentages at the time points for each grade of radiation dermatitis (RD) at each 
measurement interval should also be stated. 
h) Randomisation should be remote to the staff collecting and assessing data or providing care. 
i) Stratification should be considered when using randomisation, to ensure that important 
confounding variables, such as breast volume (where appropriate), BMI, smoking status, or use 
of chemotherapy or targeted drugs (where relevant), are balanced between the study arms. 
j) Where PROMs are used, it is useful to have patient reported outcomes in addition to 
clinician/practitioner reported assessments. The Skindex-16 is one example of a patient 
reported measure, or the RISRAS scoring system, which has a patient section for reporting 
factors such as itching and pain. 
k) Researchers should employ multivariate analysis to control for confounding variables, and to 
identify the intervention’s contribution to reducing (or preventing) radiation dermatitis in the 
context of contributions from other intrinsic or extrinsic factors. 
l) Measurement and reporting of adherence to the intervention of new products or devices is 
important, as is reporting the reasons for withdrawal, e.g. whether patients were unable to 
tolerate it or found the intervention too uncomfortable to continue, which may not be recorded 
as adverse events. 
m) Researchers should measure and document the following confounding factors: 
• smoking status 
• skin type, e.g. fair, medium, dark etc. or the Fitzpatrick skin type classification system 
• use of bolus (size and frequency of use, i.e. daily, alternate days etc.) 
• BMI 
• use of immobilisation device that may cause attenuation, and therefore increase skin/surface 
dose 
• breast size (volume preferable) where appropriate (not bra cup size) 
• relevant treatment planning parameters, including V107%, V80% (skin), if possible, depth of 
maximum dose (dmax) 
• radiotherapy dose and fractionation 
• type of radiotherapy, i.e. IMRT, VMAT, 3D conformal etc. 
• use of chemotherapy (whether sequential, concomitant, or neo-adjuvant) 
• use of targeted drugs 
• comorbid disease, such as diabetes 
• current skin care regimen and any existing skin conditions, including sensitivities and allergies 
to certain products 
• clear details of any co-interventions, e.g. if patients continue with existing skin care practices of 
moisturiser use, washing practices etc. 
 
10. Date of publication, review and updating 
 
The evidence available for the Society and College of Radiographers (SCoR) skin care guidelines must 
be reviewed at five yearly timelines, and revised if required, to ensure the evidence on which they are 
based is still valid. 
 
An unplanned review may be required due to policy changes, published evidence or the emergence 
of new technologies and interventions. Identifying the need for unscheduled review is within the roles 
and responsibilities of the SCoR professional and educational (professional officer) team, under the 
direction of the Director for Professional Policy. 
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Appendix 3
External stakeholder 
comment form
The Society & College of Radiographers (SCoR) 
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Please add extra rows as needed 
 
Please email this form to:  (insert lead officer’s name...) 
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PLEASE NOTE: The Society & College of Radiographers reserves the right to summarise and edit comments 
received during consultations. SCoR may not publish all comments received, however, you can be reassured that 
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Appendix 4
2014 Systematic review 
Appendix 4:  Systematic review 2014 
The aim of the 2014 systematic review was to determine if, since 2010, there has been any 
additional evidence which could further inform or improve current clinical practice and if so what 
the impact of this additional evidence would be.  
Method 
The same search criteria were used as in the 2010 review. Initially a search question was formulated 
using the; Population, Intervention, Control, Outcome (PICO) method (Table 1).  
Table1:  PICO method  
Population 
 
Adult patients undergoing external beam radiotherapy:  radiation 
therapy, irradiation   
Intervention  
 
Preventative measures e.g. washing practices, topical applications, 
deodorant guidance    
 and/or  
management measures - dressings, topical and medical applications  
Control Standard intervention  
Outcome  Skin reactions, radiation effect, adverse effect, radiation dermatitis, 
erythema, moist desquamation, skin care, skin reactions  
 
The review was based on a systematic search of Medline, Pub Med, CINAHL, EBSCO, Science Direct, 
ISI Web of Science and Index to Thesis. 
Hand searches of the Journal of Radiotherapy in Practice (JRP), The European Journal of Cancer (EJC), 
Radiography, Journal of Medical imaging and Radiation Science (JMIR), the International Journal of 
Radiation, Oncology, Biology, Physics (IJROB) and Radiotherapy and Oncology were also undertaken. 
In addition, a secondary evaluation of the clinical trials’ databases was examined for any ongoing 
research as well as a search of the grey literature, including index to theses and conference papers. 
Finally a broad search of Google Scholar was used as a ‘mop up’ technique to ensure no additional 
relevant research had been missed.  
Owing  to the fact that a wealth of evidence had been reviewed in the primary audit and this is a 
continuation of that work it was deemed appropriate to map out and replicate the initial search 
strategy and then where appropriate include any additional resources.  
The traditional pearl growing method begins with a single document relevant to the topic under 
review and utilizes key words for this key or seminal text, but pearl growing until more recent years 
has often been overlooked as a strategy for literature searching (Schlosser et al., 2006). The 
Comprehensive Pearl Growing (CPG) method has developed from this and uses multiple key 
documents rather than just one. It is considered to be more systematic in its approach and deemed 
an appropriate method to be used for yielding results in a systematic review  (Schlosser et al., 2006). 
For the purpose of this review, Comprehensive Pearl Growing is an appropriate and important 
method to use in the initial stages of the strategy as this is following on directly from a seminal piece 
of previous published work and one other key document.  
Table 2 indicates the key terms used within the search strategy, drawn from the seminal articles.  
Table 2:  Key terms  
Aspect  Key term  
Radiotherapy  Radiotherapy, radiation therapy, irradiation   
Outcome  Skin reactions, radiation effect, adverse effect, 
radiation dermatitis, erythema, moist desquamation, 
skin care, skin reactions, evidence-based practice  
 
Those studies included initially had to fulfil the following criteria:   
• All literature from November 2010;  
• All papers that have an English abstract; 
• Papers that assess the use of a topical agent; 
• Papers where the primary focus is skin reaction to radiotherapy. 
 
Studies excluded were either owing to not meeting the above criteria or for the following reasons:  
• Reactions caused by a pre-existing genetic or medical disposition; 
• Case studies; 
• Rare skin reactions caused by topical agents or chemotherapy drugs; 
• Papers where the primary focus is the impact of the immobilization device or radiotherapy 
planning technique on the skin reaction. 
 
All appropriate full text articles underwent quality assessment using the Scottish Intercollegiate 
Guidelines Network (SIGN) quality assessment tool. Initially the Grading of Recommendation, 
Assessment, Development and Evaluation (GRADE) system was proposed, however upon further 
investigation the SIGN tool was deemed more appropriate and relevant for this particular study. To 
ensure the correct assessment questionnaire was used, all studies were mapped against the SIGN:  
‘Algorithm for classifying study design for questions of effectiveness’ (www.sign.ac.uk, 2013) 
 
Results of Review 
A flowchart including the number of hits obtained in the database searches, those abstracts 
screened for relevance, down to the final number of articles are included in the review.  
 
Diagram 1: Flowchart of literature review 
Database searching - titles 
screened for eligibility 
(n= 143) 
Alternative sources- records 
identified and titles screened 
(n= 30) 
Records after duplicates removed 
(n= 51) 
Abstracts of records screened 
(n= 51) 
Full text articles assessed for 
eligibility 
                   (n= 18) 
Other research and grey 
literature included 
       (n=10) 
Total number of studies included in the review 
 (Including grey literature)    
 (n=24) 
Research is continually emerging within this area, possibly due to the lack of conclusive evidence and 
the disparity between the published research as highlighted earlier, therefore it was deemed 
appropriate to include within the results any relevant ‘grey literature’ such as research protocols, 
conference presentations, symposiums and ongoing research trials.  
Randomised Control Trials (RCTs) and Systematic Reviews (SR)  
• Quality assessment using the appropriate SIGN checklist was undertaken, a total of 17 
articles were available for review: 2 Systematic reviews, 14 RCTs, I case control.  
• Of the RCTs and systematic reviews (n=16):  5/15 (33%) were classed as high quality 
evidence; 8/15 (53%) classed as acceptable evidence; 3/15 (20%) rejected as unacceptable 
quality. (See  Appendix 5 for summary of articles table.) 
• The final number of studies included in the review: 2 systematic reviews, 11 RCTs and I case 
control.  
Of the RCTs (n=11)included in the final review,  nine  were studying a different topical emollient or 
product (Jensen et al., 2011; Kirova et al., 2011; Miller et al., 2011; Abbas and Bensadoun, 2012; 
Niazi et al., 2012; Graham et al., 2013; Sharp et al., 2013; Ulff et al., 2013; Herst et al., 2014,) and 
two studies were reporting the use of non-metallic antiperspirants (Watson et al., 2012; Lewis et al. 
2014). (see Appendix 6 for full systematic review report.) 
The RCTs 
Jensen et al. (2011) reported results of an RCT assessing an oil in water emulsion on 68 breast 
cancer patients experiencing radiation dermatitis following completion of radiotherapy treatment. 
Patients were randomised to either a treatment group where the emulsion was applied for 6-8 
weeks or a control in which they were not treated at all. It was considered that the emulsion would 
increase skin hydration, especially to the stratum corneum (as measured by a corneometer) and this 
would reduce clinical symptoms of radiation dermatitis. Results showed no pronounced differences 
between the two groups.  
 
Kirova et al. (2011) conducted a phase III RCT comparing Hyaluronic acid to an unspecified emollient 
placebo arm. Two hundred breast cancer patients receiving external beam radiotherapy were 
recruited with 1:1 randomization. Evaluations were undertaken weekly using the RTOG scale and 
patient pain and quality of life (QoL) were also completed on alternate weeks. The results found no 
significant difference between the 2 arms however a lower level of pain and colorimerty was seen in 
the treatment arm (P=0.46), although not statistically significant.  
 
Miller et al. (2011) also investigated the effect of a steroidal treatment, 0.1% Mometasone Furoate 
(MMF) using a double blind RCT, on 176 patients receiving external beam radiotherapy for breast 
cancer. Patients were randomised to either 0.1% MMF or to an identical appearing placebo. Patients 
underwent baseline evaluation and then at weekly intervals using the Common Terminology Criteria 
for Adverse Events (CTCAE) and patients also reported QoL and symptoms on an assessment form, as 
recommend by Schnur et al. (2013). No baseline demographic characteristics were reported in this 
study such as BMI, breast size, patient age and skin colour.  The primary endpoint of the study was 
radiation dermatitis. No significant difference was found in the mean results of the assessment for 
dermatitis as most patients only encountered grade 1 or 2 toxicity. This limited the assessment of 
how effective MMF might be on radiation induced dermatitis. The secondary endpoints of patient 
itching, irritation and annoyance, were reported as reduced in the treatment group (P=0.07), 
however this was not statistically significant. The authors concluded that further research is required 
with respect to the use of MMF. 
 
Abbas and Bensadoun (2012) conducted a non-blinded RCT on the use of an oil based emulsion, 
Trolamine®, with washing instructions versus a control group of washing only. The washing 
instructions were complex and compliance with these instructions was not assessed or evaluated. 
Patients in the treatment arm were to apply Trolamine® from day 1 of treatment and for 2 weeks 
post radiotherapy completion. Assessment of radiation dermatitis was undertaken using the RTOG 
scale. The results of the study indicated that Trolamine® can reduce the acute dermatitis particularly 
at higher grades, citing a significant difference between the treatment and control arms with 20% of 
participants in the treatment group and 53.4% in the control group developing RTOG grade III 
reaction  (P<0.01). The study does however report conflicting results from previous research 
undertaken by Elliot et al. (2006) who found no advantages to using Trolamine®.   
 
Niazi et al. (2012) phase III study investigated the use of a silver clear nylon dressing (SLND) as a 
prophylactic and interventional skin treatment for patients receiving external beam radiotherapy for 
lower gastrointestinal cancer.  Patients with both rectal and anal cancers were included in the study 
and were randomised to either receive the dressing or the normal standard of care which was 
sulfadiazine cream at the point grade 1 dermatitis became present.  It was not possible to blind the 
study due to the visible nature of the dressing, however adequate concealment was addressed. 
Forty patients’ results were reported in the trial on a 1:1 ratio and compliance in dressing application 
was evaluated on a weekly basis. There were some differences between the histological diagnosis of 
the patients and then subsequently the concurrent chemo/ radiotherapy regimes. Radiotherapy 
doses were presented as a range rather than as discreet values which may be worth noting.  The 
primary endpoint was skin toxicity on the final day of treatment and high resolution photographs 
were taken 2 weeks prior, on the last day and 2 weeks after radiation completion. To reduce bias 
due to the fact blinding could not occur, evaluation of the data was undertaken by 10 oncologists 
from multiple centres who were blinded to the intervention.  The study reports mean scores in 
favour of the SLND arm  ( p =0.01) so that SLND reduced the severity of radiation induced dermatitis 
in the included patient cohort and that it is a cheap, simple effective method to use and these 
results also further validate their results from a Phase II trial. Further discussion with the 
manufacture resulted in modification to the dressing to be integrated into a boxer short style which 
they report resulted in improved patient compliance. No further recommendations were made by 
the authors to repeat the study using the shorts or with a larger cohort.  
 
Graham et al. (2013) undertook a randomised double blind RCT to test the impact on radiation 
induced skin reactions of a barrier cream containing acrylate terpolymer (ATP) vs a 10% glycerine 
cream (Sorbolene) on women undergoing post-mastectomy radiotherapy. The primary outcome 
investigated peak and overall skin reactions using the Common Terminology Criteria for Adverse 
Events (CTCAE) scoring tool (version 3.0); frequency of grade 3 or greater reactions and mean area 
under the curve was used to assess differences between the products;  levels of moist desquamation 
was also recorded. The authors also used a photographic audit of skin scores to confirm reactions 
scored by clinicians. The majority of patients had bolus, which will have increased the overall 
severity of the skin symptoms. Eleven percent of the sample had concurrent chemotherapy, 65% 
were on hormone therapy, and radiation doses ranged from 38Gy to 56Gy in a range of 19-28 
fractions. These variable confounders were not individually or collectively assessed within the 
analysis to identify the impact on skin reactions post treatment. 
 
Randomisation was undertaken for 333 patients using a within-subjects design.  Medial and lateral 
compartments of the chest wall were allocated to one of the two cream products; 94% completed 
RT and 96% had complete skin assessment scores (actual sample for analysis n=318). Skin reactions 
were worse in the lateral compartment than the medial compartment, with moist desquamation 
rates higher laterally than medially. No significant difference was identified between the two skin 
creams for grade 3 or higher skin reactions. 
 
Interestingly only 2/3 of participants fully adhered to the guidelines on cream use. This was primarily 
related to patients either applying more cream than required or applying the cream more 
frequently. Non-adherence appeared even between medial and lateral applications and across 
products. When medial/lateral was compared, in the proportion of cases with ≥ grade 3 skin 
reaction, there was a significant difference between skin reaction rate for medial applied creams 
(Sorbolene vs barrier cream) -  18% (Sorbolene) -  vs. 28% (ATP moisturizing double barrier cream) 
respectively  (p=0.047); no significant differences between products could be identified for creams 
applied to the lateral portion of the chest wall (45% Sorbolene vs 37% barrier cream p=0.13).  The 
authors consider this a chance finding (type I error). This is a well-conducted study that shows no 
difference between cream products on the extent of acute radiation induced skin reactions. A 
number of limitations of the study are of note as follows: 
• The publication lacks a flow diagram of study participants entered and those completing RT 
and skin assessments. It is unclear how many patients were approached to be randomised 
and refused or how much missing data there is for each assessment time period. 
• There is a distinct lack of information and detail on the RT techniques employed across the 12 
participating centres. It is possible that different levels of quality assurance are achievable 
across so many centres and may have gone undetected with unknown effects on overall skin 
reactions.  
• The centres employed a range of dose and fractionation schedules, which may influence skin 
reactions. We know nothing about whether simple tangential fields were employed or 3D 
conformal techniques or field in field techniques.  
• The addition of bolus in the majority of cases will have increased the severity of skin reactions 
seen, as well as concurrent chemotherapy in some cases (chemotherapy regimens were not 
documented). 
 
Sharp et al. (2013) conducted a randomised blinded study comparing two topical agents, Calendula 
Weleda®  cream vs. Essex® (Aqueous) cream (n=411) in patients undergoing radiotherapy for breast 
cancer. The primary endpoint was the difference in the proportion of patients with acute radiation 
induced skin reactions (ARSR) assessed using the RTOG skin scoring system. The authors also 
measured quality of life using the EORTC (European Organisation for research and Treatment of 
Cancer) QLQ C30 scale, sleep disturbance and symptoms from the irradiated area using a visual 
analogue scale as well as patient experience and adherence. The incidence of severe ARSR (RTOG 
grade ≥2) was 23% in the Calendula group and 19% in the Aqueous cream group at the follow up 
time point (p=0.55). Similarly no difference was found between the groups for patient reported 
symptoms of pain, burning, itching, pulling or tenderness. No difference was found between the 
groups when comparing QoL or sleep disturbances at the follow up visit. There were adherence 
rates of 86-87%. 
There was no difference between the groups in “no” or “mild” acute radiation induced skin reactions 
at any of the assessment points, and no grade 4 toxicity was reported. Overall moist desquamation 
rates are modest (3% and 2% Calendula vs. aqueous cream respectively). This high quality study 
demonstrated no benefit from using Calendula Weleda® cream over Aqueous cream BP although 
some study limitations are worth noting:  
• There are relatively few data collection points during the course of radiotherapy ie not 
weekly, and the follow up data time point varied. 
• Information about the radiotherapy technique employed is sparse; we only know that IMRT 
was not used in any cases. 
• While the researchers were given training on use of RTOG and the RTOG has previously been 
tested for inter and intra-rater variability, it was not assessed in this study. 
• A substantial number of patients declined to participate in the study (n=250). It is postulated 
that this may be due to the participants being aware they were going to be assessed for 
smoking status. However, similar (in fact slightly higher) proportions of smokers were 
included in this study compared with other similar studies.  
 
Ulff et al. (2013) undertook a double blinded RCT investigating the use of Betamethasone® (a steroid 
cream) versus two alternative moisturising creams. The study concentrated on patients with breast 
cancer and a total of 104 patients were randomised into 3 arms:  
• 1. Betamethasone® combined with Essex® cream 
• 2. Essex® cream (moisturiser)  
• 3. Canoderm® cream (moisturiser)  
 
Patients started application of the cream to the whole of the irradiated area during week one of 
treatment and continued until two weeks post radiotherapy completion. The authors state that the 
contra-lateral breast was used as control which sounds a little misleading as it isn’t being irradiated 
but it could be interpreted that they were using it as a way of measuring increases in skin redness. 
Assessments of dermatitis were made using the RTOG scale and skin redness was measured with a 
colorimeter. All patients received adjuvant chemotherapy and baseline demographics for each 
patient were recorded such as bra size, age, and BMI.  Patients were also measured on the degree of 
itching, burning and discomfort using the Visual Analogue Scale (VAS) and Dermatology Life 
Questionnaire Index (DLQI).  
 
Patient-related measures have been highlighted as an area often neglected by the research and that 
patients are very rarely asked about their experiences (Schnur et al. 2013). It is suggested this is 
potentially due to a lack of agreement on the best scale to use but recommended that all future 
research should include at least "one patient-rated measure" (Schnur et al. 2013).   
Results of the study found a statistically significant difference in the RTOG scored skin reaction at 
week 4 between those treated with Betamethasone® combined with Essex® cream (P= 0.003) versus 
stand-alone moisturisers. Some patients developed a mild reaction but this was reported as less in 
the treatment group than the control. Although patient demographics were recorded within the 
study no reference was made to these with respect to the efficacy of the treatments. The final 
assessment was undertaken as a telephone follow-up two weeks post radiotherapy completion. The 
results may be open to a greater bias as this was patient perception led rather than researcher led 
evaluation. The authors concluded that there may be contraindications to the long term use of 
steroids, such as loss of skin integrity.  
 
Herst et al. (2014) conducted a within-subject RCT into the prophylactic use of Mepitel® film for 
breast cancer patients receiving radical external beam radiotherapy. A total of 78 patients were 
included in the study and were randomised to have the medial or lateral half of their breast/chest 
wall to receive either Mepitel® or a control of aqueous cream. It was not possible to blind the study 
due to the nature of the film being visible but patients doubled as their own control. The primary 
endpoint of the study was to evaluate extent of moist desquamation. The study reported 0% moist 
desquamation rates for the Mepitel® covered areas and 26% for the control areas (p<0.0001) and 
subsequently determined that within the Mepitel®  film cohort moist desquamation was completely 
prevented.  
 
Separations in this study ranged from 16.1cm up to 31.2 cm, and BMI mean was 27.06 (range 16.12-
42.72). The mean BMI is quite high ie >25 suggesting most of the sample were overweight although 
no association between BMI and skin toxicity was seen. It could be that the following factors led to 
the unusually high moist desquamation rates reported in the control arm of this study: 
·       larger patients, combined with 3D conformal (rather than IMRT )   
·       37% of the sample had a boost treatment,  
·       Moist desquamation rates were taken at 4 weeks post treatment 
·       Aqueous cream used in the control arm and 
·       Approximately 47% had 50Gy in 25# (rather than 40Gy in 15# or equivalent). 
 
The authors also reported that even within their control that their rates were still lower than had 
been previously presented in the literature. No further recommendations by the authors were made 
to sample a larger cohort or to undertake a multicentre RCT to further strengthen their results. It is 
also interesting to note that the control was aqueous cream which has itself recently undergone 
scrutiny and is not widely recommended as a standard of care 
Compared with the Cambridge breast trial (1) where rates of moist desquamation of 0-2% were 
reported the MD rates in this study seem high. Given the study design it would be sensible for 
Mepitel film to be tested in other centres where techniques other than 3D conformal techniques are 
used (ie simplified IMRT or field in field techniques where it has been shown that outcomes such as 
skin toxicity is better) and where the control arm does not use aqueous cream but is a comparator of 
the patients normal skin care regime under national guideline advise and where the now accepted 
regimen of 40Gy in 15# ( or equivalent) is used and detailed assessment of patient weight/size is 
given in the analysis as this has also been shown to be a significant predictor in other studies of 
acute skin toxicity. 
1.Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC, et al. The Cambridge 
Breast Intensity-modulated Radiotherapy Trial: patient- and treatment-related factors that influence 
late toxicity. Clinical oncology. 2011;23(10):662-73. 
 
Watson et al. (2012) performed a single centre non blinded RCT evaluating the use of aluminium 
based antiperspirants for 198 patients receiving external beam radiotherapy for stage I and II breast 
cancer. The authors highlight the negative impact on patients’ quality of life that can arise due to the 
restrictions on deodorant usage.  Patients were randomised into either a control group of standard 
skin care instruction which included no antiperspirant usage or the experimental group where 
patients were provided with a specific deodorant containing a "moderate amount” (21%) of 
aluminium. Both groups underwent weekly skin assessment reviews and were measured using the 
CTCAE throughout treatment and two weeks post completion. There was no measurement of 
compliance within the control arm to ensure patients were not using a deodorant. Results 
demonstrated no statistical difference between the groups with respect to skin reaction or QoL. The 
authors report that two independent RCTs were also being undertaken but with non-aluminium 
based antiperspirant and they also found no significance between the control and the experimental 
groups. The authors therefore conclude that the use of a non-metallic deodorant/antiperspirant 
does not increase the risk of a skin reaction; however they acknowledge that more research needs 
to be undertaken with respect to metallic deodorants. Watson et al (2012) are cited in the MASCC 
(Wong et al., 2013) clinical practice guidelines which make “strong recommendations to allow the 
use of antiperspirants during breast radiotherapy”.  
 
Lewis et al. (2014) conducted a randomised double blind study (n =285) assessing effects of 
aluminium based deodorants. The study consisted of three arms, 1, Aluminium –containing 
deodorant plus soap, 2, Non aluminium containing deodorant plus soap   and 3, soap only. Soap was 
low irritant pH6, free from fragrance, colour and lanolin and propylene glycol. Outcome measures: 
RTOG, sweating assessed by the Hyperhidrosis Disease Severity Scale (HDSS) plus weekly assessment 
of itching, pain and burning using a visual scale measured at 4 weeks.   
There was no association between deodorant use and RTOG score. The change in itching, pain or 
burning in the axilla was 0.02cm higher in the aluminium deodorant group compared with the 
control but this was not significant, patients in the aluminium deodorant group experienced 
significantly less sweating than the control group.  
Conclusion:  use of aluminium deodorant did not adversely affect skin reaction.  
 
Self controlled clinical trial  
Haddad et al. (2013) undertook a within-subjects trial on the use of an Aloe Vera product on 60 
patients receiving external beam radiotherapy for treatment sites within the head and neck, pelvic 
and breast regions. The anatomical treatment area was divided into two symmetrical halves and 
patients were instructed to apply the Aloe Vera product on one half of the area. Grading of 
dermatitis was via the RTOG scale. Results of this study indicated no significant difference between 
the control and the treatment halves at lower doses but indicated a positive effect on the Aloe Vera 
side at higher doses and reported statistically significant differences in support of Aloe Vera from 
week four until the end of radiotherapy. The steering group for The College of Radiographers feels 
that the study by Haddad et al. (2013) is not methodologically strong enough to refute or support 
previous published evidence in the use of Aloe Vera products. 
 
The systematic reviews  
Butcher and Williamson (2012) undertook a systematic review of the literature on the management 
of erythema and skin preservation for patients receiving external beam radiotherapy to the breast. 
All literature was assessed for quality and in total 10 studies were included in the final analysis. They 
concluded that no one product was considered superior to another. The review advocates the safe 
use of non-metallic deodorants. The review also highlights the wide variety of methods and 
assessment scales used to report study findings thus making meaningful comparisons very difficult.    
 
Chan et al. (2014) undertook a systematic review and meta-analysis which included 47 RCTs from 
1962-2012. This large date range is a slight limitation as studies conducted during the 1960s are 
likely to include orthovoltage energies and Cobalt treatments with subsequent associated skin 
reactions that are not relevant to the skin sparing effects achieved with modern linear accelerators. 
Studies examined a range of practices: 
• 6 trials investigated oral systemic therapies 
• 2 investigated washing practices 
• 4 examined deodorant use 
• 5 investigate topical steroidal therapies 
• 23 examined non-steroidal topical therapies 
• 6 investigated dressings 
• 1 investigated light emitting diode photo-modulation 
 
Thirty-six of the included studies were considered at high risk of bias, 10 rated at unclear risk and 
one as low risk; confirming our own experience of quality assessment of studies in this field. 
Allocation concealment was only reported in 22 of the 47 studies reviewed. Blinding of assessors 
was only adequately described in 21 of the 47 studies. Similarly, only 21 of the 47 studies 
adequately reported how attrition was handled in the analysis. 
 
A small meta-analysis of two studies investigating oral systemic therapy (oral Wobe-Mugos E vs. no 
medication) indicated the odds of developing a radiation induced skin reaction was 87% lower for 
people receiving Wobe-Mugos E (although heterogeneity for the studies was high I2=70%). A meta-
analysis of 226 participants from two  un-blinded studies found no difference in radiation induced 
skin reactions when comparing deodorant use to no deodorant use. Four trials investigated the role 
of topical steroidal agents on radiation induced skin reaction. Three of these studies identified no 
benefit while one small study (n=20) found a statistically significant benefit for using prednisolone 
with neomycin compared with no treatment. However, some of the topical steroid trials had small 
sample sizes and wide confidence intervals hence the results should be viewed with caution. 
Overall the review concludes that the evidence for any intervention is ‘thin’ i.e. no strong evidence 
of effect for any of the included trial products to reduce radiation induced skin reactions. The study 
concludes that patients should be advised to wash gently and using non-metallic deodorant is not 
contraindicated. Recommendations for future studies include a focus on an area of promise such as 
oral Wobe-Mugos E and oral zinc. Future studies should also attempt to clarify which patients would 
benefit from corticosteroid cream, and appropriately powered RCTs comparing different dressings 
for those that develop moist desquamation.  
 
Other published Literature 
 
Chan et al. (2012) compared the effectiveness of a natural oil-based emulsion (Moogoo Udder® 
cream) to a control of aqueous cream. The double blind randomized study included patients 
undergoing radical radiotherapy to variety of treatment sites, including breast, chest, and head and 
neck regions. The primary end points of the study were to assess the incidence of grade 2 and 3 
dermatitis, with secondary end points to assess QoL, pain and itching, throughout a course of 
treatment and up to four weeks post radiotherapy completion. Standard departmental skin care 
advice was given to both groups and measurements undertaken using the CTCAE as well as a survey 
to assess quality of life.  Results from this study have not yet been presented. 
 
Uzaraga et al. (2012) conducted a 16 patient single arm pilot study into the use of a topical gel mix 
of Amitriptyline, Ketamine.and Lidocaine (AKL) especially for the treatment of neuropathic pain 
caused by radiation induced skin reactions. The authors noted that neuropathic pain is often 
experienced by patients and there is a lack of evidence investigating how this could be managed. The 
pilot study reported that AKL gel may be effective in alleviating this type of pain particularly in those 
patients for whom standard opioids are not effective.  They concluded that following the results of 
the pilot there was a need for a Phase III multi centre RCT. 
 
Zenda et al. (2013) undertook a prospective phase II study investigating the possible reduction in the 
incidence of severe radiation dermatitis in 113 patients undergoing head and neck radiotherapy. 
They proposed the implementation of a “Dermatitis Control Program” which contains 3 well defined 
steps:  
 
Step 1 - a watchful wait approach where patients are only advised to undertake gentle 
washing;  
Step 2 - consists of supportive treatment for Grade 2 dermatitis which involves the use of 
Vaseline® and gauze;  
Step 3 - consists of supportive treatment for grade 3-4 radiation dermatitis plus the use of 
topical applications to reduce the risk of infection.  
 
This study did not advocate the use of corticosteroids or antibiotics unless an infection was present. 
The results showed that no patients developed Grade 4 Dermatitis, grade 2 and 3 were seen in 56% 
and 9.7% respectively. The authors could not report the prevention of radiation dermatitis or the 
effectiveness of corticosteroids. They acknowledge the need for further research into the use of 
corticosteroids. 
 
Robertson and Brown (2011) surveyed 237 members of the UK public in two cities to identify which 
brands of soap were considered as “mild”. Interestingly the authors undertook PH tests of the 8 
leading brands reported by the general public and found that all of them were actually acidic. The 
authors reported that patient instructions on using a “mild soap” can often be quite vague and open 
to misinterpretation and also found that 83.1% of the sampled population preferred to shower 
rather than bath and used liquid soaps rather than solid soaps and therefore highlighted possible 
implications when recommending “soaps” to patients. They also noted that when recommending a 
particular brand there are often a wide variety of options within that particular brand, so for 
example within the brand  Dove® there are  10 different types of body wash.  
 
Within the inclusion dates of this review there have been publications to the Journal of Community 
Nursing which raise some interesting points. Firstly, Trueman (2013) investigated the ability of 
healthcare practitioners to manage radiation induced skin reactions within the community and also 
highlighted the recent evidence base which shows that aqueous cream containing sodium lauryl 
sulphate can be a skin irritant. Secondly, Scott (2013) reported on an ongoing study evaluating the 
use of polymeric (PolyMem®) dressings for patients with an RTOG score of 1-2.5 over a 4 week 
period. Scott (2013) reports that the use of the PolyMem® reduced skin reactions within the first 
week of treatment when measured with clinical observations and that by week four 75% of patients’ 
skin reactions had healed.  The authors report one of the most significant findings being the decline 
in pain scores between weeks 1 and 3 when using the ‘Wong and Baker grades’ (Wong and Baker, 
1988) and a numerical rating description. This work is part of a multi centre study which is currently 
ongoing.  
 
 
Grey literature   
 
During the inclusion period of this review there have been a number of abstracts and short 
publications published, as well as conference presentations, which are of note.  
 
Hardefeldt et al. (2012) submitted a letter to the editor of Radiotherapy and Oncology for 
publication regarding a meta-analysis of deodorant use and the risk of skin toxicity in patients 
undergoing radiotherapy. Their aim was to analyse all published RCTs which investigated the adverse 
effect of using deodorant. In total they found four RCTs, three of which favoured the use of 
deodorant. They concluded that no evidence had been found that deodorant increases adverse 
events but recommended the need for more “high quality” studies to be undertaken to fully exclude 
a link.  
 
Lopez et al. (2013) submitted an abstract to the Journal Reports of Practical Oncology and 
Radiotherapy which outlined their study into the use of a hydrofibre dressing to prevent the 
progression of radiation dermatitis. They concluded that the dressings were effective in reducing 
dermatitis and could be safely used even over long periods of time.   
 
Bennett et al. (2013) published an abstract in the Journal of Medical Imaging and Radiation Sciences 
outlining a RCT into the use of Mepilex® dressing versus a control of aqueous cream in managing 
radiation skin reactions in post mastectomy patients receiving external beam radiotherapy. They 
concluded that Mepilex®Lite dressings reduce all aspects of radiation induced skin reactions.  
 
At the 2013 RTi3 Conference, Canada, Lock and Rempel (2013) presented a webinar of their research 
on the use of 3M Cavilon®, no sting barrier cream. The study method involved dividing the affected 
breast of those patients receiving external beam radiotherapy into 4 quadrants with randomisation 
to apply the cream in 2 of the quadrants. Measurements were taken using the Skin Toxicity 
Assessment tool (STAT) and photographs were also taken on day one of treatment and during the 7-
10 day post radiotherapy follow up appointment. This is an ongoing trial so no final analysis is 
available at this time.  
 
At both the UKRO and ASTRO 2013 conferences, Hindley and Dunn (2013) presented the results of a 
trial on the effectiveness of Mometasone Furoate (MMF). One hundred and twenty patients were 
randomized to receive either MMF or the emollient Diprobase®. They concluded that: “Mometasone 
Furoate cream significantly reduces radiation skin reactions when used from the start of radiation”. 
They also reported a 60% reduction in the appearance of moist desquamation. They recommended: 
“where skin reaction cannot be prevented, then Mometasone should be prescribed from the start of 
radiation until the reaction begins to subside”. However at the UKRO presentation the authors did 
highlight the need for further work to ascertain the impact of the chronic use of steroid creams.  
 
Literature rejected (following Quality assessment using the SIGN checklist) 
 
Studies from this review were excluded for a number of reasons including methodical qualities. Two 
examples of these studies have been included below. 
 Zhong et al. (2013) undertook a single centre study RCT comparing Mepilex® Lite dressing vs. 
normal skin care (cleaning with salted water) in a sample of patients undergoing radiotherapy 
following a diagnosis of nasopharyngeal carcinoma (n=88). Patients were invited to participate if 
they developed moist dermatitis post radiotherapy. The primary outcome measure was time to 
wound healing; defined as time from recruitment to the study and observation of complete re-
epithelealisation and absence of moist desquamation. In the intervention group the median time to 
wound healing was 16 days (95% CI 12-19 for Mepilex®) and 23 days for the control arm (95%CI 19-
27) p=0.009. Although on multivariate analysis initial tumour stage, n-status, radiotherapy technique 
and initial wound size were the only independent factors that determined prolonged time to wound 
healing, dressing type was no longer significant. The average increase in RISRAS scores 
demonstrated less increase in scores with the Mepilex® Lite dressings than the control arm 
(p=0.009). However, it is unclear as to why the researchers chose to present the average increase 
scores rather than the total average RISRAS scores. If patients start with a high score (ie 3 for pain 
and discomfort) and continue to get no resolution in the pain, their score will remain at 3 so will not 
increase. Thus the endpoint may give misleading results. It is also interesting to note that the patient 
reported RISRAS scores between the control and intervention arm differ by less than 0.5 (ie less than 
1 category score on the grading scheme). 
While there may be some patient comfort to be gained by using the Mepilex® Lite dressings, the lack 
of blinding and lack of assessment of scoring reliability by researchers makes establishing the true 
benefit of the dressing difficult. Owing to this unreliability, the study was rejected by the reviewers 
on quality grounds.  
Paterson, et al. (2012) undertook a within subjects RCT (with no blinding) comparing Mepilex® Lite 
dressings with aqueous cream. All women undergoing post-mastectomy RT across four RT centres 
were screened for recruitment and inclusion into the study. Eighty patients were randomised and 74 
complete data sets were available for analysis. Radiotherapy was delivered via tangential beams in 
almost all cases, however at one centre some patients were treated with skin apposition electrons 
based on clinician preference (9.5% of total sample), most had bolus although this varied between 3-
5mm (44.6% and 21.6% respectively), but bolus was less common in one of the centres. Dose 
fractionation varied but for 68% of the sample was 50Gy in 25 fractions, 52% of cases had pre 
treatment chemotherapy, and 12.2% had concurrent chemotherapy. Almost a third of the sample 
was current or ex smokers. Radiotherapy technique employed tangentials with field in field in some 
cases to reduce hot spots, although it is not known for how many cases this was employed. 
Interventions were only introduced once erythema had started and then the focus of the treated 
area remained that site despite other sites of erythema or worse skin reactions appearing later. As 
radiotherapy progressed, the area that developed moist desquamation either continued to be 
covered by the Mepilex® Lite (if already in the intervention area) or, if it was in a control area, was 
covered with dressings standard to that department ie in two centres this was Mepilex® Lite, in one 
centre it was hydrogel covered with a non adherent wound contact layer and an absorbent pad and 
in the fourth centre a cotton gauze with Sivadene cream 1% was used. 
Results showed improved average RISRAS scores for Mepilex® Lite compared with aqueous cream 
(p<0.001) although no significant difference was identified for moist desquamation (MD) rates. The 
Mepliex lite did not reduce the likelihood of the erythematous area developing into MD and this was 
primarily a function of the use of bolus across most of the centres. As the comparator arm employed 
aqueous cream, it is not clear whether Mepilex® Lite is any better than no intervention for reducing 
erythema. The patient reported RISRAS scores do point to improvements in patient related 
symptoms that maybe of note.  
However, again it is difficult to be clear whether the Mepilex® Lite would perform better than no 
intervention. In addition, the greater use of higher dose fractionations (50Gy in 25 fractions  and the 
use of bolus are likely to contribute to the erythema experienced and with different dose 
fractionation schedules, use of IMRT and avoidance of bolus, the skin reactions experienced by 
patients may be significantly less. Therefore this study was rejected primarily based on lack of 
Radiotherapy QA, no inter-rater reliability assessments and a lack of blinding.  
Diggelmann, et al. (2010) undertook a systematic inpatient controlled trial into the use of Mepilex 
lite dressings on 24 breast cancer patients.  Patients were randomised, however blinding was not 
undertaken as this was a within subjects design.  Areas of erythema were divided in half and 
randomly assigned to have either the Mepilex lite dressing or aqueous cream. Outcome measures 
included severity of skin reaction, dose build up and skin surface temperature. The primary trial 
outcome was dry desquamation, so if erythema developed into dry desquamation then Mepilex lite 
dressing was used regardless if it was assigned to aqueous cream or Mepilex lite.  RISRAS scoring was 
used, however there was no assessment of inter or intra-rater reliability.   
Patients received 50Gy in 25# and of the 28 patients recruited of these 2 patients were excluded 
because aqueous cream not used and Mepilex was not replaced correctly and it could be argued 
that they should have still been included and used as an intention to treat analysis.  
A further 2 patients were not included because erythema not reported. No power calculation for 
sample size and confounding variables such as skin type, chemo status, and hormone status not 
controlled for in the analysis. Randomisation was not concealed but undertaken based on order of 
recruitment into the trial. There was also no blinding of assessors. The study was rejected by reviews 
based on a lack of methods to minimise bias.  
 
Appendix 5
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Appendix 5:  Ongoing trials in 2014 
In order to ascertain current research being undertaken in this field, a search of the clinical trials database was undertaken (www.clinicaltrials.gov). 
The following studies were found and have been outlined in the table below.  
 
Study Title  Authors  Method  Anatomical 
areas  
Stage  Country  Hospital(s)  
A phase III double blind study on  
the efficacy of topical  Aloe Vera 
Gel on  irradiated Breast tissue  
 
Johnson JS 
Double blind phase III RCT 
into topical Aloe Vera 
comparing 2 over the 
counter aloe Vera products  
 Breast  Recruiting  USA Lewis Hall Singletary 
Oncology Center at John 
D.  Archbold Memorial 
Hospital,  
Thomasville Georgia, USA 
 
A Phase II Study Designed to 
Evaluate the Value of NeoVIDERM 
Skin Emulsion in the Prevention of 
Radiation Dermatitis for Patients 
Undergoing External Radiation 
Therapy 
Vuong T, 
Davis MB.   
Patients are randomized to 
receive either the 
Control- standard care with 
Aveeno® cream until they 
get dry desquamation then 
Flamazine®  
vs 
Treatment standard care 
with NeoVIDERM   
 
Head and 
Neck,  
Breast  
 Trial  
Terminated  
Canada  Jewish General Hospital,  
Quebec, Montreal, Canada 
Mometasone Furoate 0.1% Versus 
Eucerin on Moderate to Severe Skin 
Toxicities in Breast Cancer Patients 
Receiving Post mastectomy 
Radiation: A Randomized, Double 
Blind Trial 
 
 
 
Memorial 
Sloan-
Kettering 
Cancer 
Center 
 A double blind RCT where 
patients are  randomized to 
receive either   
Control – Eucerin® ( a 
placebo comparison) or 
Experimental- Mometasone 
Furoate 0.1% 
 
 Breast  Recruiting  USA Multi center 
1-memorial Sloan-
Kettering cancer center in 
New Jersey 
4 x Sloan-Kettering cancer 
centers in New York, USA 
A Phase II Study Designed to 
Evaluate the Value of Alkagin Paste 
in the Prevention of Radiation 
Dermatitis - for Patients 
Undergoing External Beam 
Radiotherapy 
Vuong T.  Standard care vs Aveeno 
cream (Alkagin	paste)  
Anus, 
Rectum, 
Urogenital 
system  
  Trial 
terminated  
Canada  Jewish General Hospital, 
Quebec, Montreal, Canada 
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Appendix 6:  Summary of Evidence: RCT/Systematic reviews in 2014 
++ = high quality study 
 + = acceptable quality  
 0 = rejected, unacceptable quality 
Author and 
Year  
Description  Scale or other 
measuring 
tool  
n Intervention  
and control  
Category of 
patients  
Category  
(primary 
endpoint) 
Results  P-value  QA 
Butcher et 
al 2012  
Systematic 
review  
 
 10  N/A Breast  All    + 
Chan et al 
2014 
Systematic 
Review 
 47 RCTs 
from 
1962-2012 
Trials of oral 
systemic 
therapies 
(n=6) 
Washing 
practices 
(n=2) 
Deodorant 
use (n=4) 
Topical 
steroids 
(n=5) 
Non-steroidal 
topical 
therapies 
(n=23) 
Dressings 
(n=6) 
Light 
emitting 
All included Radiation 
Induced skin 
reaction 
36/47 of 
included 
articles 
considered at 
high risk of 
bias 
10/47 rated at 
unclear risk 
Allocation 
concealment 
only reported 
in 22/47 
studies  
Blinding and 
attrition only 
adequately 
described 
21/47 
 
 
 ++ 
diode photo-
modulation 
(n=1) 
 
Abbas 2012  Non blinded 
RCT  single 
centre  
RTOG 30 Trolamine®  vs. 
standard of care  
Head and 
Neck  
Grade 1-2  
 
 
 
 
 
 
Grade 3  
 80% (12/15)  
treatment 
group  
46.6% (7/15) 
control group  
 
20%(3/15) 
treatment 
group  
53.4%(8/15) 
control group  
 
 
P<0.01 
+ 
Watson et al 
2012 
 
Non blinded 
RCT single 
centre  
CTCAE 
 
FACT-B QoL 
questionnaire  
198 Aluminium 
based 
antiperspirant  
vs. standard of 
care  
Breast  Grade 3  4/99 
treatment and 
3/99 control 
developed  
toxicity  
 
No statistical 
difference 
between 
intervention 
and control for 
QoL 
 
 + 
Haddad et al 
2013 
 
Non RCT - 
Self-controlled 
study  
RTOG  60 Aloe Vera  
self-controlled. 
Half treatment 
Head and 
Neck, Pelvis, 
Breast  
Grade  1-3 by 
week 5   
treatment half 
Grade 1  n=42 
Grade 2  n=3 
 +  
(omitted 
Q2, 3,and 
field control, 
other half 
intervention  
Grade 3  n=1 
 
Control half 
Grade1  n= 32 
Grade2  n=17 
Grade3  n=1 
 
4 on RCT 
SIGN ) 
Herst et al 
2014 
 
Intra- patient 
RCT - blinding 
not possible  
RTOG and 
Modified 
RISRAS 
 
78 Mepitel® /film 
vs. aqueous 
cream  
Breast  Moist 
desquamation  
0% 
intervention 
26% control  
P<0.001 + 
Jensen  et al 
2011  
Single Centre 
RCT  
ONS  66 WO1932 ( oil in 
water emulsion ) 
vs. no treatment  
Breast  ONS 0-3 visit 3 (day 47 
+/- 7) 
normalised 
skin higher in 
treatment 
group n=14 vs. 
control 
n=6 
 
P=0.059 + 
Kirova  et al 
2011  
Phase III RCT  RTOG 
VAS 
EORTC 
200 Hyaluronic Acid 
vs. control 
emollient  
Breast  Disappearance 
of erythema  
based 
Colormetric 
values  
 
failure = 
interruption of 
treatment  
20.4% in 
intervention 
arm 
13% in control 
arm   
 
n=23 (24.2%) 
in intervention  
arm  
n=32 (33.7%) 
in control arm  
 
 
 
P=0.46 
 
 
 
p=0.15 
+ 
Paterson et 
al 2012 
Within 
subjects RCT, 
no blinding  
RISRAS 74 Mepilex®lite 
dressings vs. 
aqueous cream 
Breast ( post 
mastectomy)  
RISRAS score  Results 
showed 
improved 
average 
RISRAS scores 
for Mepilex 
®lite 
compared 
with aqueous 
cream 
although no 
significant 
difference was 
identified for 
MD rates. 
 
(p<0.001) 0  
Miller et al 
2011 
Double blind 
RCT  
CTCAE version 
3 
Skindex-16  
176 Mometasone 
Furoate (MMF) 
vs. placebo 
cream  
Breast  CTCAE  mean 
maximal grade  
and SD (range 
0.0-3.0) 
1.2 + .85 
intervention  
 
1.3 + 0.8 
control  
 
 
 
 
 
P=0.18 
+ 
Niazi et al 
2012  
Phase III RCT - 
blinding not 
possible  
CTCAE version 
4  
44 Sliver Clear 
Nylon Dressing 
(SCND) 
vs. standard skin 
care  
Lower GI  Skin toxicity 
on final 
fraction of 
radiotherapy.  
Mean 
dermatitis and 
SD scores  
 
1.67 (1.2 SD) 
intervention 
group 
 
2.53 (1.17 SD) 
control  group  
P= 0.1 ++ 
Graham et 
al 2013 
Double blind 
RCT 
CTCAE version 
3 
Photographic 
audit  
318 barrier cream 
containing 
acrylate 
terpolymer 
(ATP)  vs. a 10% 
glycerine cream 
(Sorbolene) 
Breast (post 
mastectomy) 
peak and 
overall skin 
reactions 
using the 
CTCAE scoring 
tool (version 
3.0) 
plus a 
photographic 
audit of skin 
scores to 
confirm 
reactions 
scored by 
clinicians 
medial/lateral  
applications 
were 
compared for 
the two 
products. In  
the proportion 
of cases with ≥ 
grade 3 skin 
reaction, there 
was a 
significant 
difference for 
medial applied 
creams 18% 
(Sorbolene) vs. 
28% 
(moisturizing 
double barrier 
cream)  
 
p=0.047.   + 
Sharp et al 
2013 
Blinded RCT  RTOG  
EORTC QLQ 
C30, 
 a visual 
analogue 
scale patient 
experience 
and 
adherence 
411 Calendula 
Weleda®  cream 
vs. Essex® 
(Aqueous) 
cream 
Breast  Follow up  ARSR (RTOG 
grade ≥2) was 
23% in the 
Calendula 
group and 19% 
in the 
Aqueous 
cream group 
at follow up  
p=0.55. ++ 
Ulff et al 
2013 
Double 
Blinded RCT  3 
arm  
RTOG 
Colorimeter 
VAS 
125 Betsmethasone 
(steroid) 
+Essex® cream 
Breast  RTOG 0-1  
 
 
22/53 B+E 
7/49 
moisturisers 
 
P=0.001 
++ 
 DLQI (B+E) 
vs. 
Essex® cream 
vs. 
Canoderm® 
cream  
 
RTOG 3   
7/53 B+E 
15/49 
moisturisers  
  
Zhong et al  
2013 
Single centre 
RCT  
RISRASS 88 Mepilex® lite 
dressing vs. 
normal skin care 
(cleaning with 
salted water) 
 
Nasopharynx  
Time to 
wound healing  
Mepilex® 
median time 
to wound 
healing 16 
days (95% CI 
12-19) 
 
Control 
median time 
to wound 
healing 23days 
(95% CI 19-27)  
 
 
 
 
 
 
 
 
 
p=0.009. 
0  
Lewis et al 
2014 
Single centre 
RCT remote 
randomisation 
double 
blinded 
RTOG, HDSS 
plus visual 
scale 
285 Three arms, 
aluminium –
containing 
deodorant plus 
soap; non- 
containing 
aluminium 
deodorant plus 
soap and soap 
only. Soap was 
low irritant pH6 
free from 
fragrance, 
colour and 
Breast RTOG grade 
≥2 score   There was no association 
between 
deodorant use 
and RTOG 
score. The 
change in 
itching, pain or 
burning in the 
axilla was 
0.02cm higher 
in the 
aluminium deo 
 ++ 
lanolin and 
propylene 
glycol.  
group 
compared 
with the 
control but 
this was not 
significant; pts 
in the 
aluminum deo 
group 
experienced 
significantly 
less sweating 
than the 
control group.  
Conclusion: 
use of 
aluminium 
deodorant did 
not adversely 
affect skin 
reaction.  
Diggelmann 
et al 2010  
systematic 
inpatient 
controlled 
trial 
RISRAS N=24  Areas of 
erythema were 
divided in half 
and randomly 
assigned to have 
either the 
Mepilex lite 
dressing or 
aqueous cream 
Breast  Included 
severity of skin 
reaction, dose 
build up and 
skin surface 
temperature. 
The primary 
trial outcome 
was dry 
desquamation,  
Mepilex lite 
significantly  
decreased the 
extent or 
radiation 
induced skin 
reactions  
 
p <0.001 
0 
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2019 Summary of 
evidence table
Author and 
year 
Description Scale or 
other 
measuring 
tool (RTOG 
etc.) 
Sample size n= Intervention 
and control 
Category 
of 
patients  
Primary 
endpoint 
Results P-value QA (risk of bias) 
Robijns et al. 
2018 
A single centre 
prospective 
placebo 
controlled RCT 
RTOG 
measured at 
baseline, 40Gy 
and 66Gy time 
points, 
objective 
measures of 
skin hydration, 
transdermal 
water loss and 
pigmentation 
139, n=120 included 
in the analysis 
Photobiomodulation 
therapy vs placebo 
(control) 
Breast 
cancer 
Incidence of moist 
desquamation 
Incidence 
significantly higher in 
control arm at 66Gy 
time point OR=6 95% 
CI 1.881-19.82 
0.004 Low 
Aysan et al. 
2017 
A single centre 
double blind 
placebo 
controlled RCT 
RTOG 
measured at 
baseline and at 
5th week of RT 
Number analysed 
=47 
Boron gel, vs 
placebo (Vaseline®, 
petroleum jelly) 
Breast 
cancer 
RTOG score at week 
5 
Statistically 
significantly higher 
proportion of 
patients in the 
control arm had 
grade 2 (or above) 
RTOG score although 
patient satisfaction 
higher in control arm 
 0.03 Moderate  
Arimura et al. 
2015 
A single centre 
trial – patient 
preference, 
non-
randomised 
CTC version 4 
measured on 
alternate days 
during 
treatment, 
then after 
treatment 
once a week 
for a month 
then every 
three months 
for two years 
271 enrolled in the 
study (n=145 chose 
film dressing) 
(n=126 chose 
standard care) 
Film dressing 
(Airwall®) vs 
standard skin care 
Prostate 
cancer 
Highest grade of RD Time to grade 1 or 2 
same for both 
groups, 14% in film 
dressing group 
developed grade 2 or 
higher RD, vs 48% in 
control group 
p<0.001 High  
Baumann et al. 
2017 
Single centre 
phantom 
dosimetry study 
Assessment of 
surface dose 
with and 
without 
aluminium 
containing 
antiperspirants 
using optically 
stimulated 
Tested on a 5x5 
paper with eight 
rolls of 
antiperspirant 
Compared two 
strengths of 
aluminium 
antiperspirant 15% 
and 25% 
n/a Surface dose in cGy No difference seen 
between no 
antiperspirant and 
both perspirant 
strengths, at a range 
of gantry angles 
No 
significant 
difference  
Low (non-human 
study) 
luminescent 
dosimeters 
(OSLDs) 
Ben-David et al. 
2016 
Phase II 
prospective 
randomised 
placebo 
controlled 
double blind 
trial 
RTOG CTC 
version 3 
measured at 
baseline 
weekly during 
five weeks of 
treatment and  
two weeks 
post treatment 
n=47, 26 in the 
melatonin cream 
group, 21 in the 
placebo group 
Melatonin-
containing emulsion 
intervention vs 
placebo cream 
control. Physician 
and patient blind to 
allocated arm. 
Asked to apply the 
cream twice daily 
over the treated 
breast (but not less 
than two hours 
before treatment). 
Patients advised not 
to use any other 
marketed or natural 
product during the 
radiation period 
Breast 
cancer 
RTOG scores during 
RT and at two weeks 
follow-up. 
No difference in 
RTOG scores during 
RT, but at week 7 
(two weeks post RT) 
melatonin group 59% 
grade 0, 41% grade ½ 
vs 11% grade 0 and 
90% grade ½ in the 
placebo group 
(p=0.03).  
No difference in 
patient reported 
subjective reports 
between the groups 
p=0.03 only 
at FU 
Low 
Censabella et al. 
2016 
Single centre 
non-
randomised trial 
RTOG and 
RISRAS , 
Skindex-16 
(QoL) 
measured 
before the 
start of laser 
therapy (LT) 
and at the end 
of 
radiotherapy 
(RT) 
n=87, n=45 control 
arm (n=41 analysed) 
n=42 LT (n=38 
analysed) 
Control had 
standard skin care: 
hydrocolloid gel, 
self-adhesive 
silicone foam 
dressing (Mepilex®) 
for painful skin 
reactions. 
Intervention –
standard skin care 
plus six sessions of 
LT, given twice a 
week starting from 
fraction 20 
Breast 
cancer 
patients 
Severity of RD 
(RTOG and RISRAS) 
and QoL (Skindex-
16) 
At fraction 20 RD 
levels were 
comparable between 
groups (baseline 
score). 
In the control arm 
there was a 
significant increase in 
RTOG score grade 2 
to 29.3% at end of RT 
compared with 4.9% 
at #20 (p=0.01). In 
the LT group RD 
remained stable 
(p=0.22) with only 
one patient with an 
RTOG grade 2 at the 
end of RT. 
There were 
significant differences 
between the control 
and LT RISRAS scores 
for both patient 
reported and clinician 
reported scores in 
favour of the LT 
RISRAS 
scores total 
p=0.003 
Moderate 
Chan et al. 2019 A single blind 
randomised 
controlled 
superiority trial 
CTCAE version 
4.0 end of 
treatment 
n=197. Intervention 
arm n=89 analysed 
(n=11 lost to FU or 
exited the trial). 
Control arm n=83 
analysed (n=13 lost 
to FU or exited the 
trial) 
Intervention 
StrataXRT® vs 
control sorbolene 
Head and 
neck cancer  
Severity of RD at the 
end of RT 
Age, total dose, skin 
dose verification, 
number of fractions 
prescribed and PTV 
size were comparable 
between groups. The 
StrataXRT® group had 
higher mean BMI 
than the control arm. 
The control arm had 
greater proportion of 
patients with 
tomotherapy and 
greater number 
having 6FFF energy. 
All other 
characteristics were 
comparable between 
groups.  
Authors state that 
after adjustment BMI 
and technique (VMAT 
or tomotherapy) had 
no effect on 
outcome, At the end 
of treatment:  
StrataXRT® arm – 
grade 2 (80%) and 
grade 3 (28%); 
control arm – grade 2 
(91%) and grade 3 
(45%). Unclear why 
these add up to more 
than 100%. 
After controlling for 
cetuximab, the 
StrataXRT® arm had 
12% lower risk of 
experiencing grade 2 
skin toxicity 
(RRR=0.876, 95% CI 
0.778-0.987) and a 
36% lower risk of 
developing a grade 3 
reaction (RRR=0.648 
95%CI 0.442-0.947) 
p=0.025 
p=0.025 Moderate 
Eda et al. 2016 A double blind 
randomised 
controlled trial 
RTOG – not 
clear at what 
time point the 
RTOG was 
measured 
Number 
enrolled=40, 
number analysed 
=38, 
Intervention=18, 
control=20 
Intervention= 
glutamine 15g per 
day in three doses, 
started one week 
prior to RT 
continued until one 
week post 
treatment. Control 
received a placebo 
Breast 
cancer  
RTOG  Intervention: grade 
1= 88.9%, grade 2= 
11.1%. Control: grade 
1=0, grade 2=80%, 
grade 3=20%  
p<0.001 High 
Erridge et al. 
2016 
Audit of new 
skin care policy 
using steroid 
cream 
(betamethasone 
valerate 0.1%) 
RTOG and 
PROM via a 
questionnaire 
at the end of 
RT and two 
weeks post 
treatment 
Total sample size 
=219, cohort 1=112, 
cohort 2=107 
Patients identified 
as high risk applied 
steroid cream 
(betamethasone 
valerate 0.1%) from 
day 1 of RT and up 
to two weeks post 
treatment (once a 
day). Medium and 
high risk patients 
were also given 
Diprobase® as an 
emollient. Control 
was a cohort of 
patients treated 
prior to the 
implementation of 
the policy 
Head and 
neck, 
including 
brain, n=27 
Breast n= 
170 
Pelvis n=17 
Other n=4 
Severity of RD at the 
end of RT and two 
weeks post 
treatment 
Patient assessment at 
end of treatment: 
cohort 2 scored lower 
for itch and 
discomfort (mean 1.3 
C2 vs 3.0 C1) 
discomfort ( 2.2 vs 
3.3) respectively. 
Radiographer scored: 
RTOG 
C1 
Grade 0=8% 
Grade 1=49% 
Grade 2=34% 
Grade 3= 9% 
C2 
Grade 0=26% 
Grade 1=53% 
Grade 2=16% 
Grade 3=5% 
P<0.001 
When they compared 
those using steroid 
creams vs those not 
using steroid creams 
at the end of RT there 
was a significant 
reduction in patient 
reported redness, 
itch, discomfort and 
pain and less use of 
analgesia and lower 
sleep disturbance in 
the steroid use group 
p<0.001 High 
Fenton-Kerimian 
et al. 2015 
Pilot 
randomised 
feasibility study 
comparing 
three topical 
interventions 
CTCAE at 
baseline, each 
week during 
RT, one week 
post RT, one 
month post RT 
and three 
months post 
RT, also used 
the 
Dermatology 
Life Quality 
Index at the 
same time 
points 
n=30, n=10 per 
intervention 
Intervention 1= 
homeopathic cream 
calendula applied 
twice daily to the 
treated breast 
Int 2= hydrogel 
cream (RadiaPlex®) 
applied twice daily 
Int 3= medium 
potency steroid 
cream (0.1% 
mometasone 
furoate) twice per 
week in weeks 1 and 
2 then once daily in 
week 3 and an 
emollient 
Aquaphor® used 
daily throughout 
treatment. 
Breast 
cancer 
Severity of RD 
reported 
Little data reported. 
All patients reported 
a grade 1 reaction 
and highest skin 
reaction was grade 2 
reported in all three 
groups (interventions 
1, 2 and 3) and this 
was at one week post 
RT. 
No statistical 
difference reported 
in DLQI scores (to be 
expected given the 
small numbers per 
group) 
NS High 
Halm et al. 2014 Randomised 
feasibility trial 
RTOG at three 
weeks, and six 
weeks 
n=24, control n=11, 
intervention n=13 
Control = 
RadiaPlexRx® 
ointment 
(hyaluronic acid and 
mannan 
polysaccharides) 3x 
per day during RT 
and up to one 
month post 
treatment. 
Intervention = four 
essential oils, 
Helichrysum 
angustifolium, 
(helichrysum 2.5%) 
Boswellia cateri 
(frankincense 5%) 
Lavandula 
angustifolia 
(lavender 5%) and 
Pelargonium 
graveolens 
(geranium 5%) total 
concentration of 
17.5%. This mixture 
also had a carrier 
composition that 
Breast 
cancer 
Reported mean 
RTOG scores at 
three weeks and six 
weeks 
No difference in 
mean RTOG scores at 
3 weeks or 6 weeks. 
Rash rating were 
higher in the control 
subjects at 6 and 10 
weeks compared 
with the 
experimental group, 
pain scores were 
higher in control 
subjects at week 6 
but ulcer ratings 
were higher in the 
experimental group 
at week 6 and 10, 
none of the 
differences were 
statistically significant 
(given the small 
sample this is not 
unexpected). 
Adherence was good 
but the authors 
indicate participants 
also used other 
creams and topical 
NS High 
included jojoba, 
aloe vera, tamanu 
and evening 
primrose. This was 
applied 3x daily until 
one month FU 
agents during the 
study as time went 
on- which is likely to 
confound the results. 
Ho et al. 2018 Phase III double 
blind RCT 
CTCAE scores 
of acute 
radiation 
dermatitis 
n=143, intervention 
analysed n=64, 
control analysed 
n=60 
Intervention= 0.1% 
mometasone 
furoate vs control= 
Eucerin® original 
cream. Eucerin® 
contains the 
following 
ingredients: 
• water 
• petrolatum 
• mineral oil 
• ceresin 
• lanolin alcohol 
• phenoxyethanol 
• piroctone olamine 
Breast 
cancer 
Grade 2 or above 
CTCAE version 4 
radiation dermatitis 
with moist 
desquamation or 
any grade 3 or 
above dermatitis. 
Secondary 
endpoints were 
time to occurrence 
of maximum grade 
dermatitis and 
patient reported 
skin symptoms using 
Skindex-16 
assessments were 
by provider 
The intervention arm 
had a significantly 
lower rate of grade 2 
or grade 3 with moist 
desquamation than 
the control arm 
(43.8% vs 66.7% 
respectively 
p=0.012). The 
intervention arm had 
a lower incidence of 
maximum grade RD 
18.8% vs 33.3% 
p=0.036. 
Time to development 
of grade 2 RD was 
similar between the 
two groups but time 
to development of 
grade 3 dermatitis 
was shorter in the 
control arm, 35.5 
days vs 46 days 
(control arm) 
p<0.001. 
Univariate analysis 
identified only V110 
as the only significant 
predictor of moist 
desquamation 
p=0.0021 with 
reconstruction close 
to sig P=0.072. 
Multivariate analysis 
indicated that a 
BMI>30 HR 1.04 
p=0.02 and use of the 
control cream HR 
2.34 p<0.001 were 
predictive of moist 
p=0.012 Low 
desquamation. A 
second multivariate 
analysis showed that 
V110 was predictive 
of moist 
desquamation HR 
1.03 p=0.0021. 
Patient reported 
outcome measures 
showed no difference 
between groups 
Chan et al. 2014  Double blind 
single centre 
RCT 
CTCAE version 
4 measured at 
baseline, and 
weekly 
through 
treatment up 
to week 11, 
also measured 
patient 
reported 
outcomes 
through pain 
measure and 
Skindex-16 
n=174 randomised, 
n=89 allocated to 
cream 1 (oil-based 
emulsion), n=85 
allocated to cream 
2, n=88 analysed 
cream 1 and n=85 
analysed cream 2 
Oil-based emulsion 
containing allantoin 
vs aqueous cream 
(control). 
Creams applied at 
start of RT twice 
daily or more if 
needed until 
reaction subsided 
Breast 
cancer, lung 
cancer, and 
head and 
neck cancer 
  Cream 1 (oil base 
emulsion) showed 
significantly lower 
average skin toxicity 
scores at week 3, 
approx 0.8 vs approx 
1.0 p<0.05. However, 
patients in group 1 
had significantly 
worse average skin 
toxicity scores in 
weeks 7,8 and 9 
p<0.001. 
There was a 
significantly higher 
proportion of 
patients with a skin 
toxicity grade higher 
than grade 2 in the 
cream 1 group in 
weeks 6 (72% vs 58% 
p=0.045), 7 (71.6% vs 
41.7% p<0.001), 8 
(40% vs 24% p=0.02) 
and 9 (24.7% vs 6.6% 
p=0.001). 
No significant 
difference in time to 
event data for grade 
2 and above toxicity. 
Univariate analysis 
identified age and 
treatment site (lung 
p<0.05 Low 
vs breast) as 
significant factors 
influencing skin 
toxicity. In the 
multivariate analysis, 
lung treatment site 
was identified as a 
significant predictive 
factor for skin toxicity 
P<0.001 
Karbasforooshan 
et al. 2018 
Double blind 
single centre 
randomised 
placebo 
controlled trial 
RTOG and 
CTCAE 
measured at 
baseline and 
then weekly 
during 
radiotherapy 
(weeks 1 to 5) 
n=40, n=24 allocated 
to silymarin group, 
n=21 randomised to 
placebo, 
intervention n=20 
analysed, control 
n=20 analysed 
Intervention- 
silymarin (herbal 
medicine, dry 
extract of Silybum 
marianum, also 
known as milk 
thistle) given as a 
gel 1% containing 
80% active 
ingredient based on 
silymarin 
flavonolignans. 
Used once daily or 
placebo (matched in 
consistency and 
colour to the 
intervention gel). 
Used from the start 
of RT, used 
consecutively for 
five weeks 
Breast 
cancer (post 
mastectomy) 
  In weeks 1 and 2 both 
groups are 
comparable in terms 
of RTOG scores (20% 
grade 1 at week 2 for 
both groups). By 
week 3 the silymarin 
group demonstrates 
a non-significant 
lower toxicity rate: 
grade 1 80%, grade 2 
20% (silymarin) vs 
grade 1 45%, grade 2 
50%, grade 3 5%. By 
weeks 4 and 5 the 
reduced toxicity is 
marked and 
significant. 
Week 5 grade 1 100% 
silymarin group, 
placebo grade 1 55%, 
grade 2 40%, grade 3 
5% p=0.003 
p=0.003 (for 
week 5 data) 
Low 
Lam et al. 2019 Within subject’s 
experimental 
design single 
centre 
RTOG 
measured at 
baseline, and 
baseline 
photographs 
were taken on 
day 1 of 
treatment. Of 
the weekly 
RTOG scores, 
the highest 
was recorded 
for score 
during 
n=56 randomised 
(over two years) 
n=27 randomised to 
lateral and n=29 
randomised to 
medial for barrier 
film (BF).  
For lateral applied 
BF, data available 
for analysis of 
blinded photographs 
was n=24. 
For medial applied 
BF, data available 
Barrier film (alcohol-
free film formulated 
from two polymers. 
For the half of the 
breast not covered 
with film, standard 
care was used that 
included using 
Glaxal Base® cream, 
which is similar to 
aqueous cream. 
BF started on first 
day of treatment. 
Applied twice per 
Breast 
cancer 
  Patient reported 
outcomes, no 
significant difference 
in reported scores 
seen for burning, 
pulling and 
tenderness for those 
with BF applied to 
medial, one 
significant 
improvement in 
score for itching 1.14 
vs 2.06 p=0.035. 
In cases where the BF 
p=0.041 for 
laterally 
placed BF 
Moderate 
treatment. The 
photographs 
taken at 
baseline and 
FU were 
assessed blind 
for analysis of 
blinded photographs 
was n=29 
week, not applied 
between last RT 
session and FU 
appointment 
was applied to the 
lateral only, for 
burning was there 
seen a significant 
difference in patient 
reported scores, 0.92 
vs 1.83 (p=0.047), no 
confidence interval 
presented. No 
significant difference 
seen between BF and 
standard care for 
time to development 
of grade 2 RD. 
 
RTOG during 
treatment – some 
errors in results 
presented for 
calculated numbers 
with grade 2 or more 
RTOG (numbers 
presented not added 
correctly). 
In those with lateral 
BF grade 2 or more 
RD 17.3% vs 27.6% 
for no film p=0.041. 
For medial cases 
17.2% for the BF 
cases and 9.6% for no 
film p=0.76. 
 
Post treatment no 
difference seen in 
grade 2 or above 
scores for BF vs no 
film. There was no 
significant difference 
seen in the RTOG 
obtained from 
photographs 
Møller et al. 
2018 
RCT patient own 
control 
CTC scored by 
RTT blinded to 
randomisation. 
Patient 
reported 
outcome 
surveys (PROs) 
101 n=79 analysed Intervention: 
Mepitel® applied to 
lateral or medial 
breast. Control: 
opposite side 
treated as per 
guidelines i.e. using 
moisturiser and for 
itch/steroids 
Breast 
cancer 
To investigate 
patient reported 
symptoms related 
to radiotherapy 
dermatitis and to 
examine patient 
preferences using 
Mepitel® film 
compared to 
standard skin care. 
Secondary, compare 
to general 
population 
CTC scores: no 
significant difference 
in grades 1 to 3 at 
end of treatment or 
at 14 days. Patient 
reported outcomes 
were that the film 
was comfortable, and 
patients felt it made 
a difference. At 14 
days pain was 
reduced (p.0.001) 
and sensitivity of the 
skin (p<0.01) as well 
as itching 
Pain reduced 
p.0.001  
Low 
Näf et al. 2018 Pilot study CTC scored by 
nurse and 
doctor, grade 2 
s2,4,6 and 8 
weeks 
20 int in analysis. 
100 controls 
Intervention: 
administration of 
the Camellia 
sinensis 
nonfermentatum 
(CSNF) 0.4% lotion 
seven days prior to 
RT, preventative gel 
CSNF 2.5% 
administered 1-2 
hours prior to 
radiotherapy. 
Control: 
comparative group 
had treatment 
related to care 
guidelines i.e. 
Excipial® or 
Bepanthol® or 
Ialugen® cream 
Breast 
cancer 
To assess 
effectiveness of 
NPE® of CNSF 
extract in 
prevention and 
recovery of acute 
radiation induced 
skin reactions 
CTC scores not 
significantly different. 
Showed trend, 
significant delay in 
grade 2 
 NS High 
Rades et al. 
2019 
RCT CTCAE v4 57 (n=28 Mepitelâ 
n=29 standard care 
Intervention: 
Mepitel® film 
started on first day 
continued until 
grade 2 moist 
desquamation. Film 
changed twice 
weekly. Control: 2-
5% urea and fatty 
acid cream 
Head and 
neck cancer 
stratified 
between 
groups 
Comparison of 
Mepitel® film to 
standard skin care 
for prevention of 
grade 2 radiation 
dermatitis 
46.4 % of patients 
had sensitivity to 
Mepitel® (13 of 28) 
so study stopped at 
interim analysis. At 
50Gy 8/23 (34.8%) in 
the intervention 
group had grade 2 
and 10/28 (35.7%) in 
control group (NS). At 
60Gy grade 2 rates 
were 65.2% (15/23) 
and 59.3% (16/27) in 
the control (NS) 
See results 
column 
Low 
Ogita et al. 2019 RCT Sebum content 
and 
composition. 
Sebumeter at 
four time 
points 2,4 
weeks and 3 
months 
81 (80 randomised), 
n=74 analysed 
(intervention=16) 
(control=64), then 
from this group post 
whole breast 
radiotherapy 
(WBRT), 
intervention n=32 
and control n=32 
Intervention: 
prophylaxis used 
heparinoid 2x daily 
from first txt until 2 
weeks after WBRT. 
Control: no 
moisturiser but 
reassigned at 2 
weeks after WBRT 
to receive 
moisturiser or not 
Breast 
cancer 
Explore time course 
and water content 
of stratum corneum 
to assess skin 
damage with 
heparinoid cream 
Intervention 
significantly reduced 
sebum content 
overall. No 
differences seen 
between groups but 
confusing analysis 
See results 
column 
High 
Schmeel et al. 
2018 
RCT patient own 
control 
RTOG and 
EORTC 
recorded 
weekly, RISRAS 
but not 
reported 
62 (56 analysed) Intervention: 
hydrofilm. Control: 
5% urea 
Breast 
cancer 
Compare 
prophylactically 
applied hydrofilm 
dressings with 
standard skin care 
using moisturising 
5% urea 
Significantly reduced 
severity of RTOG 
mean 0.35 and 1.33 
in the control with 
p<0.001. 
RTOG/EORTC end of 
treatment severity: 
grade 0 48% film vs 
control 12.5%, grade 
1 39.3% vs 46.4%, 
grade 2 12.5%.vs 
30.4%, moist 
desquamation 0% vs 
10.7% 
p<0.001 High 
Sekiguchi et al. 
2015 
RCT Sebum content 
and 
composition. 
Sebumeter at 
four time 
points 2,4 
weeks and 3 
months. Diary 
for compliance 
(acute 
radiation 
dermatitis 
ARD) scores 
i.e. clinician 
rated score 
749 women 
assessed: 
intervention 14 and 
control 32 
Intervention: 
prophylaxis used 
heparinoid 2x daily 
from first txt until 
two weeks after 
WBRT. Control: no 
moisturiser 
Breast 
cancer 
Efficacy of 
heparinoid 
moisturiser as 
prophylactic agent 
Skin dryness was 
significantly higher in 
the control group at 2 
and 4 weeks. Itching 
and pain VAS scores 
generally higher at 
last day, No 
significant differences 
at 3 months 
See results 
column 
High 
Sekiguchi et al. 
2018 
RCT Water content, 
and severity 
scoring none 
to very severe 
2 to 4 weeks 
after RXT 
749 women 
assessed: 
intervention 32 and 
control 32 
Intervention: 
prophylaxis used 
heparinoid 2x daily 
from first txt until 
two weeks after 
WBRT. Control: no 
moisturiser  
Breast 
cancer 
Efficacy of 
heparinoid 
moisturiser as 
prophylactic agent 
Skin dryness 
significant difference 
between groups 
between moisturiser 
and no moisturiser 
(p=0.01). No 
significant clinician 
rated skin toxicity or 
patient reported 
except pain scores at 
last day of RT 
p=0.01 High 
Sio et al. 2016 RCT CTCAE v3 4 
PROS (LASA) 
assessed at 
baseline and 
weekly 
167 women Intervention:  
topical 0.1% 
mometasone. 
Control: no 
moisturiser 
Breast 
cancer 
Dermatitis evolution 
of mometasone 
furoate 
Radiation symptoms 
started between 
weeks 4-7 and 
subsided after week 
8. CTCAE showed no 
significant 
differences. 
Significant 
differences in PROs 
over time between 
arms (p=0.001) 
P=0.001 Low 
Togni et al. 2015 RCT Camera visual 
intensity and 
colour analysis. 
RTOG 
 114 
n=55 Boswellia 
cream, n=59 base 
cream 
Intervention: 
Boswellia cream, 
control base cream   
Breast 
cancer 
Safety and efficacy 
of boswellia-based 
cream for 
prevention of 
adjuvant skin 
damage 
RTOG grade 2 toxicity 
71.2% for control and 
54.6% boswellia 
cream. Not 
significant. Claims in 
abstract it is able to 
reduce erythema, no 
regression for risk 
factors. Skin colour 
intensity less in 
intervention but not 
significant 
p=0.066 High 
Ulff et al. 2017 Long-term 
follow-up from 
trial comparing 
normal breast 
tissue 
RTOG. Skin 
thickness using 
ultrasound. 
Dryness 
measured. 
Cosmetic 
results. Six 
years after 
treatment 
60 (intervention=28, 
control=32) 
Intervention: 
betamethasone 
0.1%. Control: 
moisturiser 
Breast 
cancer 
Evaluate whether 
treatment with 
potent steroid 
during adjuvant 
ExBRT is associated 
with late toxicity 
Skin atrophy not 
noted in any of the 
60 patients. No 
significant differences 
between normal 
tissue and treated 
with steroids. Ten 
(17%) had noticeable 
skin changes. Three 
(5%) had altered skin 
pigmentation 
NS Low 
Ulff et al. 2017 RCT RTOG. VAS of 
itching, skin 
irritation 
686 Intervention: 
betamethasone 17-
valerate cream, 
Applied seven days 
per week until two 
weeks after RT. 
Control: moisturiser 
Breast 
cancer 
Test hypothesis that 
preventative topical 
steroid treatment 
instituted at start of 
radiotherapy can 
ameliorate acute 
radiation dermatitis 
Patients receiving 
hypofractionated RT 
developed less skin 
reactions than those 
treated with control 
Those on steroid 
cream had 
significantly less skin 
reactions regardless 
of RT schedule 
p<0.001 Low 
Ryan Wolf et al. 
2018  
Phase 2 multi-
site, 
randomised, 
double blind, 
placebo 
controlled trial 
Baseline, 
weekly after 
every fifth RT 
session, at the 
end of RT (end 
RT), and 1 
week after RT 
completion. 
RDS scale, 
digital imaging, 
completion of 
three self-
report 
questionnaires, 
McGill Pain 
Questionnaire, 
Skindex-29, 
Symptom 
Inventory  
578 total:   
intervention=283 
and control=295  
Intervention: 
curcumin capsule, 
four capsules 3x 
daily for full course 
of RT and one week 
post RT with food.                                                       
Control: placebo 
capsule, four 
capsules 3x daily for 
full course of RT and 
one week post RT 
with food   
Breast 
cancer 
To determine the 
efficacy of oral 
curcumin, one of 
the biologically 
active components 
in turmeric, at 
reducing radiation 
dermatitis severity 
(RDS) at the end of 
RT, using the RDS 
scale, compared to 
placebo 
No significant 
difference in mean 
RDS score at end RT 
between curcumin 
and placebo.                                                                                                                                    
No beneficial effect 
reported from using 
curcumin 
 p=0.565 end 
of RT  
Moderate 
Strouthos et al. 
2017 
Non-
randomised 
single centre 
study 
Weekly CTCAE  
and physical 
assessment,  
weekly VAS,  
weekly 
photographs  
70 total:  
intervention=25, 
control (no 
intervention)=45 
Photobiomodulation 
(PBM) LED therapy  
Breast 
cancer 
To evaluate the 
beneficial role of 
photobiomodulation 
therapy in 
preventing/reducing 
radiation dermatitis 
during radiotherapy 
for breast cancer. 
Primary endpoint 
RD grade and pain  
8% of PBM group 
experienced grade 1 
RD and 12% grade 3 
RD. 55.6% of control 
group experienced 
grade 1 RD, 40% 
grade 2 and 4.4% 
grade 3 (resulting in 
RT pause). 48%  of 
matched group grade 
1, 44% grade 2 and 
4% grade 3                                                                                                  
RD lower in 
PBM group 
compared to 
control 
p=0.0211 
Low  
Hoopfer et al. 
2015  
Phase III RCT  10-point 
Catterall skin 
scoring profile 
(CSSP) scoring, 
six-point Likert 
scale for 
severity and 
changes in  
burning, 
itchiness, pain 
and dryness. 
Maximum 
CSPP scores  
for erythema, 
dry and moist 
desquamation 
<  50%  and > 
50% of field  
248 in total : 81 aloe 
cream, 77 
placebo,79 powder  
1. aloe cream  
2. placebo cream:  
composed of 
Aquatrix II™. 
Both creams 
subjected to 
bioassay testing.  
3. dry powder: non-
metallic baby 
powder or 
cornstarch to intact 
skin followed by one 
month of Glaxal 
Base® cream post 
RT  
Breast 
cancer 
Phase III RCT to test 
hypothesis that the 
use of aloe would 
lead to a one point 
reduction in RISR 
severity and a 
decrease in 
symptom severity 
compared with a 
traditional dry 
powder skin care 
regime 
Mean of max CSSP 
value: 6.27 for the 
powder, 6.96 for the 
aloe (p=0.227 and 
6.99 for the placebo 
(p=0.845). 
These did not meet 
the one point 
difference that was  
deemed to infer 
clinical significance. 
 
Symptom severity 
(pain) reported 
significant changes 
with 9/67 powder 
arm rating pain as 
high, 21 /72 aloe 
cream and 25/74 for 
the placebo when 
reported one week 
post RT  
 
            
Intervention 
p=0.227,  
placebo 
p=0.845 
Low  
Rollman et al. 
2015 
Double blind 
randomised 
pilot study  
CTCAE v3.0 
scale,  
Skindex-16, 
skin 
experience 
diary (SED). 
Baseline, 
weekly 
intervals 
during RT, six 
weeks post 
treatment 
completion  
42 in total: 
intervention=28, 
control=14 
Emu oil, placebo 
(cottonseed oil).  
Applied 1.5ml 2x 
daily for duration of 
RT and up to six 
weeks post RT. 
Not applied sooner 
than four hours 
before delivery of 
RT.  
Had to have used 
before 3rd fraction.  
No other creams or 
oils.  
Discretion by 
provider as to other 
supportive 
treatments for 
symptom relief. Any 
Skin treatments 
were documented  
Breast 
cancer 
Demonstrate the 
feasibility and safety 
of using an oil-based 
product during 
breast cancer 
radiotherapy  
PROM from Skindex: 
average scores 7.4 vs 
10.4 for the 
intervention and 
control respectively.  
Lower mean scores 
for all areas: 
emotional, symptoms 
and functional.  
 
Peak CTC toxicity 
occurred at week 6 of 
intervention group, 
appeared slightly 
worse but "not 
statistically 
significant" (not 
reported statistically, 
just narrative)  
p=0.29 Pilot study  
Cui et al. 2015 Single 
institution, 
prospective 
study  
RTOG and VAS 
also used  
94 in total, 47 in 
each group  
Intervention: 
administration of 
olive oil 3 x daily 
from #1 and for two 
weeks post RT 
completion.  
Control: placebo 
(water) during RT 
(not specified if 
same as above) and 
for two weeks post 
treatment 
completion   
 
Nasopharynx 
Evaluate the effect 
of olive oil on 
radiation dermatitis  
Grade 1 and 2 
reactions in 93.6% 
intervention and 
72.3% of control  
grade 3 in 6.4% of 
intervention and 
27.7% of control  
p<0.001 Moderate 
Censabella et al. 
2017 
Single 
institution, non-
randomised 
with historical 
controls   
WHO criteria 
for grading 
acute 
cutaneous 
toxicities  
222 in cohort plus 
two matched 
historical groups 
from two previous 
studies, 136 and 100 
respectively, but half 
of each of these 
were excluded due 
to a change in RT 
technique 
Numbers analysed 
N= 202 (hydrogel 
gp) n=131 
(Dexpanthenol 
group) n=87 
(dexpanthenol and 
hydrogel group). 
Hydroactive colloid 
gel to the irradiated 
area  
Breast 
cancer 
The efficacy of this 
same hydroactive 
colloid gel in the 
prevention of RIMD, 
with the hypothesis 
that using this agent 
preventively would 
be even more 
beneficial with 
respect to incidence 
and onset time of 
RIMD. 
Incidence of RIMD 
6.9% in intervention 
arm v's 35.1% and 
12,6% in the 
historical control 
arms  
The difference in 
moist desquamation 
was significant when 
looking at medium 
and larger breasted 
patients P<0.0001 In 
univariate analysis 
breast size and use of 
the hydrogel as a 
preventative 
measure were the 
only significant 
factors that 
contributed to the 
incidence of moist 
desquamation. 
p<0.0001 High 
Manas et al. 
2015 
Randomised 
clinical trial 
CTCAE and 
EORTC QLQ 
with breast 
and head and 
neck modules 
n=102, number 
analysed n=98 (four 
excluded as did not 
meet inclusion 
criteria) 
Topical R1 was 
applied once per 
day within two 
hours of RT, R2 
applied four times a 
day (three times 
during the day and 
last application just 
before bedtime). R1 
and R2 applied from 
first day of RT until 
two weeks post 
treatment. 
Control= use of a 
urea-containing 
ointment 5% wt/wt 
urea. Applied from 
day 1 until two 
weeks post 
treatment 
Breast 
cancer and 
head and 
neck cancer 
Primary end point 
was progression to 
grade 3 or 4 CTC RD. 
Secondary were 
overall response 
rate and effects on 
quality of life 
(EORTC QLQ) 
Significant 
differences seen in 
grade of toxicity 
between intervention 
and control arm at 
each time point. At 
end of RT 57% of 
patients in the R1 R2 
group had RD 
compared with 100% 
in the control arm 
p<0.0001.Two weeks 
post RT, 33.3% of the 
R1 R2 patients and 
66% of the control 
had RD p=0.0003. 
QoL score showed 
benefits for the R1 R2 
patients in terms of  
skin dryness, stinging 
and desquamation 
for patients with 
breast cancer and 
reduced use of 
medication for pain 
for those with head 
and neck cancer. No 
actual data is 
presented to confirm 
the extent of the 
differences stated 
p<0.0001 High 
 
 
OR = Odds ration common statistical abbreviation 
CI = Confidence interval 
HR= Hazard ratio 
NS= None significant 
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2019 Review summary of 
evidence table
Author and Year Description Scale or other measuring tool (RTOG etc.) Sample size n= Intervention and control Category of patients primary endpoint Results P-value QA (Risk of bias )
Robijns et al 2019 A single centre prospective placebo controlled RCT RTOG measured at baseline, 40Gy and 66Gy time points, objective measures of skin 
hydration, transdermal water loss and pigmentation
139, n=120 included in the analysis Photobiomodulation therapy, placebo (control) Breast cancer Incidence of moist 
desquamation
Incidence sig higher in control arm at 66Gy time point OR=6 95%CI 1.881-19.82 0.004 Low
Aysan et al 2017 A single centre double blind placebo controlled RCT RTOG measured at baseline and at 5th week of RT number analysed =47 Boron gel, placebo (Vaseline, petroleum jelly) Breast cancer RTOG score at week 5 Statistically sig higher proportion of patients in the control arm had grade 2 (or above 
) RTOG score p=0.03) although patient satisfaction higher in control arm).
Moderate 
Arimura et al 2015 A single centre trial- patient preference non 
randomised.
CTC version 4 measured an alternate days during treatment, then after treatment 
once a week for a month then every 3 months for 2 years.
271 enrolled in the study (n=145 chose FD) (n=126 chose standard care). FD- Airwall, vs standard skin care Prostate cancer Highest grade of RD Time to grade 1 or 2 same for both groups, 14% in FD group developed grade 2 or 
higher RD, vs 48% in control group.
p<0.001 High 
Baumann et al 2017 Single centre phantom dosimetry study Assessment of surface dose with and without aluminium containing anti-
perspirants using optically stimulated luminescent dosimeters (OSLDs)
tested on a 5x5 paper with 8 rolls of antiperspirant Compared two strengths of aluminium antiperspirant 15% and 25% n/a Surface dose in cGy No difference seen between no antipersp and both perspirant strengths, at a range of 
gantry angles,
no sig diff Low (non human study)
Ben-David et al 2016 Phase II prospective Randomised placebo controlled 
double-blind Trial.
RTOG CTC version 3 measured at Baseline
Weekly during 5 weeks of treatment and 
2 weeks post treatment
n=47, 26 in the melatonin-cream group, 21 in the placebo group Melatonin-containing emulsion intervention placebo cream control, 
physician and patient blind to allocated arm asked to apply the cream 2x 
daily over the treated breast (but not less than 2 hours before treatment). 
Pts advised not to use any other marketed or natural product during the 
radiation period.
Breast Cancer RTOG scores during RT 
and at 2 weeks follow up.
No difference in RTOG scores during RT, but at week 7 (2 weeks post RT)Melatonin 
group, 59% grade 0, 41% grade ½ vs 11% grade 0 and 90% grade ½ in the placebo 
group (p=0.03). 
No difference in patient reported subjective reports between the groups.
p=0.03 only at FU Low
Censabella et al 2016 Single centre non-randomised trial RTOG and RISRAS , Skindex-16 (QoL) measured before the start of laser therapy and 
at the end of radiotherapy
n=87, n=45 control arm (n=41 analysed) n=42 LT (n=38 analysed) Control had standard skin care-hydrocolloid gel, self-adhesive silicone 
foam dressing (Mepilex) for painful skin reactions
Intervention-standard skin care plus 6 sessions of LT-give 2x per week 
starting from fraction 20
Breast Cancer patients Severity of RD (STOG and 
RISRAS) and QoL (Skindex-
16)
At fraction 20 RD levels were comparable between groups (baseline score)
In the control arm there was a significant increase in RTOG score grade 2 to 29.3% at 
end of RT compared with 4.9% at #20(p=0.01). In the LT group RD remained stable 
(p=0.22) with only 1 patient with an RTOG grade 2 at the end of RT.
There was significant differences between the control and LT RISRAS scores for both 
patient reported and clinician reported scores in favour of the LT.
RISRAS scores total p=0.003 Moderate
Chan et al 2019 A single blind Randomised controlled superiority trial. CTCAE version 4.0 end of treatment n=197, Intervention arm n=89 analysed (n=11 lost to FU or exited the trial) 
Control arm n=83 analysed (n=13 lost to FU or exited the trial)
Intervention StrataXRT, control Sorbolene Head and Neck cancer Severity of RD at the end 
of RT
Age, Total dose, skin dose verification, number of fractions prescribed and PTV size 
were comparable between groups. The StrataXRT group had higher mean BMI than 
the control arm.
The control arm had greater proportion of patients with tomotherapy and greater 
number having 6FFF energy.
All other characteristics were comparable between groups 
Authors state after adjustment BMI and technique (VMAT or tomotherapy had no 
effect on outcome) but it is not clear if they controlled for FFF or FB- FFF beams show 
a modest increase in surface dose compared with flattened beams so if not 
controlled for this could have an impact on outcomes in the control arm.
At the end of treatment StrataXRT arm- grade 2 (80%) grade 3 (28%), control arm 
grade 2 (91%) and grade 3 (45%)- I’m not sure why these add up to more than 100%?
After controlling for Cetuximab the StrataXRT arm had 12% lower risk of experiencing 
grade 2 skin toxicity ( RRR=0.876, 95% CI 0.778-0.987) and a 36% lower risk of 
p=0.025 moderate
Eda et al 2016 A double-blind Randomised controlled trial RTOG - not clear at what time point the RTOG was measured number enrolled=40 number analysed =38, I=18, Control=20 Intervention= Glutamine 15g per day in 3 doses started 1 week prior to RT 
continued until 1 week post trt, control received a placebo
Breast cancer none given Intervention grade 1= 88.9%, grade 2= 11.1%, Control grade 1=0, grade 2=80%, grade 
3=20% sig p<0.001
p<0.001 High
Erridge et al 2016 Audit of new skin care policy using steroid cream 
(Betamethasone valerate 0.1%.)
RTOG and PROM via a questionnaire at the end of RT and 2 weeks post treatment. Total sample size =219 cohort 1= 112, cohort 2 = 107 "Patients identified as high risk, applied steroid cream from day 1 of RT and 
up to 2 weeks post trt (once a day) Betamethasone valerate 0.1%. Medium 
and high risk patients were also given Diprobase as an emollient. Control 
was a cohort of patients treated prior to the implementation of the policy."
H+N including brain n=27
Breast n= 170
Pelvis n=17
Other n=4
Severity of RD at the end 
of RT and 2 weeks post 
treatment
Patient assessment at end of treatment Cohort 2 scored lower for itch and 
discomfort (mean 1.3 C2 vs 3.0 C1) ( 2.2 vs 3.3) respectively.
Radiographer scored RTOG
C1
Grade 0=8%
Grade 1= 49%
Grade 2= 34%
Grade 3= 9%
C2
Grade 0=26%
Grade 1= 53%
Grade 2= 16%
Grade 3= 5%
P<0.001
When they compared those using steroid creams vs those not using steroid creams 
at the end of RT there was a significant reduction in patient reported redness, itch, 
discomfort and pain and less use of analgesia and lower sleep disturbance in the 
p<0.001 High
Fenton-Kerimian 2015 Pilot randomised feasibility study comparing three 
topical interventions
CTCAE at baseline, each week during RT, one week post RT, one month post RT and 
three months post RT, also used the Dermatology Life Quality Index at the same 
time points
N=30, n=10 per intervention Int 1= homeopathic cream calendula applied twice daily to the treated 
breast
Int 2= Hydrogel cream (RadiaPlex) applied twice daily
Int 3= medium potency steroid cream (0.1% mometasone fuorate) twice per 
week in weeks 1 and 2 then once daily in week 3 and an emollient Aquaphor 
Breast Cancer Severity of RD reported NS High
Halm 2014 Randomised feasibility trial RTOG at 3 weeks, and 6 weeks n=24, control n=11, Int n=13 Control = RadiaPlexRx ointment (hyaluronic acid and mannan 
polysaccharides) 3x per day during RT and up to one month post 
treatment.
I= 4 essential oils, Helichrysum angustifolium, (Helichrysum 2.5%) Boswellia 
cateri (Frankincense 5%) Lavandula angustifolia (Lavenda 5%) and 
Pelargonium graveolens (Geranium 5%) total concentration of 17.5% this 
mixture also had a carrier composition that included Jojoba, aloe vera 
Breast cancer Reported mean RTOG 
scores at 3 weeks and 6 
weeks
Little data reported.
All patients reported a grade 1 reaction and highest skin reaction was grade 2 
reported in all three groups (Interventions 1, 2 and 3) and this was at one week post 
RT.
No statistical difference reported in DLQI scores (to be expected given the small 
numbers per group).
NS High
Ho 2018 Phase III double blind RCT CTCAE scores of acute radiation dermatitis N=143, I analysed n=64, Control analysed n=60 Intervention= 0.1% mometasone furoate vs Control= Eucerin original 
cream.Eucerin contains the following ingredients:• Water
• Petrolatum
• Mineral Oil
• Ceresin
• Lanolin Alcohol
• Phenoxyethanol
• Piroctone Olamine
Breast cancer  grade 2 or above CTCAE 
version 4 radiation 
dermatitis with moist 
desquamation or any 
grade 3 or above 
dermatitis.
Secondary endpoints were 
time to occurrence of 
maximum grade dermatitis 
and patient reported skin 
symptoms using Skindex-
16
Assessments were by 
The intervention arm had a significantly lower rate of grade 2 or grade 3 with moist 
desquamation than the control arm (43.8% vs 66.7% respectively P=0.012). The 
Intervention arm had a lower incidence of maximum grade RD 18.8% vs 33.3% 
P=0.036.
Time to development of grade 2 RD was similar between the two groups but time to 
development of grade 3 dermatitis was shorter in the control arm 35.5 days vs 46 
days (control arm) P<0.001.
Univariate analysis identified only V110 as the only significant predictor of moist 
desquamation P=0.0021 with reconstruction close to sig P=0.072.
Multi variate analysis indicated that a BMI>30 HR 1.04 P=0.02 and use of the control 
cream HR 2.34 P<0.001 were predictive of moist desquamation. A second 
Multivariate analysis showed that V110 was predictive of moist desquamation HR 
1.03 P=0.0021.
P=0.012 Low
Chan 2014 (ref 75) Double-blind single centre RCT CTCAE version 4 measured at baseline, and weekly through treatment up to week 
11, also measured patient reported outcomes through pain measure and Skindex-
16
N=174 randomised, n=89 allocated to cream 1 (oil based emulsion), n=85 
allocated to cream 2, n=88 analysed cream 1 and n=85 analysed cream 2
oil-based emulsion containing allantoin vs aqueous cream (control)
Creams applied at start of RT twice daily or more if needed until reaction 
subsided.
Breast cancer, Lung cancer 
and head and neck cancer
Cream 1 (oil base emulsion) showed significantly lower average skin toxicity scores at 
week 3 approx. 0.8 vs approx. 1.0 p<0.05, however, patients in group 1 had 
significantly worse average skin toxicity scores in weeks 7,8 and 9 P<0.001
There was a significantly higher proportion of patients with a skin toxicity grade 
higher than grade 2 in the cream 1 group in weeks 6 (72% vs 58% P=0.045), 7 (71.6% 
vs 41.7% P<0.001) 8 (40% vs 24% P=0.02)and 9 (24.7% vs 6.6% P=0.001)
No significant difference in time to event data for grade 2 and above toxicity.
Univariate analysis identified age and treatment site (lung vs breast)as significant 
factors influencing skin toxicity, in the multivariate analysis lung treatment site was 
identified as a significant predictive factor for skin toxicity P<0.001
P<0.05 Low
Karbasforooshan et al 2018 Double-blind single centre randomised placebo 
controlled trial
RTOG and CTCAE measured at baseline and then weekly during radiotherapy (weeks 
1 to 5).
N=40 N=24 allocated to Silymarin group n=21 randomised to placebo, 
intervention n=20 analysed, control n=20 analysed
Intervention- Silymarin (herbal medicine, dry extract of S. marianum, also 
known as milk thistle) given as a gel 1% containing 80% active ingredient 
based on silymarin flavonolignans used once daily, or placebo (matched in 
consistency and colour to the intervention gel)
Used from the start of RT used consecutively for 5 weeks.
Breast Cancer (post 
mastectomy)
In weeks 1 and 2 both groups are comparable in terms of RTOG scores (20% grade 1 
at week 2 for both groups). By week 3 the Silymarin group demonstrates a non-
significant lower toxicity rate Grade 1 80% grade 2 20% (Silymarin) vs Grade 1 45%, 
grade 2 50%, grade 3 5%. By weeks 4 and 5 the reduced toxicity is marked and 
significant.
Week 5 Grade 1 100% Silymarin group, (almost unbelievable) placebo grade 1 55%, 
P=0.003 (for week 5 data) Low
Lam et al 2019 Within subjects experimental design-single centre RTOG measured at baseline and baseline photographs were taken on day 1 of 
treatment, of the weekly RTOG scores the highest was recorded for score during 
treatment. The photographs taken at baseline and FU were assessed blind.
N=56 randomised (over 2 years) n=27 randomised to lateral and n=29 
randomised to medial for BF. 
For lateral applied BF data available for analysis of blinded photographs was n=24
For medial applied BF data available for analysis of blinded photographs was n=29
Barrier Film (alcohol-free film formulated from two polymers, the half of the 
breast not covered with BF standard care was used, that included using 
Glaxal based cream which is similar to aqueous cream.
BF started on first day of treatment. Applied twice per week, not applied 
between last RT session and FU appointment.
Breast Cancer Patient reported outcomes, no sig difference in reported scores seen for burning, 
pulling and tenderness for those with BF applied to medial, one sig improvement in 
score for itching 1.14 vs 2.06 P=0.035.
For cases where the BF was applied to the lateral only for burning was there seen a sig 
difference in patient reported scores, 0.92 vs 1.83 (P=0.047) no CI presented. No 
significant difference seen between BF and standard care for time to development of 
grade 2 RD.
RTOG during treatment – some errors in results presented for calculated numbers 
with grade 2 or more RTOG.
In those with lateral BF Grade 2 or more RD 17.3% vs 27.6% for no film P=0.041.
For medial cases 17.2% for the BF cases and 9.6% for no film P=0.76
Post treatment no difference seen in grade 2 or above scores for BF vs no film. There 
P=0.041 for laterally placed BF moderate
Moller et al 2018 RCT pt. own control CTC scored by RTT blinded to randomisation. PROS 101 N=79 Intervention: Mepitel applied to lateral or medial breast.  Control: Opposite 
side treated as per guidelines i.e. using moisturiser and for itch/steroids
Breast To investigate PR 
symptoms related to radio 
dermatitis and to examine 
patient preferences using 
mepitel film compared to 
standard skin care. 
Secondary compare to 
general population
CTC scores: no significant difference in grades 1 to 3at end of treatment or at 14 
days. Patient reported outcomes were that the film was comfortable and patients felt 
made a difference, at 14 days pain was reduced (p.0.001) and sensitivity of the skin 
(p<0.01) as well as itching
pain reduced p.0.001 Low
Naff et al 2018 Pilot study CTC (ARSM) scored by nurse and doctor G2 s2,4,6 & 8 weeks 20 int in analysis. 100 controls Intervention: Administration of the CSNF 0.4% lotion 7 days prior to RT, • 
Preventative gel CSNF 2.5% administer 1-2 hours prior to radiotherapy. 
Control: Comparative group had treatment related to care guidelines i.e. 
Excipal or nepanthol or Ialugen cream
Breast To assess effectiveness of 
NPE of CNSF extract in 
prevention and recovery 
of acute radiation induced 
skin reactions
CTC scores not significantly different showed trend. Significant delay in grade 2  P =0.014 High
 Rades et al 2019 RCT CTCAE v4 57 (28 MEP/ 29STD) Intervention: Mepitel film started on first day continued until Grade 2 
moist desquamation MEP changed 2x weekly. Control: 2-5% urea and fatty 
acid cream
Head and neck stratified 
between groups
Comparison of Mepitel 
film to standard skin care 
for prevention of grade 2 
radiation dermatitis
46.4 % of patients had sensitivity to MEP (13 of 28) so study stopped at interim 
analysis at 50Gy 8/23 (34.8%) in the mEP group had Grade 2 and 10/28 (35.7%) in 
STD group (NS). At 60Gy grade 2 rates were 65.2% (15/23) and 59.3% (16/27) in the 
STD NS
see results column Low
Ogita et al 2019
RCT
Sebum content and composition Sebumeter at 4 time points 2,4,weeks and 3 
months
81 (80 rand) 74 analysed (I=16) (C=64) then from this group post WBRT I n=32 
and control n=32
Intervention: prophylaxis used heparinoid 2x daily from first txt until 2 
weeks after wbrt. Control: No moisturiser but reassigned at 2 weeks after 
WBRT to receive moisturiser or not
Breast explore time course and 
water content of strateum 
Corneum to assess skin 
damage with heparinoid 
cream
Rxt significantly reduced sebum content overall. No differences seen between groups 
but confusing analysis
see results column High
Schmeel et al 2018
RCT pt. own control
RTOG and EORTC recorded weekly, RISRAS but not reported 62 (56 analysed) Intervention: hydrofilm. Control: 5% urea Breast compare prophylactically 
applied hydrofilm 
dressings with standard 
skin care using 
moisturising 5% urea
Significantly reduced severity of RTOG mean 0.35 and 1.33 in the control with 
p<0.001 RTOG/EORTC end of treatment severity Grade 0 48% film  control 12.5%, 
Grade 1. 39.3%--46.4%, Grade 2 12.5%...30.4%, Moist desquamation 0%  10.7%
p<0.001 High
Sekiguchi  et al 2015 RCT Sebum content and composition Sebumeter at 4 time points 2,4,weeks and 3 
months. Diary for compliance ARD scores i.e. clinicians rated score
749 women assessed  I 14 and C 32 Intervention: prophylaxis used heparinoid 2x daily from first txt until 2 
weeks after wbrt. Control: No moisturiser
Breast Efficacy of heparinoid 
moisturizer as 
prophylactic agent
Skin dryness was significantly higher in the control group 2 and 4 weeks . Itching and 
pain VAS scores generally higher at last day, No significant differences at 3 months
see results column High
Seliguchi et al 2018 RCT Water content, and severity scoring none to very severe 2 to 4 weeks after RXT 749 women assessed  I 32 and C 32 Intervention: prophylaxis used heparinoid 2x daily from first txt until 2 
weeks after wbrt. Control: No moisturiser 
Breast Efficacy of heparinoid 
moisturizer as 
prophylactic agent
Skin dryness significant difference between groups between moisturiser and no 
moisturiser (p0.01). No significant clinicians rated skin toxicity or patient reported 
except pain scores at last day of RT
p<0.001 High
Sio et al 2016 RCT CTCAE v3 4 PROS (LASA) assessed at baseline and weekly 167 women Intervention:  topical 0.1% mometasone. Control: No moisturiser Breast Dermatitis evolution of 
mometasone furoate
Radiation symptoms started between week 4-7 and subsided after week 8 . CTCAE 
showed no significant differences. Significant differences in PROS over time  between 
arms(p0.001)
p<0.001 Low
Togni  et al 2015 RCT camera visual intensity and colour analysis. RTOG Intervention: base cream. No control reported  Breast Saftey and efficacy of 
Boswellia based cream for 
prevention of adjuvant 
skin damage
RTOG grade 2 toxicity 71.2% for control and 54.6% boswelellua cream. Not 
significant. Claims in abstract  it is able to reduce erythema, no regression for risk 
factors. Skin colour intensity less in intervention but not significant
p=0.009 High
Ulff et al 2017 Long term follow up from trial comparing normal 
breast tissue
RTOG. Skin thickness using ultrasound. Dryness measured. Cosmetic results. 6 
years after treatment
60(I=28, C=32) Intervention: betamethasone 0.1%. Control: Moisturiser Breast evaluate whether 
treatment with potent 
steroid during adjuvant 
EXBRT is associated with 
late toxicity
Skin atrophy not noted in any of the 60 patients. No significant differences between 
normal tissue and treated with steroids. 10 (17%) had noticeable skin changes. 3 
(5%) had altered skin pigmentation.
P<.0.001 Low
Ulff et al 2017 RCT RTOG.VAS of itching, skin irritation 686 Intervention: betamethasone-17 valeroate cream, Applied 7 days per week 
until 2 weeks after RT. Control Moisturiser
Breast Test hypothesis that 
preventative topical 
steroid treatment 
instituted at start of 
radiotherapy can 
ameliorate acute radiation 
dermatitis
Patients receiving hypofractionated RT developed less skin reactions than those 
treated with CTR. Steroids had significantly less skin reactions -.0.001 regardless of 
RT schedule
P<.0.001 Low
Wolf et al 2018 phase 2 multi-site, randomized, double-blinded, 
placebo-controlled trial
baseline, weekly after every fifth RT session, at the end of RT (End RT), and 1 week 
after RT completion
 RDS scale , digital imaging , completion of three self-report questionnaires, McGill 
Pain Questionnaire,  Skindex-29,  Symptom inventory 
578 total  Intervention= 283  and  Control =295  . Intervention: curcumin capsule- 4 capsules 3x daily for full course of RT 
and 1 week post RT with food                                                       Control: 
Placebo capsule -  4 capsules 3x daily for full course of RT and 1 week post 
RT with food  
Breast To determine the efficacy 
of oral curcumin, one of 
the biologically active 
components in turmeric, 
at reducing radiation 
dermatitis severity (RDS) 
at the end of RT, using the 
RDS scale, compared to 
placebo.
no significant difference in mean RDS score at End RT between curcumin and 
placebo.                                                                                                                                    No 
beneficial effect reported from using Curcumin
 p=0.565 end of RT Moderate
Strouthos et al  2016 non-randomised single centre study weekly CTCAE  and physical assessment.  weekly VAS,  Weekly photographs 70  total  Intervention=25 control ( no intervention)= 45 photobiomodulation	LED	therapy	 Breast To evaluate the beneficial 
role of Photo-
biomodulation therapy in 
preventing/reducing 
8% of PBM group experienced grade 1 RD and 12% grade 3 RD.             55.6% of 
control group experienced Grade 1 RD 40% grade 2 and 4.4% grade 3 ( resulting in RT 
pause)    48%  of matched group grade 1 , 44% grade 2 and 4% grade 3                                                                                                 
RD lower in PBM group compared 
to control P=0.0211
Low 
Hoopfer et al  2015 Phase III RCT 10 point Catterall skin scoring, 6 point Likert tool for severity  and changes in  
burning, itchiness, pain and dryness , Maximum CSPP scores  for erythema, dry and 
moist desquamation <  50%  and > 50% of field 
248  in total  : 81 to Aloe cream /77to placebo/79 to powder 1. Aloe cream 
2. placebo cream:  composed of Aquatrix II 
Both creams subjected to bioassay testing 
3. Dry powder: non-metallic baby powder or corn-starch to intact skin 
followed by one month of Glaxal based cream post RT. 
Breast Phase III RCT to test 
hypothesis that the use of 
Aloe would lead to a 1 
point reduction in RSR 
severity and a decrease in 
symptom severity 
compared with a 
traditional dry powder 
skin care regime
 Mean of Max CSSP value: 6.27  for the powder, 6.96 for the aloe ( P=0.227  and 6.99 
for the placebo (P=0.845)
 These did not meet the 1 point difference that was  deemed to infer clinical 
significance 
 Symptom Severity (pain)  reported significant changes with  9/67 powder arm  rating 
pain as high, 21 /72 aloe cream and 25/74 for the placebo when reported 1 week 
post RT 
 Intervention: P=0.227   placebo 
P=0.845
Low 
Rollman et al 2015 double -blinded randomised pilot study CTCAE v3.0 scale - 
Skindex 16
SED ( Skin experience Diary) 
baseline, weekly intervals during RT 6 weeks post treatment completion 
42 in total intervention=28 Control = 14 EMU oil/ placebo ( cottonseed oil)  Applied 1.5Ml 2x daily for duration of 
RT and up to 6 weeks post RT 
Not applied sooner than 4hrs before delivery 
Had to have used before 3rd Fraction 
No other creams or oils 
Discretion by provider as to other supportive treatments for symptom 
relief any Skin treatments were documented 
Breast Demonstrate the 
feasibility and safety of 
using an oil based 
product during breast 
cancer radiotherapy 
PROM  from Skindex : average scores 7.4 V's 10.4 for the intervention and control 
respectively 
Lower mean scores for all areas: emotional, Symptoms and functional 
Peak CTC toxicity occurred at week  6 of intervention group appeared slightly worse 
but "not statistically significant" ( not reported statistically just narrative ) 
P=0.29 pilot study 
Cui et al 2015 single	institution,	prospective	study	 RTOG and VAS also used 94 in total  47 in each group  Intervention: administration of olive oil 3 X daily from #1 and for 2 weeks 
post RT completion. 
Control: placebo ( water)during RT ( not specified if same as above) and for 
2 weeks post treatment completion  
	Nasopharynx evaluate the effect of olive 
oil on radiation dermatitis 
Grade I and II reactions in 93.6% intervention and 72.3% of control 
Grade III in 6.4% of intervention and 27.7% of control 
p<0.001 Moderate
Censebella et al 2016 single	institution,		non	randomised	with		historical	
controls		
WHO criteria for grading acute cutaneous toxicities 222 in cohort plus 2 matched  historical groups from  2 previous studies  136 
and 100  respectively  but ½ of each of these were excluded due  to a change in RT 
technique
Hydroactive colloid gel to the irradiated area Breast  the efficacy of this same 
hydroactive colloid gel in 
the prevention of RIMD, 
with the hypothesis that 
using this agent 
preventively would be 
even more beneficial with 
respect to incidence and 
onset time of RIMD.
Incidence of RIMD 6.9% in intervention arm v's 35.1%  and 12,6% in the historical 
control arms 
p<0.001 High
Manas et al 2015 Randomised clinical trial CTCAE and EORTC QLQ with breast and head and neck modules n=102, number analysed n=98 (4 excluded as didnt meet inclusion criteria) Topical R1 was applied once per day within 2 hours of RT, R2 applied 4 
times a day, 3 times during the day and last application just before bedtime. 
R1 and R2 applied from first day of RT until 2 weeks post trt.
Control= use of a urea-containing ointment 5% wt/wt urea. Applied from 
day 1 until 2 weeks post treatment.
Breast cancer and head and 
neck cancer
Primary end point was 
progression to grade 3 or 
4 CTC RD
Secondary were overall 
response rate, and effects 
on QoL (EORTC QLQ)
Significant differences seen in grade of toxicity between intervention and control arm 
at each time point. At end of RT 57% of patients in the R1 R2 group had RD 
compared with 100% in the control arm P<0.0001 2 weeks post RT 33.3% of the R1 
R2 patients and 66% of the control had RD P=0.0003
QoL score showed benefits for the R1 R2 patients in terms of  skin dryness, stinging 
and desquamation for patients with breast cancer and reduced use of medication for 
pain for those with H+N cancer no actual data is presented to confirm the extent of 
the differences stated.
P<0.0001 High
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Radiation	Dermatitis	Information	Sheet	for	Radiotherapy	
Healthcare	Professionals	
This information has been written to support radiotherapy healthcare professionals in providing 
advice to patients about skin care and includes guidance on assessing and managing skin toxicity. 
Key	principles	of	effective	skin-care	management	
1. Knowledge of intrinsic and extrinsic factors that may affect the development and severity of 
radiation dermatitis. 
2. Documentation of current skin care regimen and existing skin conditions, including 
sensitivities and allergies to certain products. 
3. Use of a standardised tool for radiation dermatitis assessment for all patients undergoing a 
course of radiotherapy (RTOG is recommended.  See Table 2). 
4. Adherence to a standardised assessment process that includes a baseline assessment and 
weekly assessments during treatment using the standardised assessment tool. 
5. Mandatory local training for all staff assessing skin toxicity, to ensure accurate reporting and 
maintenance of consistent management protocols. 
6. Regular audit of skin reactions to collate accurate data on frequency and severity. 
7. An emphasis on empowering patients to use products they are familiar with and to self-
monitor their skin, being proactive to improve comfort and minimise the risk of developing 
severe skin reactions. 
8. Testing within a well-designed randomised controlled trial any new product or device 
designed to reduce radiation dermatitis, before its implementation. 
Incidence	
• Radiation dermatitis can appear at any time but is more likely in treatment schedules over 10 
fractions. 
• Reactions peak towards the end of treatment and may worsen for 10–14 days after treatment 
completion. 
• Most patients find their skin has improved around 4 weeks after treatment finishes. 
• If skin has blistered or broken, healing may take longer. 
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Influencing	factors	
It is important to be aware of factors that can influence the severity of skin reactions. 
Prior to the start of radiotherapy, patients should be identified as being at low, medium or high risk 
based on intrinsic and extrinsic factors. 
Table 1: Intrinsic and extrinsic factors that influence the severity of skin reactions. 
Intrinsic	factors	 Extrinsic	factors	
Demographic	or	disease-related	characteristics	 Treatment-related	characteristics	
Age, ethnic origin, smoking, obesity, breast size, 
hormonal status, presence of infection, co-
existing diseases (such as diabetes, 
cardiovascular disease hypermobile Ehlers–
Danlos syndrome), skin type. 
Technique, dose, volume, fractionation, beam 
energy, use of bolus, immobilisation devices, 
addition of systemic anti-cancer therapies 
(SACTs).  Clinical site of treatment, e.g. areas 
containing skin folds, such as the head and 
neck, breast, and axilla. 
 
Assessments	and	management	
Before	radiotherapy	begins	(baseline	assessment)	
Before radiotherapy begins, the following assessments are recommended: 
• Formally assess and document RTOG score (see Table 2). 
• Discuss and document the condition of the skin on and around the site of treatment. 
• Ensure any pre-existing skin conditions, such as infection, sun burn, eczema, etc. are recorded. 
• Discuss and document patients’ skin care routines, including any products that are already 
being used for a medicinal nature (e.g. creams for eczema – such as hydrocortisone). 
• Assess, discuss and document intrinsic and extrinsic factors, providing appropriate support 
and information (e.g. smoking cessation, extra care if skin folds in the treatment area).  Those 
patients with intrinsic or extrinsic influencing factors are at a higher risk of developing a 
significant skin reaction and should therefore be monitored frequently. 
• Provide self-care advice (see Radiotherapy Skin Reactions: Information for Patients). 
• Discuss the likelihood of radiation dermatitis developing and the possibility of permanent 
radiotherapy-related side effects to the skin, e.g. increased skin sensitivity, hyper- or hypo-
pigmentation, and what precautions to take.  For example, advise patients to reduce sun 
exposure to the treatment area and to use sunscreen with SPF 50 (sun protection factor 50). 
During	radiotherapy	
Throughout radiotherapy, the skin should be checked every day and patients should be asked if they 
have noticed any changes to their skin.  The following assessments are recommended on (at least) a 
weekly basis: 
• Assess, discuss and document any changes to the patients’ skin or skin care routines. 
• Encourage self-monitoring of skin changes and support documentation and discussion of 
these with the radiotherapy team. 
• Ask about any symptoms experienced including pain, itching or sleep disturbance. 
• Formally assess and document the RTOG score (see Table 2). 
• Provide advice and support to promote comfort (see Radiotherapy Skin Reactions: 
Information for Patients). 
• Consider over-the-counter or prescription medicines such as analgesics as appropriate.  
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At	the	end	of	radiotherapy	
 
• Inform patients of the potential for skin reactions to worsen and ‘peak’ around 10–14 days 
after the last treatment session. 
• If patients require ongoing wound management, ensure this is communicated to primary care 
teams. 
• Encourage patients to contact the radiotherapy department or clinical nurse specialist if they 
have ongoing skin reactions that they are concerned about or that are not as expected. 
Late	effects	of	radiotherapy	
There is a small risk that patients may have a delayed skin reaction months or years after their 
treatment.  There is an increased risk for patients that received SACT in addition to radiotherapy.  You 
may encounter patients with long-term complications at follow-up clinics, in the community, or when 
seeing a patient for a re-treatment.  Examples of late effects include: 
• Fibrosis 
• Lymphoedema 
• Cellulitis  
• Telangiectasia 
These late effects can impact on the quality of patients’ lives and may not resolve over time; therefore, 
they should be included in any local site-specific patient information where particularly relevant.  
Referral to a dermatologist or appropriate lymphoedema management service may be required.  
There are also local community and charity support groups able to offer support in managing these 
conditions. 
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Table 2: Radiation Therapy Oncology Group (RTOG) acute radiation dermatitis grading criteria. 
 
Grade	0	 Grade	1	 Grade	2a	 Grade	2b	 Grade	3	
No visible change to 
the skin 
 
Faint or dull 
erythema 
 
Mild tightness of the 
skin and mild itching 
may occur. 
Tender or bright 
erythema 
 
Skin may feel tighter, 
itchy and/or sore.  
Patchy moist 
desquamation 
 
Areas where skin has 
broken down can be 
seen. Yellow/pale 
green exudate may 
be visible on the 
surface. Soreness and 
oedema are evident.  
Confluent moist 
desquamation 
 
More pronounced 
areas of broken skin 
can be seen. 
Yellow/pale green 
exudate are visible. 
Soreness and oedema 
are evident.  
ASSESSMENTS	
Weekly assessments and RTOG score Daily assessments and RTOG score 
AIMS	OF	CARE	
• To promote hydrated skin and maintain skin integrity. 
• To promote comfort. 
• To reduce risk of complications of 
further trauma and infection. 
• To promote comfort. 
GUIDANCE	
MOISTURISE:	
Advise the patient to continue moisturising with preferred products. 
If the patient is not already using a moisturiser, advise them to start. 
 
ENCOURAGE	SELF-CARE:	
Discuss self-care guidelines and ensure that the patient has sources of 
information to refer to. 
 
STEROID	OR	CORTISONE	CREAMS: 
Steroid or cortisone creams should only be used following advice from an 
independent prescriber or from staff qualified to dispense medication on 
Patient Group Directives. Contraindications for using these creams are broken 
skin or signs of infection. 
 
ANALGESIA:	
Ensure adequate analgesia is prescribed for the patient if needed. 
 
IF	THE	SKIN	BREAKS:	
Patients should be advised to discontinue using any cream and should be 
advised on, or provided with, appropriate dressings. If there are signs of 
infection, undertake screening. Increase skin assessments to daily frequency. 
Seek further advice, if required, from a practitioner trained in radiotherapy-
induced skin reactions and wound care or tissue viability. 
MOISTURISE:	
Continue to apply moisturiser to skin within the 
treatment field that is still intact. 
 
ENCOURAGE	SELF-CARE:	
Discuss self-care guidelines and ensure that the 
patient has sources of information to refer to. 
Follow skin care guidelines and ensure patient has 
information sources to refer to.  
 
DRESSINGS:	
Use appropriate dressings/products on broken skin, 
e.g. non-adhesive, silicone low adhesion. 
Do not use paraffin/petroleum jelly-based products 
or gentian violet. 
 
ANALGESIA:	
Ensure adequate analgesia is prescribed for the 
patient if needed. 
 
INFECTION	SCREENING:	
Take a swab if there are signs of infection and 
arrange antibiotic treatment if infection is indicated. 
If you are unsure, seek advice from the wound care team, tissue viability specialists or dermatology. 
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Radiotherapy	Skin	Reactions:	Information	for	Patients	
Introduction	
This information describes the skin reactions you may develop during and after your radiotherapy. It 
also provides advice on how you can look after your skin. 
A skin reaction will only occur in the area being treated. Ask your radiographers and clinical nurse 
specialist where this is if you are not sure. If you have any questions that are not answered by this 
document, please talk to your radiographers and clinical nurse specialist. 
How	might	my	skin	react	to	treatment?	
A radiotherapy skin reaction is likely for most patients. It will not happen straight away but tends to 
develop gradually throughout treatment, and usually starts to settle 2–4 weeks after treatment 
finishes. 
During the course of your radiotherapy, you may develop a skin reaction in the area being treated. 
You may notice one or more of the following: 
• Your skin may become gradually pinker or darker, depending on your skin colour. 
• Your skin may feel dry or tight, and sore. 
• A rash may appear and feel itchy and this may feel worse when you get warm or hot. 
• Sometimes the skin may blister or peel. If this happens, tell your radiographers and clinical 
nurse specialist; they will be able to give you further advice and provide any gel or dressings 
that might be needed. 
• You may get an ‘exit rash’ (this is where the radiotherapy beam causes a reaction in the area 
opposite to where it goes in). This will depend on how and where you are being treated. Tell 
your radiographers and clinical nurse specialist if you see or feel anything on your skin that 
concerns you. 
What	can	make	my	skin	reaction	worse?	
If you develop a skin reaction during the course of your radiotherapy, a number of factors that may 
affect the reaction include: 
• If you are prescribed a higher dose of radiation for your type of cancer. 
• If you receive treatment to areas where your skin folds, such as the groin, breast, buttocks or 
armpit; these areas can be warm, moist and rub together, making the skin more sensitive. 
• If you receive treatment to the head and neck area (due to the sensitive nature of the skin and 
the tendency for this area to be exposed to the sun). If you are receiving treatment on your 
neck, you can help by covering this area with a cotton or silk scarf when you go outside. 
• If you are prescribed chemotherapy and/or immunotherapy alongside radiotherapy (due to 
their combined effects). 
• If you smoke (as this can affect the oxygen levels in your skin). Please ask for advice if you 
need help to stop or to cut down on smoking. 
• If you have other conditions such as diabetes and heart disease (as these may affect the overall 
well-being of your skin). Please tell your radiographers and clinical nurse specialist if you have 
any other health conditions so that it can be noted in your records. 
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Skin	care	advice	
Tell your radiographers and clinical nurse specialist about your usual daily skin care routine. They will 
let you know if any changes are advised. 
Please keep notes of any differences to your skin so that you can share these with your radiographers 
and clinical nurse specialist. Please also tell them if your skin reaction is painful, so that they can 
recommend pain relief. Talk to your radiographers and clinical nurse specialist about any worries you 
have. 
Reactions to your skin cannot be prevented, however, there are things you can do to help yourself 
feel more comfortable. 
Health	and	well-being	
• It will help your overall health if you keep up an intake of at least 6–8 glasses of water a day 
and eat a nutritionally well-balanced diet that includes fruit, vegetables, whole grains and lean 
protein. You can ask your radiographers and clinical nurse specialist to provide examples and 
to explain the importance of staying hydrated and eating a healthy diet in more detail. If you 
are receiving treatment to your abdominal area they may recommend a different diet. 
• If your skin is not blistered or peeling, you may go swimming. It is best to shower immediately 
afterwards to wash off the chlorine and then apply moisturiser. Please stop swimming if it 
irritates your skin. 
• Avoid sun exposure and protect the treated area from direct sunlight. You can wear a brimmed 
hat and/or cover up with clothing. Continue to protect the treated area from the sun for at 
least one year after you have finished treatment. Because your skin will be more sensitive, use 
sunscreen with SPF 50 (sun protection factor 50). 
• You may find it more comfortable to wear loose-fitting clothing made of natural fibres, such 
as cotton or silk. 
Hygiene	and	moisturising	
• When washing and bathing, make sure the water is not too hot; wash the skin gently with 
products you would normally use and gently pat dry. 
• Please continue to use the moisturiser you prefer and like to use. No specific moisturiser can 
be recommend for use during and after treatment as there is not sufficient evidence to 
support the use of one product over another. 
• Use moisturiser frequently; gently smooth it onto your skin until it is absorbed. The aim is to 
help keep your skin supple. 
• If you do not currently use a moisturiser, speak with your radiographers and clinical nurse 
specialist and they will be able to suggest a few options for you. 
• You do not need to wipe your moisturiser off before receiving treatment, but please do not 
apply moisturiser immediately before your treatment. 
• Please stop using moisturiser if it irritates your skin and talk to your radiographers and clinical 
nurse specialist. 
• If your skin blisters or peels, stop using moisturiser in that particular area and ask your 
radiographers and clinical nurse specialist for more advice. 
• Please continue to use the deodorant you normally use, unless it irritates your skin; stop if 
your skin blisters or peels. 
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‘DON’Ts’	for	the	treatment	area	
• Avoid rubbing the area. 
• Avoid or reduce shaving, if possible, unless advised differently by your radiographers and 
clinical nurse specialist. 
• Do not use wax, creams or lasers for hair removal on or close to the treated area during your 
treatment. 
• Do not use sticky tape on the area (such as ElastoplastTM or MicroporeTM). 
• Avoid using make up, hair dye, perfumes and aftershave on or close to the treated area. 
After	treatment	
• When you finish receiving treatment, your skin reaction may worsen for the following 10–14 
days before starting to improve. 
• If your skin has blistered or peeled it may take longer to heal. 
• About 4 weeks after treatment finishes, most patients find that their skin has improved. 
• The treated area will continue to be more sensitive than the rest of your skin, even once you 
have completed your radiotherapy, especially to heat and sunlight. 
Do	you	have	any	questions?	
Please talk to your radiographers and clinical nurse specialist. They are here to help you during and 
after your treatment. 
 
Published 2020 by The Society and College of Radiographers 
Appendix 13
Patient infosheet skin care
A5 leaflet






Appendix 13
Patient infosheet skin care
A5 leaflet - PRINT READY


Appendix 14
Skin care presentation
Radiation Dermatitis Information for 
Radiotherapy Healthcare Professionals
What current evidence is there to give the 
optimal skin care advice to patients 
undergoing radiotherapy?
Introduction
§ Turesson et al. (1996) demonstrated that the number of basal 
cells in the epidermis declines during fractionated RT due to 
increased cell cycle arrest and reduced mitosis. This causes a 
thinning of the epidermis and an inflammatory reaction and the 
variation in the reaction appears to be a genetic predisposition 
related to individual DNA repair capacity. (Chang-Claude et al., 2005; 
Pinar et al., 2007; Andreassen and Alsner, 2009)
§ Certain clinical factors can aid in the prediction of which 
patients are more likely to experience a significant radiation 
reaction. (Russell et al., 1994; Russell 2010)
Influencing factors
§ It is important to be aware of factors that can influence the 
severity of skin reactions.
§ Prior to the start of radiotherapy, patients should be identified as 
being at low, medium or high risk based on intrinsic and 
extrinsic factors.
Extrinsic factors Intrinsic factors 
Radiotherapy
Technique, dose, fractionation, beam 
energy, and modality of radiotherapy.
Age. Ethnic origin. Skin type
Site of treatment 
e.g. skin folds
Breast size. Hormonal status
Bolus, immobilisation devices Nutrition
Radiosensitisers
Some Cytotoxic agents can increase the 
severity of reaction e.g. Cisplatin, 5-
Flurouracil, Mitomycin C.
Smoking. Alcohol 
Chemicals/ thermals/ mechanical 
irritants 
Co-morbidities
e.g. diabetes, cardiovascular disease
Addition of systemic anti-cancer 
therapies (SACTs). 
Previous damage
Trauma
Obesity
Infection
UV exposure
Incidence
§ Radiation dermatitis can appear at any time but is more likely in 
treatment schedules over 10 fractions.
§ Reactions peak towards the end of treatment and may worsen for 
10–14 days after treatment completion.
§ Most patients find their skin has improved around 4 weeks after 
treatment finishes.
§ If skin has blistered or broken, healing may take longer.
The extent of the problem?
2014 data
0
2
4
6
8
10
Approximately what percentage of patients in your department get 
erythema 
Don't know
91%-100%
81%-90%
71%-80%
61%-70%
51%-60%
41%-50%
31%-40%
21%-30%
11%-20%
0%-10%
0
2
4
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10
12
14
16
Approximately what percentage of patients in your department get
moist desquamation 
Don't know
91%-100%
81%-90%
71%-80%
61%-70%
51%-60%
41%-50%
31%-40%
21%-30%
11%-20%
0%-10%
Systematic Reviews
§ An extensive literature review was undertaken of over 300 
articles from 1980 to October 2010. 
§ Two systematic reviews of skin care literature proved 
invaluable in determining the more robust evidence base. 
(Bolderston et al., 2006; Kedge 2009)
§ 2014 systematic review undertaken using PICO method and 
SIGN to determine if, since 2010 there has been any additional 
evidence. Three systematic reviews also reviewed. (Butcher and 
Williamson, 2012;  Schnur et al., 2013; Chan et al., 2014)
§ 2019 systematic review undertaken using PICO method and 
pearl growing to identify new literature since 2014
2019 Systematic Review
§ The current review included a search of multiple databases as well 
as a hand search of a number of relevant journals and 
supplemented by searches of the grey literature to include ongoing 
trials.  The systematic review was registered with the Prospero 
database (registration CRD42019148161). 
§ Thirty-three studies were included in the results and discussion. All 
included research was assessed for quality, with recommendations 
based on the studies assessed as having low opportunity for bias.
§ However, significant challenges still arise with respect to the 
research conducted.
2019 Systematic Review
Quality assessment was completed by 3 researchers assessing study
quality independently; 2 independent reviews were completed on each
article. The review has been reported using the PRISMA group guidelines
The review aimed to answer 
the following questions:
§ Is there new research evidence to support a change in advice 
given to patients undergoing radiotherapy about how to care for 
their skin before during and after a course of radiotherapy in terms 
of washing, drying, deodorant or cream use?
§ Is there new evidence to support the use of topical agents?
§ Is there new evidence to support the use of dressings, medical 
devices, oral medications or barrier films?
The 2019 evidence base for 
prophylactic skin care (1)
The review identified a number of key areas which have been and 
are currently being researched.
§ Some studies have made strong recommendations for the use of 
prophylactic topical steroids. In spite of this, other published 
research recommends exercising a degree of caution and that 
there is a need for more work to be undertaken, particularly to 
determine any long term implications of using steroids. Therefore 
it is recommended that steroid creams should be reserved 
prophylactically for patients scored at a high risk of radiation 
dermatitis.
§ Photobiomodulation (laser therapy) shows positive benefits 
but long-term possible consequences of this approach have not 
been assessed and further research is needed.
The 2019 evidence base for 
prophylactic skin care (2)
§ Barrier films demonstrate mixed results due to poor patient 
compliance or high withdrawal rates in some studies. The positive 
results tend to be in studies where the dose fractionations are over 
40Gy. Patients with breast cancer in the UK should be routinely 
treated with 40Gy in 15 fractions, therefore for patients with 
breast cancer treated with a hypofractionated regimen there does 
not appear to be any advantage of using a barrier film. For 
patients with cancers in the head and neck region where higher 
doses are utilised there may be a benefit but the evidence base 
is inconclusive and weak to support this as routine 
practice.
§ There are a range of other interventions that have been tested, 
only a few assessed as low risk of bias and need additional 
research to confirm the findings before they could be 
recommended for wide use.
2019 systematic review
Overall, the evidence base is 
not strong enough 
to either support or refute the use of 
any particular product for topical application
Consensus 2019
There are two areas where a more general consensus on 
guidance is closer to being achieved. 
§ Firstly with respect to the use of aqueous cream:
This has now been reclassified in the British National Formulary 
(BNF) as a soap substitute and should not be used as a leave-on 
moisturiser. 
§ Secondly with respect to the use of deodorant:
Where a much stronger evidence base refutes the adverse 
impact that deodorants were once thought to have. (Bennett, 2009; 
Watson et al., 2012; Wong et al., 2013)
2019 systematic review
1. There is a need for more research investigating the impact of 
dosimetry in modern radiotherapy planning on subsequent skin 
reactions.
2. Prior to the start of radiotherapy patients should be 
identified as being at low, medium or high risk based on 
intrinsic and extrinsic factors.
3. Where centres want to consider implementing a new topical 
intervention or a new device to reduce radiation dermatitis we 
would recommend teams first test the new product/device 
within a well-designed randomised controlled trial to 
ensure the research evidence is robust enough to inform 
practice.
Future research (1)
§ There should be a clear scientific rationale for introduction of 
the new product or device.
§ Where possible RCTs testing a topical agent or device should be 
placebo-controlled. 
§ Where barrier films are the focus of the investigation researchers 
should use a within-subjects design with the barrier film 
placed on half of the area of skin to be irradiated (on the other 
half of the treated area, standard skin care using simple 
moisturisers and standard washing instructions should be used). 
Future research (2)
§ Assessors should be blinded to the intervention as should patients 
if possible.
§ Measure/score skin at baseline prior to radiotherapy.
§ Researchers should measure and document confounding 
factors.
§ A standard skin toxicity scoring system should be used, for 
example RTOG. Assessors should be trained to use the tool and an 
assessment of inter and intra-rater reliability should be 
undertaken.
§ RTOG scores are categorical (ordinal level) data and 
presentation of the data should be by percentage of each 
grade at each measure point during radiotherapy and post 
radiotherapy. Using a mean score to make judgements about the 
performance of an intervention can be misleading. 
Future research (3)
§ Randomisation should be remote to the staff.
§ Randomisation should consider stratification to ensure 
important confounding variables are balanced.
§ Use of PROMs, it is useful to have patient reported outcomes in 
addition to clinician/practitioner reported assessments. 
§ Researchers should employ multivariate analysis to control for 
confounding variables, and to identify the contribution of the 
intervention to reducing (or preventing) radiation dermatitis in the 
context of other intrinsic or extrinsic factors.
§ Measurement and reporting of adherence to the intervention of 
new products or devices is important as is the reporting of the 
detail for withdrawals.
Future research needed (4)
§ Evaluation into wet versus dry shaving and perfume and 
make-up use is needed.
§ Evaluation of treatment aftercare requires review to ensure local 
continuity and consistency of care across the patient pathway.
§ Further investigations into the skin care reactions: superficial, 
orthovoltage, and proton beam radiotherapy are required.
§ Patient preferences and compliance.
Before radiotherapy begins 
(baseline assessment) (1)
§ Formally assess and document RTOG score.
§ Discuss and document the condition of the skin on and 
around the site of treatment.
§ Ensure any pre-existing skin conditions, such as infection, sun 
burn, eczema, etc. are recorded.
§ Discuss and document patients’ skin care routines (including 
any routinely used products on or near the site of treatment).
Before radiotherapy begins 
(baseline assessment) (2)
§ Assess, discuss and document intrinsic and extrinsic factors, 
providing appropriate support and information (e.g. smoking 
cessation, extra care if skin folds in the treatment area).  Those 
patients with intrinsic or extrinsic influencing factors are at a 
higher risk of developing a significant skin reaction and should 
therefore be monitored frequently.
§ Provide self-care advice.
§ Discuss the likelihood of radiation dermatitis developing and the 
possibility of permanent radiotherapy-related side effects to the 
skin, e.g. increased skin sensitivity, hyper- or hypo-pigmentation, 
and what precautions to take.  For example, advise patients to 
reduce sun exposure to the treatment area and to use sunscreen 
with SPF 50 (sun protection factor 50).
Prophylactic skin care (1)
A lack of evidence to support 
prophylactic use of any specific product 
2014 data:
49% of departments do not assess 
what a patient currently uses
Prophylactic skin care (2)
Evidence indicates that gentle skin and hair washing should be
unrestricted for patients and there should be:
no restriction to using a specific type of soap 
2014 data: 
74% of departments report washing restrictions
Prophylactic skin care (3)
Evidence indicates that deodorant use should be unrestricted for
patients and there should be:
no restriction to using a specific type of 
deodorant 
2014 data:
55% departments are still saying ‘no deodorant’ 
Breast cancer patients who are 
advised not to use a deodorant often 
cite this as one less area of control 
they have in their life and they note 
concern regarding body odour. 
(Komarnicki, 2010) 
Recommendations 
§ Wash the skin gently and gently pat dry. (Aistars, 2006; Bolderston et 
al., 2006; Aistars and Vehlow, 2007; Butcher and Williamson, 2012)
§ Use a moisturiser that is sodium lauryl sulphate free. (Tsang and 
Guy, 2013; Patel et al., 2013)
§ Continue to use normal deodorant (unless this irritates the 
skin), but discontinue if the skin is broken. (Bennett, 2009; Butcher 
and Williamson, 2012; Watson et al., 2012; Wong et al., 2013)
Health and well-being
§ It will help overall health if patients have an intake of at least 6–8 
glasses of water a day and eat a nutritionally well-balanced 
diet. If patients are receiving treatment to the abdominal area a 
different diet may be needed.
§ If the skin is not blistered or peeling, allow patients to go 
swimming. Advise to stop swimming if it irritates.
§ Avoid sun exposure and protect the treated area from direct 
sunlight. Continue to protect the treated area from the sun for at 
least one year after treatment. Use sunscreen with SPF 50.
§ Advise comfortable loose-fitting clothing made of natural 
fibres, such as cotton or silk.
During radiotherapy
Throughout radiotherapy, the skin should be checked every day and 
patients should be asked if they have noticed any changes to their 
skin.  The following assessments are recommended on (at least) a 
weekly basis:
§ Assess, discuss and document any changes to the patients’ skin 
or skin care routines.
§ Encourage self-monitoring of skin changes and support 
documentation and discussion of these with the radiotherapy 
team.
§ Ask about any symptoms experienced including pain, itching or 
sleep disturbance.
§ Formally assess and document the RTOG score.
§ Provide advice and support to promote comfort.
§ Consider over-the-counter or prescription medicines such as 
analgesics as appropriate.
Erythema
Recommendation 2019:
Continue with own self care 
skin moisturiser 
2014 data: 
29 ISSUED the product
15 products cited
Erythema tends to occur at
2000-4000 cGy
Dry desquamation
2014 DATA:
33 ISSUED the product
13 products cited
Dry desquamation occurs 
mainly at 3000 cGy and 
higher 
Recommendation 2019:
Continue with own self care 
skin moisturiser and assess if steroid 
cream required
Moist desquamation 
2014 data:
40 ISSUED the product
22 products cited
Moist desquamation tends 
to occurs at 4000 cGy and 
higher 
Recommendation 2019
Use appropriate dressing/product on 
broken skin to reduce further trauma and 
infection. 
Suitable products would be non-adhesive, 
silicone low adhesion, non or low 
paraffin/petroleum jelly based. 
Things to consider as an issuer 
With a wide variety of products currently available there are bound 
to be variations in product utilisation and availability; therefore, 
careful assessment and justification is paramount. 
? What are the variation of ingredients in products that use the 
same generic name e.g. aloe vera?
? Is a product actually worth the cost? 
? How available and reliable is the supplier?
? How often does a product need to be applied?
? How easily is the product applied? 
At the end of radiotherapy
§ Inform patients of the potential for skin reactions to worsen and 
‘peak’ around 10–14 days after the last treatment session.
§ If patients require ongoing wound management, ensure this is 
communicated to primary care teams.
§ Encourage patients to contact the radiotherapy department or 
clinical nurse specialist if they have ongoing skin reactions that 
they are concerned about or that are not as expected.
Late effects of radiotherapy
There is a small risk that patients may have a delayed skin reaction 
months or years after their treatment.  There is an increased risk for 
patients that received SACT in addition to radiotherapy.  You may 
encounter patients with long-term complications at follow-up clinics, in 
the community, or when seeing a patient for a re-treatment.  Examples 
of late effects include:
§ Fibrosis, Lymphoedema, Cellulitis (an infection which requires antibiotic 
treatment),Telangiectasia
Late effects of radiotherapy
Late effects can impact on the quality of patients’ lives and 
may not resolve over time; therefore, they should be included in any 
local site-specific patient information where particularly relevant.  
Referral to a dermatologist or appropriate lymphoedema
management service may be required.  There are also local 
community and charity support groups able to offer support in 
managing these conditions.
The current position
§ Overall, the evidence base is not strong enough to either 
support or refute the use of any particular product for 
topical application.  
§ Currently, some of the skin care provided may not actually 
alleviate the problem and indeed may even compound the effect. 
§ Are we actually providing skin care advice to patients based on 
traditional knowledge and a paternalistic approach to healthcare? 
(Harris, 2002)
The patient perspective
Health is:
" ... a state of complete physical, psychological, and social well-being, 
and not 
merely the absence of disease or infirmity.“ 
WHO (1978)
“ We are people, not just bodies.”
Patient 7: Harris (1995)
As Gosselin, et al. (2010) noted:
“patients prefer to take action rather than do nothing” 
Key principles of effective 
skin-care management (1)
§ Knowledge of intrinsic and extrinsic factors that may affect the 
development and severity of radiation dermatitis.
§ Documentation of current skin care regimen and existing skin 
conditions, including sensitivities and allergies to certain products.
§ Use of a standardised tool for radiation dermatitis assessment 
for all patients undergoing a course of radiotherapy (RTOG is 
recommended).
§ Adherence to a standardised assessment process that 
includes a baseline assessment and weekly assessments during 
treatment using the standardised assessment tool.
Key principles of effective 
skin-care management (2)
§ Mandatory local training for all staff assessing skin toxicity, to 
ensure accurate reporting and maintenance of consistent 
management protocols.
§ Regular audit of skin reactions to collate accurate data on 
frequency and severity.
§ An emphasis on empowering patients to use products they are 
familiar with and to self-monitor their skin, being proactive to 
improve comfort and minimise the risk of developing severe skin 
reactions.
§ Testing within well-designed randomised controlled trials 
any new product or device designed to reduce radiation dermatitis, 
before its implementation.
Conclusion
§ The extent of skin conditions is largely unknown. Although the 
majority of skin reactions subside after a few weeks, some can be 
prolonged and affect a patient’s quality of life. 
§ It may not be possible to stop or even reduce the rates of skin 
reaction from occurring, but there may be comfort and 
psychosocial benefits that skin care products provide. 
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